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1 Abstract
Elucidating the precise function of individual protein kinases within complex signal transduction
cascades represents one of the greatest challenges in molecular biology. Protein kinases are enzymes
that catalyze the transfer of a phosphate group from ATP to proteins. In doing so, they promote
alterations within the intricate network of intracellular signal transduction pathways. Deregulated
signal transduction pathways caused by aberrant kinase activity drives a multitude of diseases.
Because of this, protein kinases have become one of the most intensively pursued classes of drug
targets. A comprehensive functional analysis of individual kinases involved in the biology of health
and disease is challenging and requires the development of specific inhibitors that can discriminate
between highly homologous proteins. Most available protein kinase inhibitors are low molecular
weight compounds that address the kinases active site and, thus, block kinase activity. These
inhibitors have been proven useful for therapeutic applications but their use as research tools is
often hampered by their lack of specificity.
Herein, it was investigated if aptamers represent a promising new class of kinase inhibitors for
chemical biology research that might overcome this limitation. Aptamers are single-stranded nucleic
acids that adopt complex three-dimensional strucures. More importantly, aptamers are often able
to modulate the function of their target protein in a highly specific manner. In this thesis, the
potential of aptamers as selective protein kinase inhibitors was studied for two important kinases:
G protein-coupled receptor kinase 2 (GRK2) and extracellular signal-regulated kinase 2 (Erk2).
GRK2 is a key regulator of G protein-coupled transmembrane receptors and Erk2 is crucial for the
regulation of proliferation and di↵erentiation in cells.
The ATP-competitive aptamer C13 and GRK2 were used to unravel the molecular determinants
which contribute to the aptamer´s highly specific interaction with its target. Crystallographic
structures and biochemical assays revealed that the ATP-competitive aptamer forms extensive
interactions both within and outside of the active site which contribute to its specificity and ability
to block kinase activity.
The two novel Erk2-binding aptamers C3 and C5 revealed that aptamers can bind distinct sites
on one target and are able to employ ATP-competitive or allosteric modes of action in respect
to kinase activity perturbation. This demonstrates their potential as domain-specific inhibitors.
Aptamer C5 was shown to interfere with Erk2 activity in an ATP-competitive manner. Aptamer
C3, on the other hand, recognized the MAP kinase (MAPK) insert region of Erk2. The intriguing
ability of C3 to target MAPK insert specific functions was monitored in an activation cascade assay.
In this assay, the aptamer was able to inhibit the activation of Erk2 by its upstream kinase Mek1
and to prevent subsequent substrate phosphorylation.
Most importantly, this study implies that RNA aptamers can provide a new class of potent tools
to manipulate intracellular kinase activity in neurons. Using aptamer C5, it was shown for first
time that the application of an aptamer during whole-cell patch-clamp recordings o↵ers a unique
and generally applicable strategy to monitor spatio-temporal e↵ects on individual protein kinases
during neuronal functions.
In summary, this thesis demonstrates the versatile potential of RNA aptamer as specific protein
kinase inhibitors for chemical biology research and opens the avenue towards their application as
tools to specifically interfere with kinase activity during neuronal signaling.
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2 Zusammenfassung
Die pra¨zise Charakterisierung individueller Proteinkinasen in intrazellula¨renr Signaltransduktion-
skaskaden ist eine der gro¨ßten Herausforderungen der Molekularbiologie. Proteinkinasen sind En-
zyme, die den Transfer der terminalen Phosphatgruppen von ATP auf Substratproteine katalysieren.
Dadurch ko¨nnen Kinasen weitreichende Vera¨nderungen innerhalb der komplexen Signaltransduk-
tionskaskaden bewirken. Fehlregulationen innerhalb von Signaltransduktionskaskaden, die durch
anormale Proteinkinaseaktivita¨t hervorgerufen wird, spielen eine entscheidende Rolle bei verschiede-
nen Krankheiten. Aufgrund dieser Implikation sind Proteinkinasen eine der wichtigsten Anker-
punkte fu¨r die Entwicklung von Arzneimitteln.
Eine umfassende funktionale Analyse von individuellen Proteinkinasen ist schwierig und er-
fordert die Entwicklung von Inhibitoren, die zwischen fast homologen Proteinen unterscheiden
ko¨nnen. Die meisten Proteinkinaseinhibitoren sind niedermolekulare Wirksto↵e, die an an das ak-
tive Zentrum binden und dadurch die Enzymaktivita¨t inhibieren ko¨nnen. Diese ATP-kompetitiven
Substenzen sind wichtig fu¨r therapeutische Anwendungen. Fu¨r Forschungszwecke sind sie allerdings
nur sehr bedingt geeignet, da sie oft nicht spezifisch genug sind.
Innerhalb dieser Dissertation sollte untersucht werden, ob Aptamere die Probleme anderen In-
hibitoren umgehen und dadurch als eine neuartige Klasse von Kinaseinhibitoren fu¨r
Forschungszwecke eingesetzt werden ko¨nnen. Aptamere sind kurze, einzelstra¨ngige Nukleinsa¨uren,
die sich in dreidimensionale Strukturen falten ko¨nnen. Zudem sind Aptamere sind oft in der Lage,
die Funktion ihres Zielpproteins zu modulieren.
Im Rahmen der vorliegenden Arbeit sollte der Einsatz und die Funktionsweise von Aptameren
untersucht werden, die die Proteinkinasen Erk2 und GRK2 adressieren. GRK2 spielt eine wichtige
Rolle in der Regulation von G-Protein gekoppelten Rezeptoren. Die Kinase Erk2 ist unerla¨sslich
fu¨r die Proliferation und Di↵erenzierung von eukaryontischen Zellen.
Anhand des ATP-kompetitiven Aptamers C13 und der Kinase GRK2 wurde untersucht, welche
molekularen Interaktionen das Aptamer mit seiner Zielkinase eingeht. Durch kristallographische
und biochemische Untersuchungen konnte gezeigt werden, dass das ATP - kompetitive Aptamer
weitla¨ufige Interaktionen sowohl innerhalb als auch außerhalb des aktiven Zentrums eingeht. Diese
Interaktionen tragen zu einem hohen Maße zu der hoch a nen und spezifischen Bindung bei.
Der Einsatz der neuen Aptamere C3 und C5, die an die Kinase Erk2 binden, zeigt, dass Ap-
tamere an verschiedene Epitope an einem Protein binden und dadurch die Kinaseaktivita¨t in ATP
kompetitiver oder nicht ATP kompetitiver Weise beintra¨chtigen ko¨nnen. Dies veranschaulicht das
Potential von Aptameren als doma¨nenspezifische Inhibitoren. Es konnte nachgewiesen werden, dass
Aptamer C5 mit ATP um die Bindung an Erk2 konkurriert und die Aktivita¨t inhibiert. Aptamer
C3 bindet an das sogenannte MAP kinase (MAPK) Insert. Die Fa¨higkeit von C3 als doma¨nen-
spezifischer Inhibitor konnte experimentell nachgewiesen werden. In diesem Versuch konnte gezeigt
werden, dass C3 die Aktivierung von Erk2 durch Mek1 bewirkt. Die Wirkung von C3 setzt sich
auch auf die Aktivierung von Substratproteinen fort.
In dieser Dissertation wurde erstmals gegen Kinasen gerichtete Aptamere als Intramere zur
Analyse zellula¨rer Signaltransduktionswege in Neuronen eingesetzt. Der Einsatz von Aptameren
wa¨hren Patch Clamp Messungen ist eine neuartige Methode, um den E↵ekte von Aptameren auf die
Funktion von Kinasen mit hoher zeitlicher und ra¨umlicher Auflo¨sung zu messen. Diese Messungen
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legen nahe, dass Aptamer C5 eine neuronale Funktion von Erk2 inhibiert.
Die Ergebnisse dieser Arbeit unterstreichen die Bedeutung von Aptameren als Werkzeuge fu¨r
die Erforschung von Proteinkinasen innerhalb neuronaler Signaltransduktionskaskaden.
4
3 Introduction
3.1 Signal transduction pathways
Cells receive and respond to a variety of extracellular stimuli, such as growth factors [1] or neuro-
transmitters [2]. In order to process these stimuli, cells have to employ a sophisticated system of
molecular receptors and intracellular signaling pathways, also called signal transduction cascades
[3]. Most receptors are transmembrane proteins, which bind to molecules outside the cell and sub-
sequently transmit the signal to cytosolic signaling pathways [4, 5]. These intracellular signaling
pathways typically branch and intersect via diverse protein e↵ector and second messenger cascades,
enabling cells to coordinate information from multiple receptors and to regulate multiple e↵ector
systems at the same time [3].
3.1.1 Protein kinases
Protein kinases are key regulators of signaling pathways and, thus, control virtually all aspects of
cellular life, including metabolism, transcription, cell-cycle progression, and neuronal and immuno-
logical functions [6].
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Figure 3.1: Protein kinase reaction. Eukaryotic protein kinases catalyze the transfer of the  -
phosphate group from ATP (red) to hydroxyl groups on serine/threonine or tyrosine residues (blue).
ATP: adenosine triphosphate, ADP: adenosine diphosphate.
Protein kinases are enzymes that catalyze the transfer of the terminal phosphate group from
adenosine triphosphate (ATP) to amino acid residues on proteins (Figure 3.1). In eukaryotes,
protein kinases phosphorylate the hydroxyl groups of serine/threonine or tyrosine residues. More
than 86% of protein phosphorylation occurs on serine residues, 12% on threonine residues, and 2%
on tyrosine residues [7]. Prokaryotes generally employ histidine kinases for signaling [8–10]. Even
though this modification exists in eukaryotes, little is known about its function in humans [11].
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3.1.2 Protein phosphorylation as a regulatory mechanism
The phosphate group transferred by kinases acts as a molecular “switch” that is able to control
extremely complex signal transduction cascades by formation and reorganization of dynamic protein
interaction networks (Figure 3.2) [12, 13].
The unique size and charge properties of covalently attached phosphates can activate or inhibit
proteins through allosteric conformational changes or by interfering with substrate recognition [14–
16]. Moreover, it allows for specific and inducible recognition of phosphoproteins by phosphospecific-
binding domains in other proteins [17]. This, in turn, can promote alterations in protein–protein
interactions.
The phosphate group is predominantly dianionic at a physiological pH, which allows it to partic-
ipate in the formation of hydrogen bonds and electrostatic interactions [17]. The phosphate group
is particularly suited for interacting with the guanidinium group of arginine residues. Arginines
contain a planar structure that can form direct hydrogen bonds to the negatively charged phosphate
groups [12, 17].
protein protein
P
protein kinase
protein phosphatase
ON/OFF
Figure 3.2: Schematic representation of the molecular switch induced by protein kinases.
Phosphorylation alters the activity of target proteins and turns them on or o↵. The reaction is reversible
and the phosphate group can easily removed by protein phosphatases. P: phosphate group.
More importantly, however, is the feature that protein phosphorylation is a reversible process,
which sets the protein switches back to its original state [13]. At a physiological pH, phosphate
esters are chemically stable in aqueous solution but the original hydroxyl group and free phosphate
can easily be regenerated by hydrolysis of the phosphate easter via protein phosphatases [17, 18].
3.1.3 The human kinome
Serine/threonine-directed protein kinases were first discovered in 1955 by Fischer and Krebs who
demonstrated that the activation of glycogen phosphorylase b to glycogen phosphorylase a was
dependent on a protein kinase action together with ATP [19–21]. In 1979, Hunter and colleagues
identified phosphotyrosine as the product of a protein kinase activity of a viral oncoprotein which
was later identified as the tyrosine kinase vSrc [22, 23]. From then on, the number of identified
kinases increased.
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Figure 3.3: The human kinome. Based on sequence and functional homology, eukaryotic protein
kinases can be grouped into nine families: AGC (including PKA [protein kinase A], PKG [protein
kinase G] and PKC [protein kinase C] families), CAMK (Ca2+ /calmodulin-regulated kinases), CK1
(casein kinase 1 family), CMGC (including CDKs [cyclin-dependent kinases], MAPKs [mitogen-activated
protein kinases], GSK [glycogen synthase kinases] and CDK-like kinases), STE (related to yeast sterile
kinases), tyrosine kinases and TKL (tyrosine kinase-like). RGC (receptor guanylate cyclase kinases)
and an additional group labelled as ”other” are omitted from this figure. Figure taken from [7].
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In 2002, the landmark study of Manning and colleagues revealed that the human genome codes
for 518 putative protein kinases [7]. Most kinases have a common evolutionary origin and share
highly conserved catalytic residues and mechanisms [24]. Based on sequence homology of the kinase
domain and in comparison to other species, the human kinome could be assigned to nine major
groups (Figure 3.3). Within most groups, the kinases also share related functions [7]. In total, the
so-called ”human kinome” is so important for cellular functions that it represents almost 2% of the
human genome [7, 24, 25].
The majority of protein kinases are serine/threonine-directed and 90 kinases are tyrosine kinases
(58 receptor tyrosine kinases). In addition, there is a small number of dual-specificity kinases that
can act as both tyrosine and serine/threonine kinases (such as Mek´s) [12, 26].
Besides active kinases, 48 human proteins are currently known to have kinase-like domains
but lack one or more of the conserved catalytic site residues in the kinase domain [27]. Thus,
they are coined ”pseudokinases”. In addition to active protein kinases and pseudokinases, the
kinase superfamily contains lipid kinases, carbohydrate and/or small molecule-targeting kinases
(e.g. nucleotide kinases) [28]. In some cases, these kinases can also phosphorylate proteins [29].
3.1.4 Structural overview of the catalytic domain
Most eukaryotic protein kinases share similar bi-lobed catalytic domains (or ”kinase domains”) with
conserved residues at critical positions required for catalysis (Figure 3.4A, B) [30]. A deep cleft
between the large and small lobe forms the active site where ATP is bound and the phosphotransfer
reaction occurs [31].
Within the active site (Figure 3.4B), the adenine ring of ATP forms hydrogen bonds between
N1 and N6 and the peptide backbone of the hinge region which connects the two lobes. Nonpolar
aliphatic groups line the pocket and provide van der Waals forces to the purine moiety of ATP [32].
The ribose and triphosphate moieties of ATP bind in a hydrophilic channel which extends to the
substrate binding site. One important characteristic of this channel is the conserved glycine-rich
loop that interacts with the ↵- and  - phosphate groups of ATP (Figure 3.4 [33–35]).
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Figure 3.4: Catalytic domain and molecular interactions with ATP. A) Ribbon representation
of the kinase domain of G protein coupled receptor kinase 2 (GRK2) (Protein Data Bank ID code
3UZT). Structural features are annotated. The activation loop is marked in cyan and the glycine-rich
loop in green. The ↵C-helix and the hinge region are marked in orange and red, respectively. The PH
and RH domains of GRK2 are omitted for clarity. B) Simplified illustration of the molecular contacts
between the ATP and conserved active site residues and cofactors. Figure B taken from [12].
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The kinase activation segment influences both substrate binding and catalytic e ciency [31].
It contains several structural features (Figure 3.4A). A conserved Asp–Phe–Gly motif (DFG) is
located at the start. Next to it lies the activation loop, which di↵ers in length and sequence, and a
loop that recognizes phoshorylatable residues on substrate proteins [36, 37]. The activation loop is
the most flexible part of the activation segment. For many kinases, phosphorylation of regulatory
sites within the loop is required for kinase activation. The phosphorylation usually promotes a
rearrangement of the loop which leads to the organization of catalytic active site residues and the
phosphoacceptor binding-site [12, 36]. Phosphorylation of the activation loop can also regulate
substrate- or ATP-binding [37, 38]. Other kinases are not activated by phosphorylation. Instead,
they can be activated or inhibited by accessory peptides, proteins, or lipid cofactors [39, 40]
Activation of kinases usually involves changes in the orientation of the ↵C-helix in the small lobe
and the activation segment in the large lobe [41]. The active kinase then switches between open
and closed conformations in the course of the catalytic cycle [42]. In inactive kinase conformations,
the ↵C-helix of the small lobe is rotated away from the ATP- binding site. This prevents the
interaction of a glutamate residue of the ↵C-helix with a conserved lysine residue. In active kinase
conformations, this lysine residue helps in the positioning of ATP and participates in the catalytic
reaction [43, 44].
The DFG motif of the activation loop is also crucial for catalysis. In active conformations,
the negatively charged aspartate residue binds to ATP either directly or through coordinating
magnesium ions [41]. The phenylalanine residue interacts with the ↵C-helix and the nearby catalytic
loop via hydrophobic contacts and thereby plays a key role for their correct positioning. In inactive
kinase conformations, this residue is often turned in toward the ATP-binding site [32, 41]. The
glycine residue is the last amino acid of the DFG motif and is highly conserved among the kinome,
but its role remains unclear [41].
The catalytic loop of most eukaryotic protein kinases consists of a conserved His–Arg–Asp
(HRD) motif. The HRD aspartate positions the hydroxyl acceptor group in the peptide substrate
[37]. The HRD histidine provides a link which interacts with the DFG aspartate and the DFG
phenylalanine [45]. The HRD arginine stabilizes the conformation of the activation loop by serving
as a sca↵old for the catalytic loop, phosphorylation site, and the DFG motif [46].
3.1.5 Substrate specificity and interactions
Phosphorylation is among the most abundant of post-translational modifications made to proteins
[47]. Since the initial discovery of phosphorylated proteins by Levene and Alsberg in 1906, 500,000
potential phosphorylation sites in the human proteome and 25,000 phosphorylation events were
described for 7,000 human proteins [12].
Because of the high homology of their active sites, protein kinases use many di↵erent mechanisms
to maintain specificity in signaling pathways. The specificity for tyrosine- over serine-/threonine-
directed phosphorylation often results from the depth, charge, or hydrophobicity of the kinase
domain [48]. The phosphorylation site of substrate proteins is recognized and positioned by a
consensus amino acid sequence that is located immediately N-terminal and C-terminal to the hy-
droxyl acceptor group in the peptide substrate. The consensus amino acid sequence of the substrate
proteins have a complementary sequence epitope on the kinases, which interact based on charge,
hydrogen bonding, or hydrophobic interactions [49].
In addition to these interactions, protein kinases contain other consensus amino acid sequences
(so - called docking domains) which enhance their fidelity and the e ciency of their action. These
epitopes are located located distal or in proximity to the active site and have been found in a
variety of kinases and their activators, substrates, sca↵olds, or adaptor proteins [50, 51]. Again, the
interaction of kinases with other proteins is mediated by charge, hydrogen bonding, or hydropho-
bic interactions. Docking domains create binding sites for other proteins, and thus, increase local
concentrations or enable the orientation of substrates in the active site [52–54]. Docking domains
facilitate the localization of protein kinases to distinct subcellular compartments or structures and,
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thereby, add another additional layer of specificity [55, 56]. Moreover, docking domains can also
participate through allosteric mechanisms in positive or negative regulation of kinase activity [57–
59].
3.2 Elucidating the human kinome
Aberrant signaling from over 180 kinases has been shown to contribute to the onset or progression
of human pathologies, including inflammatory, cardiovascular, metabolic, and neurodegenerative
diseases or cancer, making kinases one of the most heavily investigated drug targets for the phar-
maceutical industry [29, 60, 61].
Elucidating the function of individual kinases during health and disease might open new oppor-
tunities to address unmet medical needs [62]. Since the approval of the first protein kinase inhibitor
drug Imatinib for the treatment of chronic myelogenous leukemia (CML) in 2001 [63, 64], more
than 20 kinase inhibitors have been approved in the USA [62, 65].
A comprehensive analysis of the kinome is challenging because signal transduction pathways are
a highly dynamic network with multiple cascades diverging and converging in response to diverse
stimuli [66]. Moreover, signal transduction pathways are controlled by complex regulatory feedback
loops or have compensatory mechanisms, which hamper the evaluation of individual components at
a certain time-point [67–69]. Hence, it is not surprising that the detailed functions of many human
kinases during development, cellular homeostasis, or disease biology remain to be solved. A recent
survey by Fedorov and colleagues found that only a minor fraction (50 kinases) has been studied
in detail by both academia and pharmaceutical industries. More than 100 kinases have completely
unknown function, and about 50% of all kinases are largely uncharacterized [64].
Over the last century, classical genetic approaches employed mutagenesis strategies to elucidate
the function of particular kinases by investigating the relationship between genes and phenotypes
[70]. However, this strategy is very time consuming and might be prone to o↵-target e↵ects, such
as lethality or functional compensation by related genes [71]. An alternative approach to the in-
vestigation of kinases with classical genetic strategies is represented by RNA interference (RNAi)
technologies [72–75]. Potential drawbacks of these methods include incomplete target depletion,
o↵-target e↵ects, and toxicity [76, 77].
3.2.1 Protein kinase inhibitors
Exogenous control over protein kinase activity with kinase inhibitors has emerged as a complemen-
tary approach to investigate cellular signaling pathways and, of course, as a therapeutic strategy
for the treatment of diseases [70]. In contrast to genetic or RNAi-based approaches, protein kinase
inhibitors do not a↵ect kinases at the gene expression level but on the protein level [78, 79].
3.2.1.1 Small molecules
Most currently used inhibitors or modulators of protein function are low molecular weight com-
pounds, so-called small molecules [79]. These inhibitors have a molecular weight below 700 Dalton
and can be identified by in vitro testing, cell-based high-throughput screenings, or rational design
approaches [80–84].
Small molecules are often cell permeable, rather stable, and can be applied in a conditional
fashion at any time point of interest [71]. Small molecules o↵er additional advantages: they can
easily be chemically synthesized and modified, o↵ering low-production costs and low batch-to-batch
variability [85].
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The vast majority of small molecules were identified by their ability to inhibit protein kinase
activity, often resulting in inhibitors that target the ATP-binding site in its inactive or active
conformation [86]. By preventing ATP from binding, ATP-competitive inhibitors are capable of
inhibiting phosphorylation of substrates and downstream signaling in cells. Since the ATP-binding
site is highly conserved among the kinome, ATP-competitive inhibitors are often promiscuous and
have o↵-target e↵ects [87–91].
Synergistic e↵ects on multiple kinases are not only acceptable but are also often desirable for
therapeutic applications. For example, most cancer therapy-approved ATP-competitive inhibitors
are known to target multiple kinases [92, 93]. However, the inhibition of multiple kinases can also
induce adverse side e↵ects, such as cardiac toxicity [94].
The use of protein kinase inhibitors for research applications requires high a nity and specificity.
Thus, the interpretation of functional data from ATP-competitive inhibitors is limited, making it
di cult to draw conclusions about functions specific to one kinase as opposed to several kinases.
Furthermore, ATP-competitive inhibitors often do not allow for the investigation of distinct, kinase
activity-independent functions, including sca↵olding activity, or the blockage of protein-protein
interactions [70, 95].
Given these limitations, a general need for alternative approaches to kinase inhibition has
emerged in order to better control specificity. Significant e↵ort is spent on the design of inhibitors
that target alternative sites, for example an allosteric site [96]. Some allosteric small molecule kinase
inhibitors induce conformational changes to modulate activity whereas other allosteric inhibitors
directly compete with protein-protein interactions [97–99]. These inhibitors tend to exhibit the
highest degree of specificity because they utilize binding sites and regulatory mechanisms that are
unique to a kinase [33, 100]. Allosteric inhibitors might provide approaches to di↵erentially regulate
the subtypes of a kinase within a subfamily which may have similar or the same substrates and
high overall sequence similarity [100].
The identification of allosteric small molecule kinase modulators, in particular those that inter-
fere with protein-protein interactions, is di cult to achieve and requires precise knowledge of the
structural features of the putative allosteric site and sophisticated proteomic approaches (pharma-
cophore modeling, three-dimensional database and virtual high-throughput screening as well as low
throughput functional screening) [100]. Moreover, interfaces that are involved in protein-protein
interactions are di cult to target with small molecules because they are typically hydrophobic,
relatively flat and often lack deep grooves where small molecules can bind [101].
3.2.1.2 Biologics
Biologics, such as monoclonal antibodies, antibody-derived fragments or peptides, can also be
employed as allosteric kinase modulators. Because of their large size, they can dock to a large
surface on the kinase which o↵ers a greater opportunity to block protein function with higher
specificity [102].
Antibodies recognize epitopes on target proteins that are usually made up of 5-8 amino acids
with high a nity and specificity [103]. Antibodies against antigens can be derived by hybridoma
technology, DNA-based immunization, phage display libraries, and transgenic animals [104–106]. In
clinical settings, monoclonal antibodies or antibody-derived fragments are often utilized to address
extracellular targets, such as cell surface receptors with intracellular tyrosine kinase activity, and
thereby block intracellular signaling cascades [107]. However, the identification and production of
these antibodies is laborious and could become very expensive [108]. Moreover, the performance of
the same antibody tends to su↵er from batch to batch variations.
Antibodies and antibody-derived fragments typically cannot pass the plasma membrane, but
can be delivered into or expressed inside cells [109, 110]. The lack of cell permeability limits the ap-
plication of antibodies as intracellular protein kinase inhibitors. To date, only few antibody-derived
inhibitors were used in eukaryotic cells to inactivate oncogenic kinases [110, 111].
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Peptide inhibitors are often identified based on specific recognition sequences or docking domains
found in binding partners. Alternatively, peptide-based inhibitors can be identified by screening
assays [112]. Peptides that copy the motif surrounding the phosphoacceptor site have the potential
to act as substrate competitive inhibitors. Peptides that are derived from the docking domains
of cognate binding partners prevent phosphorylation without grossly a↵ecting the kinase activity
[113].
Peptides have been successfully used as kinase inhibitors inside eukaryotic cells [113, 114]. How-
ever, the application of peptides as kinase inhibitors is not always successful. This likely results
from large surface areas that are covered by protein-protein-interactions (approximately 1600 ±
400 A2), whereas smaller surface area can be covered by a peptide sequence [115]. Furthermore,
the intracellular application of peptides is challenging because peptides do not cross cell mem-
branes readily and require the addition of hydrophobic entities, such as fatty acids, or the use of
protein transduction domains, such as the nuclear localization signal sequence of NF-kappaB p50
[114, 116, 117].
3.3 Aptamers
An extremely promising alternative class of molecules that might overcome the limitations of small
molecule- or biological-based approaches are aptamers. Aptamers are short, single-stranded oligonu-
cleotides (ssRNA and ssDNA) that can bind to target molecules specifically by adopting complex
two and three-dimensional structures [118].
Aptamers can recognize a broad variety of target molecules, such as organic dyes [119], amino
acids [120], peptides [121], proteins [122], and viruses [123] to whole cells [124]. The dissociation
constants of aptamer-target interactions are comparable to those of antibodies and can reach the
picomolar range [125]. Similar to small molecule inhibitors, aptamers are produced by chemical
synthesis with extreme accuracy and reproducibility [108].
Aptamers often reveal remarkable specificity in discriminating between structurally similar
molecules, such as theophylline and ca↵eine [126], or homologous proteins isoforms [127]. The
often highly specific interaction between aptamers and their targets results from structure compat-
ibility and non-covalent interactions, including stacking of aromatic rings, electrostatic forces, van
der Waals forces, and hydrogen bonds [128].
High-a nity aptamers have been identified against a broad variety of protein families, includ-
ing cytokines, kinases, proteases, kinases, cell-surface receptors and cell-adhesion molecules [129].
Because of their size, aptamers are often capable of modulating the function of their target protein
by blocking a single domain of a protein while leaving the remainder of the protein functional [130].
Thus, aptamers represent an attractive opportunity to elucidate the function of kinase targets that
are otherwise not accessible through specific small molecules.
3.3.1 SELEX
Most aptamers derive from an iterative in vitro selection process, termed “Systematic Evolution of
Ligands by EXponential enrichment” (SELEX) [131, 132]. During a classical SELEX experiment
(Figure 3.5), a random sequence library (or pool) of 1014-1015 ssDNA or ssRNA molecules of up
to 100 nucleotides in length, is employed. The random sequence region is flanked by constant
sequences required for primer annealing and enzymatic amplification [133, 134].
In the case of RNA SELEX, a library of ssRNA molecules is prepared by in vitro transcription
of double-stranded DNA (dsDNA) templates, usually using recombinant T7 RNA polymerase.
The initial ssRNA library is then exposed to target molecules. By removing unbound molecules,
sequences that bind with high a nity to the target molecule can be recovered. After RT-PCR and
in vitro transcription, the SELEX library is subjected to the next selection round [135].
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Figure 3.5: SELEX. Schematic representation of the SELEX process.
After additional rounds of selection with increasing selection pressure, the diversity of the SE-
LEX library decreases and candidate aptamers are enriched. As a consequence, the a nity of the
enriched library increases during successful SELEX experiments. A typical SELEX is conducted
until no further change in a nity can be observed. The final SELEX round is then cloned and se-
quenced. Monoclones are then grouped into families according to homology in their random region.
Lastly, putative aptamers are tested for binding a nity and specificity [134].
Notably, SELEX against proteins is not limited to full length proteins but can also be applied
to peptides and protein domains [136]. While traditional SELEX techniques require a soluble, pure
form of the target protein [137], newer methods have been developed to identify aptamers in a
complex mixture, such as whole-cells [138] or living animals [139, 140]. Nowadays, automated plat-
forms and massive sequencing techniques enable high-throughput parallel selections of aptamers
to several protein targets at once [141, 142]. Hence, aptamers can be easily obtained and used to
elucidate the function of a defined protein or protein domain.
3.3.2 Chemical modification of aptamers
While the activity of unmodified RNA (and DNA) aptamers is often suitable for in vitro experi-
ments, aptamer use for cellular applications requires higher stability to prevent nuclease-mediated
degradation [129]. Therefore, a key factor in developing nucleic acids aptamers has been the intro-
duction of chemical modification to individual nucleosides.
Chemical modifications are accessible by enzymatic incorporation or chemical synthesis during
[143] or after the SELEX process [144–146]. The most widely used and commercially available mod-
ifications involve the substitution of the ribose ring with 2´- desoxy - amino pyrimidines [147–149],
2´- desoxy - fluoro pyrimidines [150, 151] and 2´- O - methyl ribose purines and pyrimidines [152]
(Figure 3.6). A study demonstrated that these types of modification can increase serum stability
from less than one second for a completely unmodified RNA aptamer to more than 81 hours [145].
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Figure 3.6: Chemical ribonucleotide modifications. Chemical structure of a guanine ribonu-
cleotide with A) 2´-amino, B) 2´-fluoro, or C) 2´-O-methyl modifications.
Chemical modifications are not only utilized to increase the serum stability of aptamers, they also
allow for the site-specific introduction of chemical functionalities which can be used for conjugation,
such as primary amines, thiol precursors, and aldehyde precursors [129, 153, 154]. For example, so-
called starter nucleotides can be utilized to facilitate the incorporation of chemical modifications at
the 5‘-end. By employing the starter nucleotide guanosine-monophosphorothioate (GMPS), RNA
aptamers can easily be modified with fluorescent dyes, biotin, or other functional entities [155].
The wealth of available chemical modifications enables the application of aptamers as reporters
for diagnostic applications, such as in vivo and in vitro imaging [156], or histochemical staining
[157]. Moreover, chemical modifications support the capability of aptamers for many di↵erent cell-
targeting approaches [158–163]. Among them, one elegant application demonstrated the generation
of phototoxic aptamers for the targeted photodynamic therapy of specific cancer cells [164–166].
Aptamers that are selected against cell surface proteins specifically expressed only on the surface
of cancer cells can be modified at their 5´-ends with chlorin e6, a photodynamic agent. Upon
internalization into the tumor cells, light-activated cytotoxicity then induces cancer cell-specific
killing.
3.3.3 Intramers
Aptamers do not only have the potential to target proteins for in vitro or extracellular applications.
It has become increasingly evident that aptamers can retain their ability to modulate the biological
function of their targeted protein inside cells [167, 168].
In 1990, a pioneering study by Sullenger and colleagues reported the use of small structural
RNAs as a new approach for inhibiting proteins and enzymes within cells [169]. Sullenger and co-
workers could demonstrate that decoys of a small HIV RNA region, called TAR, could be used to
inhibit HIV virus replication in cellular models. This study paved the way for the use of aptamers
as so-called intramers to interrupt, modulate, or define the functions of a wide range of target
proteins within cells [167].
Aptamers cannot readily cross cell membranes. Nevertheless, the introduction of aptamers into
cells can easily be facilitated. To this end, the transfer of the genetic information required to
synthesize an RNA aptamer within the target cell itself can be achieved, for example, by employing
expression plasmids [170–179], or by utilizing virus-based approaches (adeno- [180, 181], vaccinia
[182, 183], or lenti virus [184] ).
For intracellular expression, the aptamer sequences are often expressed between flanking regions
or as multivalent constructs to stabilize the aptamers within the cytoplasm [185]. To achieve this,
the aptamers are fused to self-cleaving ribozymes, aberrantly spliced mRNAs, tRNAs, or embedded
into U6 small nucleolar RNA [175, 184, 185].
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Furthermore, several studies have shown that DNA or RNA aptamers can directly be delivered
into the cytosol by microinjection [186], in the context of liposomes [187–190], or by employing
nanoparticles [191] (Figure 3.7).
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Nucleus
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Figure 3.7: Introduction of aptamers into cells. For intracellular applications, aptamers can
be introduced into cells with a variety of methods, including A) lipofection, B) expression vectors, C)
microinjection, or D) viral delivery vectors.
3.3.3.1 Intramers against nuclear targets
Many examples have shown that aptamers can inhibit endogenous protein targets in the nucleus
and, thus, can act as antagonists for nucleic acid binding proteins [168]. Among these aptamers,
Ishizaki et al. identified an unmodified-RNA aptamer that blocked the DNA-binding activity of the
transcription factor E2F with high a nity and inhibited fibroblast proliferation when microinjected
into cells [186]. Subsequently, Martell and co-workers selected for a high a nity chimeric tRNA-
E2F1 aptamer construct that would facilitate gene therapy approaches. The newly selected aptamer
inhibited E2F1-mediated transactivation by up to 80% in human HEK 293 cells [171].
Another interesting example described the e↵ect of intramer expression in an animal model
[192]. The target is Drosophila melanogaster B52 protein, a factor which is essential for pre-mRNA
splicing [193]. The expression of B52 below or above certain levels induces developmental defects
or lethal phenotypes [194]. Developmental e↵ects caused by overexpression of B52 could be rescued
by expression of a pentameric variant of the aptamer [192].
One of the best examples of the intracellular ability of aptamers as a tool to study biological
functions of proteins or protein domains was demonstrated with an aptamer that targets the p50
subunit of the transcription factor NF-kappa B [195]. NF-kappa B plays an essential role in inflam-
mation, innate immunity, and cancer [196]. The RNA aptamer was shown to compete with DNA
for binding to the transcription factor [195]. Intracellular expression of the NF-kappa B aptamer
under the control of the RNA polymerase III U6 promoter resulted in the inhibition of constitutive
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NF-kappa B-mediated gene transcription in mammalian cells and cell growth defects in xenografts
which were not observed with a non-binding negative control RNA [181]. Moreover, the inhibitory
e↵ect of the aptamer could be reversed by the addition of a complementary RNA sequence (an-
tidote). On the basis of these results, Mi and co-workers used the aptamer as a research tool to
determine whether the tumor suppressor protein p53 is required for the resistance to doxorubicin
in non-small cell lung cancer [180].
3.3.3.2 Intramers against targets in the cytoplasm
A number of studies further demonstrated that intramers can be used inside the cytoplasm to
elucidate biological activities of target proteins or protein domains [168].
Blind et al. selected RNA aptamers against the intracellular domain of the  2 integrin LFA-1, a
transmembrane protein that is important to the regulation of cell adhesion to intercellular adhesion
molecule-1 (ICAM-1) [182]. Employing a T7 polymerase-controlled expression system enabled the
transcription of the intramers in the cytoplasm. More importantly, intramer expression translated
into a biological e↵ect, as measured by reduction of cell adhesion to immobilized ICAM-1.
Mayer et al. applied the same T7 polymerase-controlled expression system to investigate the
function of the Sec7 domain of cytohesin1 [183], a small guanine nucleotide exchange factor (GEF)
for ARF GTPases [197]. Cytohesin1 inhibition in vitro by the RNA aptamer M69 correlated with
the modulation of cell adhesion and cytoskeletal rearrangement in Jurkat T-cells, revealing the
important role of cytohesins in T-cell movement [183].
Because aptamer M69 interacted with both cytohesin1 and cytohesin2 [183], Theis et al. selected
a new RNA aptamer, termed K61, which specifically targets cytohesin2 [188]. Their work revealed
that intramers have the capacity to inhibit protein function without utilizing expression vectors.
Transfection of the unmodified RNA aptamers K61 and M69 into human HeLa cells inhibited
transcriptional activation through the serum-response element (SRE) promotor. Moreover, Theis
and co-workers demonstrated that aptamers M69 and K61 induced specific down-regulation of
the Erk1/2 MAP kinase pathway by investigating the phosphorylation status of Elk-1. Elk-1 is
a transcription factor which promotes survival, cell division, and motility through regulation of
immediate-early genes, such as c-Fos and c-Myc [198].
Taken together, these examples clearly show that intramers are potent and specific tools to study
the function of closely related proteins or individual domains within distinct cellular compartments.
Furthermore, intramers can also be adapted as biosensors to analytical applications in order to
monitor cellular metabolites [199, 200], proteins [201], or RNA [202–205].
3.3.4 Aptamer-displacement assay
Even though aptamers can be applied as modulators of protein function in cell-based assays and
even in vivo studies [167, 168], they can also be used to facilitate the identification of putative
small molecule drug candidates in aptamer-displacement assays [206]. Aptamer-displacement as-
says are based on the competition of an aptamer by a small molecule. Since aptamers that bind
to proteins are often specific and are capable of modulating protein function, small molecules iden-
tified by aptamer-displacement screening often exhibit similar inhibitory properties on the same
target proteins [206]. Hence, aptamer-displacement assays o↵er a promising alternative to inhibitor
identification by functional assays because binding partner-dependent interactions are not required.
A displacement assay of aptamer M69 enabled the identification of the small molecule SecinH3
as a novel inhibitor for cytohesins [206]. SecinH3 inhibited both insulin receptor [207] and EGF
receptor signaling [189], and inhibited the proliferation of cancer cell lines [189].
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3.4 Aptamers as protein kinase inhibitors
Aptamers that target receptor tyrosine kinases can be utilized to prevent subsequent intracellular
downstream signaling in a similar way to monoclonal antibodies. Recently, Li and colleagues [208]
described an aptamer which binds to cells expressing the epidermal growth-factor receptor (EGFR).
By outcompeting EGF from binding to the receptor, the aptamer blocked receptor autophospho-
rylation, and prevented proliferation of tumor cells.
Until now, no intramer has been reported to target kinase activity within cells. Nevertheless,
several very promising aptamers that recognize and inhibit protein kinase C (PKC) [127], G protein-
coupled receptor kinase 2 (GRK2) [209], and extracellular signal-regulated kinase 2 (Erk2) [210]
have been described. Remarkably, most of these aptamers recognize the ATP-site, but neverthe-
less, exhibit high specificity. Since RNA aptamers against GRK2 and Erk2 play a fundamental role
during this thesis, special emphasis is put both on their identification and the physiological role of
the kinases in the following sections.
3.4.1 G protein-coupled receptor kinase 2 (GRK2)
G protein-coupled receptor kinases (GRKs) and arrestins participate in the regulation of G protein-
coupled receptor (GPCRs), a large family of membrane receptors of key physiological and pharma-
cological importance [211, 212].
Figure 3.8: Simplified model of  -adrenergic receptor and GRK2 signaling in the my-
ocardium. 1) Upon agonist binding,  -adrenergic receptors activate adenylyl cyclase (AC) and cyclic
adenosine monophosphate (cAMP) production through coupling to heterotrimeric G proteins to enhance
cardiac inotrophy and chronotrophy. 2) G protein-coupled receptor kinase 2 (GRK2) phosphorylates
the activated receptor to attenuate signaling. 3) Once phosphorylated, the receptor binds to  -arrestin.
 -arrestins modulate intracellular GPCR signaling and promote the endocytosis of the receptor, leading
to its dephosphorylation and degradation or recycling back to the plasma membrane. CA = cate-
cholamines, bAR =  -adrenergic receptor, p = phosphate group, GRK2 = G protein coupled-receptor
kinase 2,    = G  -subunits, AC = adenylyl cyclase, PKA = protein kinase A, ATP = adenosine
triphosphate, cAMP = cyclic adenosine monophosphate. Taken from [211].
GRK2 and the  -adrenergic receptor ( -ARs) family of GPCRs are crucial to the regulation
of heart rate and myocardial contraction in response to catecholamines (epinephrine and nore-
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pinephrine) [213, 214]. Upon activation,  -ARs undergo a conformational change, which enables
the activation of e↵ector proteins (e.g. adenylyl cyclase, phospholipases) via heterotrimeric G pro-
teins. In turn, cAMP accumulates within the cells, which leads to the activation of protein kinase
A (PKA). PKA phosphorylates calcium-recognizing proteins and some myofilament components.
Thereby, it promotes positive changes in cellular metabolism as well as inotropic and chronotrophic
responses [212, 215].
GRK2 is recruited to the agonist-occupied, activated  -AR through interaction with subunits
of heterotrimeric G-proteins (G   subunit) and phosphatidylinositol (4,5)-bisphosphate (PIP2)
[216, 217]. Subsequently, GRK2 phosphorylates several residues inside the cytosolic component
of the receptor [218]. The phosphorylation enhances the receptor´s a nity for  -arrestin adaptor
proteins.  -arrestin binding leads to the receptor´s uncoupling from G proteins and attenuates the
receptor´s surface signaling [219]. Furthermore, arrestin binding promotes receptor internalization
via clathrin-mediated endocytosis and elicits G protein-independent signaling pathways [220, 221].
Inside the endosomal compartment,  -ARs are dephosphorylated and then either recycled back to
the plasma membrane or degraded [220].
In addition to its classical role in mediating GPCR phosphorylation and arrestin binding, GRK2
has emerged as a key regulator of diverse signaling pathways and displays a very complex interac-
tome. GRK2 has been associated with the modulation of signal transduction pathways by inter-
acting with G↵ and G -subunits and non-GPCR substrates, including receptor tyrosine kinases,
cytoskeletal proteins, and transcription factors [211].
3.4.1.1 GRK2 as a drug target
Over the last two decades, GRK2 has emerged as a promising target for heart failure therapy [222].
Heart failure is the leading cause of mortality in Western countries [212]. It is associated with a loss
of  -AR density which results in impaired cardiac function, rendering the heart incapable to pump
enough blood to meet the requirements of the body [214, 223]. At early stages of heart disease,
GRK2 activity is often found to be up-regulated [224–227]. The postulated therapeutic potential of
cardiac-specific GRK2 inhibition was demonstrated with various transgenic approaches in a variety
of animal models [228–231]. Deregulated GRK2 signaling has also been linked to other human
pathologies, such as Alzheimer’s disease [232], granulose cell tumors [233], and inflammation [234].
Elucidating the complex GRK2 interactome could contribute significantly to the development of
novel therapies for all these diseases. Serine/threonine kinase inhibitors that are known to inhibit
GRK2 activity include the natural products staurosporine [235], sangivamycin [236], and balanol
[237]. However, their application as research tools is di cult because these inhibitors are known to
target multiple kinases. Recently, several lead inhibitory compounds for the GRK2/GRK3 family
were developed by Takeda Pharmaceuticals (Figure 3.9), [238]. These compounds target the active
site and inhibit GRK2/GRK3 activity [239].
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Figure 3.9: Inhibitors of GRK2. Chemical structures of two small molecule GRK2 inhibitors that
were discovered by Takeda Pharmaceutical Company LTD [238].
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3.4.1.2 RNA aptamers as inhibitors of GRK2
Specific and potent inhibitors for GRK2 were not available for a long time. Several decades ago,
natural products (see above), peptides, and the synthetic compound suramin were the only available
inhibitors of GRK2 activity [240–243]. Due to low specificity, low potency, or cytotoxic e↵ects, these
substances revealed limited usefulness as tools for the characterization of GRK2 activity [209, 244].
The lack of specific inhibitors led to the development of a novel molecular class of GRK2
inhibitors for the functional characterization of GRK2 activity. In 2008, Mayer and colleagues
described the identification and characterization of the RNA aptamer C13 [209]. C13 was observed
to bind to GRK2 with an a nity of 78.2 ± 2.6 nM.
Aptamer C13 was isolated from an automated in vitro selection procedure. For their selection,
Mayer et al. applied a RNA library consisting of a structurally predefined stem region of 13
nucleotides that flanked a 20 nucleotide random region (Figure 3.10A). Additional sequences were
included at the 5´- and 3´-ends to facilitate reverse transcription and PCR amplification. C13 was
shown to reflect most of the structural constrains of this library (Figure 3.10B). In accordance with
the library design, C13 could easily be truncated by excluding the primer binding sites (Figure
3.10C). The resulting aptamer, termed C13.51, revealed similar a nity for GRK2 as C13 (101.2 ±
7.2 nM).
U
C
G
A
GU
U
C
G
G
G
U
A
G
C
A
C
A
G
A
CCA
U
ACGG
GAG GA A
A
A
CU
U
G
U
G
U
C
A
A
C
C
C
G
G
G
G
C
5‘-
.
..
A
C
G
AUC
GG
.AA
CUA GAU
AGU
A
G A
AGGAGAG
G
G
CUUUCGUGG
CCC A
A
G
G
A
.
20
40
50
60
70
90
C13
U
U
C
G
G
G
U
A
G
C
A
C
A
G
A
CCAU
ACGG
GAG GA A
A
A
CU
U
G
U
G
C
A
A
C
C
C
G
G
G
.
..
40
50
60
70
G
G C
G.U
C13.51
B
5´ 3´
A
N20
stem
5‘-
Figure 3.10: In vitro selection of aptamer C13. A) Design of the constrained RNA library
comprising a 13-nt stem structure with a central A-A mismatch and a 20-nt random region (N20,
bold). Additional sequences were included at the 5´- and 3´-ends to facilitate reverse transcription
and PCR amplification. B) Sequence of the selected aptamer C13 and C) its truncated variant C13.51.
The nucleotide numbers of C13.51 were adapted from C13. Nucleotides in bold represent the selected
sequence. Modified from [209].
Aptamer C13 had been the most potent inhibitor of GRK2 kinase function reported so far.
It inhibited GRK2 activity in vitro with an IC50 value of 4 nM. Binding studies with the kinase
domain of GRK2 and ATP-competition assays suggest that the aptamer acts as an ATP-competitive
inhibitor.
More importantly, however, was the finding that this ATP-competitive aptamer revealed high
specificity and thus, represents a promising research tool. C13 demonstrated no or only insignificant
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activity towards ten tested protein kinases from distinct kinase groups according to Manning et al.
(Section 3.1.3 [7]). The aptamer was also capable of discriminating between kinases from the GRK
superfamily, as inhibition of GRK5 activity was observed at a 20-fold higher IC50 value [209].
3.4.2 Extracellular signal-regulated kinase 2 (Erk2)
Extracellular signal-regulated kinase 2 (Erk2) and the highly homologous kinase Erk1 belong to
the mitogen-activated protein kinase (MAPK) superfamily [245]. The MAP kinase superfamiliy
includes the Erk family, the p38 MAP kinase family, and the c-Jun N-terminal kinase (JNK) MAP
kinase family [245].
The Erk1/2 MAP kinase pathway promotes cell growth, proliferation, survival, di↵erentiation,
motility, and angiogenesis [246, 247]. The pathway becomes activated in a variety of cell types by
mitogenic and other stimuli, including growth factors [248], Ca2+ influx [249], cytokines, osmotic
stress, and activated G-protein coupled receptors [250].
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Figure 3.11: Simplified model of the Erk1/2 signaling cascade. Upon binding of EGF (Protein
Data Bank ID code 1EGF) or other growth factors, receptor tyrosine kinases (e.g. EGF receptors) acti-
vate the Erk1/2 MAP kinase signaling cascade via the GTPase Ras. Ras activates the first MAP kinase
Raf. Raf activates the second MAP kinase Mek1/2. Mek1/2 are the activating kinases for Erk1/2. Ac-
tivated Erk1/2 catalyze the phosphorylation of targets in the cytosol or in the nucleus. EGF: epidermal
growth factor, EGFR: epidermal growth factor receptor, Mek: Mitogen-activated protein kinase kinase,
Erk: extracellular signal-regulated kinase, p90: p90 ribosomal S6 kinase, p: phosphorylated residue.
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Erk1/2 activation in response to growth factors is induced by receptor tyrosine kinases, such as
the epidermal growth factor receptor (EGFR, Figure 3.11) [251]. Typically, epidermal growth factor
(EGF) binding to the EGF receptor induces dimerization of two receptor monomers and autophos-
phorylation of specific tyrosine residues within the C-terminal domain [252]. These phosphorylated
residues generate binding sites for adaptor proteins, such as growth factor receptor-bound protein
2 (GRB2) [253]. GRB2 then recruits the guanine nucleotide exchange factor SOS to the plasma
membrane. SOS, in turn activates the membrane-bound GTPase Ras by catalyzing the exchange of
GDP to GTP [254]. In its GTP-bound state, Ras recruits inactive Raf kinases from the cytoplasm
to the plasma membrane and activates their serine/threonine kinase function [255]. Upon activa-
tion, Raf activates the mitogen-activated protein kinase kinases 1 and 2 (Mek1/2). Mek1/2, in
turn, catalyze the activation of their sole e↵ectors Erk1 and Erk2 by phosphorylating the activation
loop residues Thr202 and Thr204 of Erk1, and Thr185 and Tyr187 of Erk2 [247].
Erk1 and Erk2 share 84% sequence identity and only little is known about their functional
di↵erences [256, 257]. They are activated in parallel [258] and were found to target the same
substrates [259]. Activated Erk1/2 catalyze the phosphorylation of serine and threonine residues on
over 160 substrate proteins [260, 261]. Most activated Erk1/2 molecules translocate into the nucleus
and only a smaller portion of Erk1/2 as well as Mek1/2 and Raf molecules migrate into distinct
subcellular compartments, including mitochondria, endosomes, plasma membrane, cytoskeleton,
and Golgi apparatus, where they control specific functions [262, 263].
Inside the nucleus, Erk1/2 phosphorylate and regulate various transcription factors, including
Elk-1, c-Myc, and c-Fos [261, 264], and promote changes in gene expression [265, 266]. In addition,
Erk1/2 can directly regulate transcriptional repression and chromatin remodeling [267]. Erk1/2
substrates in the cytoplasm include phosphatases, kinases, cAMP phosphodiesterase 4 (PDE4),
cytosolic phospholipase A2 (cPLA2), cytoskeletal proteins, apoptotic proteins, ion channels, and
regulatory and signaling molecules [245, 261].
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3.4.2.1 Erk1/2 signaling in neurons
In the central nervous system (CNS), Erk1/2 play an important role in normal proliferation and
di↵erentiation [245]. Moreover, accumulating evidence has shown that the Erk1/2 signaling pathway
is associated with learning and memory storage in the mammalian brain [268].
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Figure 3.12: Activation of Erk1/2 signaling in response to synaptic signaling. Calcium
influx, either through NMDA (N-methyl-D- aspartate) - type glutamate receptors (NMDARs) or voltage-
gated calcium channels (VGCCs) triggers the activation of Erk1/2 signaling. Erk1/2 phosphorylates
extranuclear targets such as the voltage-dependent potassium channel KV 4.2. Mek: Mitogen-activated
protein kinase kinase, Erk: extracellular signal-regulated kinase, p: phosphorylated residue. Modified
from [269].
Activation of the Erk1/2 signal transduction cascade in response to synaptic signaling is initiated
by calcium influx into the postsynapse through synaptic N-methyl-d-aspartate receptors (NMDARs)
[270, 271] or voltage-gated calcium channels (VGCCs, Figure 3.12) [272, 273]. In neurons, Erk1/2
control postsynaptic 5 - methyl - 4 -isoxazolepropionic acid (AMPA) receptor tra cking and inser-
tion [274–276], outgrowth and stabilization of postsynaptic spines [277, 278], and activity-dependent
translation and targeting of mRNAs [278–280]. Furthermore, Erk1/2 catalyze the phosphorylation
of voltage-dependent potassium channel KV 4.2 subunits (Figure 3.12) [281]. Phosphorylation by
Erk1/2 was described to inhibit the channels activity [282] and to decrease the potassium current
[283].
In addition to the regulation of cytosolic targets, Erk1/2 propagate signals into the nucleus.
Erk1/2, or kinases activated by Erk1/2, regulate gene expression by phosphorylating transcription
factors, such as c-Jun and c-Fos [284–288] or CREB [289].
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3.4.2.2 Structure and functional domains of Erk2
Erk1/2 have a bi-lobed kinase structure with conserved residues for ATP-binding and catalysis as
described for a typical protein kinase in Section 3.1.3 and shown in Figure 3.4.
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Figure 3.13: Extracellular signal regulated kinase 2 (Erk2). Ribbon representation of the A)
inactive or B) active conformation of Erk2 (Protein Data Bank ID codes 1ERK, 2ERK). Structural
features are annotated. The glycine-rich loop and the activation loop residues are marked in green and
cyan, and D-site recruitment site (DRS) and F-site recruitment site (FRS) residues are annotated in
blue and red, respectively. The activation loop phosphorylation site residues Thr185 and Tyr187 are
labeled in pink. In inactive Erk2 (A), the two lobes of the kinase domain are rotated away from each
other. Once Erk2 becomes phosphorylated (B), the two lobes of the kinase domain rotate 5.4  closer.
The activation segment refolds and the conserved aspartate side chain of the DFG sequence faces into
the ATP-binding pocket and coordinates Mg2+ [290]. In addition, the aC-helix of the small kinase
lobe rotates and becomes a part of the active site by positioning a conserved lysine residue required for
ATP-binding and catalysis [290, 291]. Conformational changes also include the docking domains and
MAP kinase insert region.
Erk1/2 possess two independent docking domains to interact with substrate proteins, activat-
ing kinases, or inactivating phosphatases (Figure 3.12) [245]. The so-called D-site recruitment site
(DRS) is located opposite of the catalytic cleft and is comprised of negatively charged and hy-
drophobic components. The F-site recruitment site (FRS) is located near the activation segment
and catalytic cleft.
The docking sites of interacting proteins are interspersed. Some binding partners contain either
a D-docking site or F-docking site, both sites or none of these sites [292]. For example, phospho-
rylation of the transcription factor Elk-1 requires binding of Erk2 to both D- and F-docking sites
[293] whereas p90-RSKs and Erk1/2 interact via a D-docking site motif [294].
Another functional domain of Erk2, the MAP kinase insert, is located at the C-terminus (Figure
3.12). The MAP kinase insert is a sequence insertion that distinguishes the MAP kinase superfamiliy
from other kinases [245]. In Erk2, this domain has been associated with diverse kinase activity -
dependent and - independent functions, including the interaction of Erk2 with regulatory proteins
[295, 296] or e↵ectors [297, 298], nuclear translocation [299, 300], or DNA-binding activity [301].
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A study from Robinson et al. demonstrated that the MAP kinase insert is also involved in the
activation of Erk2 by Mek1 [295]. They demonstrated that point mutations within the MAP kinase
insert of Erk2 abolished the interaction of Erk2 with Mek1 in a yeast-two-hybrid screen and resulted
in reduced activation after over-expression of constitutive Mek1 inside cells.
3.4.2.3 The Erk1/2 pathway as a drug target
Erk1/2 are versatile protein kinases that regulate many cellular functions: They are crucial for
the regulation of proliferation, di↵erentiation and survival [246, 247] and some forms of neuronal
plasticity in the central nervous system [302, 303]. However, aberrant Erk1/2 activation is also
associated with many human pathologies, such as cancer [246, 247] or neurodegerative diseases
[302]. Erk1/2 activity is upregulated in all of these cases, suggesting that direct inhibition of
Erk1/2 might be beneficial for therapeutic applications.
Accordingly, the Erk1/2 MAP kinase pathway is considered an important therapeutic target,
in particular for cancer therapy. In more than 30% of all human malignancies, amplification or
gain-of-function mutations in genes that encode for receptor tyrosine kinases, Ras and/or Raf are
potent drivers of oncogenesis [304]. Surprisingly, amplifications or gain-of-function mutations in
genes encoding for Erk1/2 are absent in cancer [305].
In recent years, several successful therapeutic strategies have been identified for cancer therapy.
Thereby, Erk1/2 signaling is inhibited either by targeting cell surface receptors or proteins upstream
of Erk1/2 [306]. In contrast, the development of direct inhibitors of Erk1/2 has been less successful.
Most available Erk1/2 inhibitors are ATP-competitive small molecule inhibitors with various degrees
of specificity [307].
In addition, non ATP-competitive Erk1/2 inhibitors that target the a specific part of the DRS -
docking site on either active Erk2 or inactive Erk2 have been described [308, 309]. These inhibitors
revealed the intriguing potential of Erk1/2 domain-specific inhibition in cellular studies [307] and
model organisms [308, 309].
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Figure 3.14: Small molecule Erk1/2 inhibitors. Chemical structures of the DRS - docking domain
inhibitor 76 [307] and the ATP-competitive inhibitor FR180204 [310].
3.4.2.4 RNA-based Erk1/2 inhibitors
In 2001, Seiwert and colleagues identified the first RNA aptamers that recognize Erk1/2 [210].
They performed a nitrocellulose membrane-based in vitro selection experiment to identify RNA
aptamers that discriminate between the active, diphosphorylated and inactive, non-phosphorylated
conformation of Erk2. In order to remove RNA molecules that recognize epitopes unique to both
conformational states of Erk2, they included additional negative selection steps using inactive Erk2
in the SELEX process. Their SELEX approach yielded two di↵erent families of RNA aptamers,
coined “family I” and “family II” aptamers. The family II aptamer bound with a KD of 10 nM to
the active conformation of Erk2 and with 10-fold lower a nity to the inactive variant. Moreover,
the familiy II aptamer was shown to potently inhibit Erk2 activity and to recognize Erk2 in an ATP-
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dependent manner. Seiwert and colleagues were able to truncate this aptamer from 135 nucleotides
down to 63 nucleotides. The truncated aptamer, termed ”TRA”, retained its functionality [210].
In contrast, the simultaneously enriched family I aptamers revealed similar a nity (KD values
of approximately 2 nM) towards inactive and active Erk2 and inhibited Erk2 activity in a substrate-
dependent manner. A truncated version could not be generated for this aptamer. Most remarkably,
both family I and II aptamers exhibited high specificity for Erk2 and the closely related MAP kinase
Erk1 and did not inhibit the activity of other MAP kinases of the p38 and JNK superfamilies.
Vaish and colleagues utilized these Erk2-targeting aptamers for the design of allosteric ribozymes
[311]. Allosteric ribozymes are RNA enzymes whose activity is modulated by the binding of an
e↵ector molecule to an aptamer domain, which is located apart from the ribozymes active site.
Thus, they act as precise molecular switches which are controlled by the presence or absence of a
specific e↵ector [312, 313]. By utilizing the described Erk2-binding aptamers, Vaish and colleagues
designed allosteric ribozymes that were controlled by the active or inactive conformation of Erk2
[311]. These allosteric ribozymes enabled the detection of active or inactive Erk2 in vitro and in
mammalian cell lysate. The latter, however, was only described for recombinant, inactive Erk2 and
not for endogenous Erk2. Notably, the allosteric ribozyme for active Erk2, whose Erk2-recognizing
domain is based on the sequence of the TRA aptamer, was not employed within cell lysate.
3.4.2.5 In vitro selection of novel Erk2-binding aptamers
The Erk2-inhibiting aptamer TRA (Figure 3.15A) was supposed to be used as an Erk2 inhibitor
in cell-based assays [314]. However, TRA was selected in Hepes bu↵er in the absence of any
monovalent cations [210]. Binding studies performed by Mayer and co-workers implicated that the
binding of TRA was a↵ected in a high salt containing phosphate bu↵er (PBS, supplemented with
3 mM MgCl2) [314]. Since monovalent cations, such as potassium ions, are highly abundant within
the cell, this sensitivity to ionic conditions would likely impair the intracellular application of TRA.
In order to identify an Erk2-binding aptamer that stills shares the same favorable properties as
the TRA aptamer, but would be less susceptible to di↵erent ion concentrations, a re-selection with a
partially randomized library based on the sequence of TRA was performed prior to this thesis [314].
In 85% of all cases (Figure 3.15A), the library had the original nucleotide at a defined position as
in TRA, but the remaining three nucleotides were at 5% probability each [314]. This library was
subjected to an automated in vitro selection protocol targeting active, diphosphorylated Erk2. To
optimize the binding to Erk2 under high ionic conditions, PBS bu↵er supplemented with 3 mM
MgCl2 was chosen as the selection bu↵er. This bu↵er has been shown in previous experiments to
give rise to aptamers that are adaptable to intracellular applications [182, 183].
The most promising aptamer derived from this selection was aptamer C5 [314]. Compared to
TRA, C5 bears twelve mutations located mainly in the central stem and upper bulged region (Figure
3.15B). Based on secondary structure predictions and TRA-homology modeling, these mutations
are supposed to lead to a stabilization of the central stem and allow building in additional base
pairs in the upper bulged region.
An additional selection was performed in order to obtain an aptamer that recognizes epitopes
present of both the active and inactive conformation of Erk2 [314]. In contrast to the previous
SELEX which yielded aptamer C5, a completely randomized library was utilized and inactive Erk2
was employed as the target. The selection was again performed in PBS bu↵er, supplemented with
3 mM MgCl2, and yielded aptamer C3 (Figure 3.15C).
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Figure 3.15: RNA aptamers targeting Erk2. Proposed secondary structure of the RNA aptamers
A) TRA, B) C5, and C) C3. A) The sequence of TRA was adapted according to [210]. Nucleotides
that were randomized and utilized in a doped library for reselection are highlighted in bold letters. B)
Reselection of the doped library against active Erk2 yielded the RNA aptamer C5. Secondary structure
prediction of the aptamer C5 shown is based on the structure of TRA. Nucleotides initially randomized
are depicted in bold letters. Nucleotides that di↵er from TRA are highlighted in green. C) Secondary
structure prediction of C3.
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4 Aim of this study
The aim of this study was to investigate the potential of RNA aptamers as a novel class of selective
protein kinase inhibitors for chemical biology research.
Within the past decades, low molecular weight compounds have often been used as protein
kinase inhibitors. Most of these inhibitors block kinase activity by interfering with ATP-binding.
However, the evolutionary relatedness and structural conservation of the ATP-binding site often
lead to unforeseen cross reactivity, which limits their application as research tools.
Several very promising aptamers that recognize and inhibit protein kinase C (PKC) [127], G
protein-coupled receptor kinase 2 (GRK2) [209], and extracellular signal-regulated kinase 2 (Erk2)
[210] were described. In contrast to many low molecular weight inhibitors, these RNA aptamers
have been shown to inhibit the activity of their respective kinases with high specificity. Competi-
tive binding experiments with ATP, kinase activity assays, or binding studies with isolated kinase
domains provide strong evidence that these aptamers act by addressing the active site and thus
sterically prevent ATP from binding.
The residues that ATP-competitive inhibitors can interact with in the active site are highly
conserved among the kinome and the precise aspects of how ATP-competitive aptamers derive
their high specificity are yet unknown. Thus, the first part of this project sets out to examine the
molecular interaction of aptamer C13 and GRK2. Aptamer C13 is the most potent inhibitor of
GRK2 activity in vitro. GRK2 is involved in the regulation of G protein-coupled transmembrane
receptors and is associated with heart failure. Elucidating the precise determinants which contribute
to the high specificity of the aptamers may aid in the development of novel inhibitors.
The Erk1/2 MAP kinase pathway promotes cell growth and proliferation and has often been
found to be deregulated in human malignancies. Unfortunately, specific inhibitors for Erk1/2 are
still rare. An ATP-competitive RNA aptamer, coined TRA, represented one of the most promising
Erk2 inhibitors. It blocked the activity of the MAP kinase Erk2 with high a nity and specificity
in vitro. However, the binding of TRA to Erk2 was also a↵ected by ionic strength, which hampers
its application in cell-based studies. Therefore, two novel Erk2-recognizing aptamers, termed C3
and C5, were selected prior to this thesis.
In the second part of this thesis, the novel Erk2-recognizing aptamers C3 and C5 will be explored
to gain a refined biochemical understanding for their potential as specific protein kinase inhibitors.
In order to investigate the assessments of C3 and C5 in a more complex cellular system, their
sensitivity to ionic strength and specificity, will be investigated.
By recognizing di↵erent sites on the same protein kinase, aptamers can provide fundamental
insight into domain-specific protein functions. To analyze if the aptamers C3 and C5 can be utilized
as domain specific inhibitors, their putative binding sites and modes of actions will be identified.
Aptamers that interfere with protein kinase activity inside cells might aid in unravelling the
complex interplay between kinase signaling in health and disease. In the final piece of the project,
distinct cellular assays will be utilized to elucidate the ability of aptamers C3 and C5 to interfere
with Erk1/2 signaling within cells and to answer the question if aptamers can be employed as a
new class of molecular tools for chemical biology research.
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5 Results
This chapter describes the investigation of the potential of RNA aptamers as selective inhibitors for
the protein kinases G protein-coupled receptor kinase 2 (GRK2) and extracellular signal-regulated
kinase 2 (Erk2).
In the first part, the molecular determinants of the C13-GRK2 complex are investigated to elucidate
how ATP-competitive aptamers derive their high specificity (Section 5.1).
The second part of this chapter extends the concept of RNA aptamers as selective protein kinase
inhibitors towards the MAP kinase Erk2 and describes the characterization and validation of novel
Erk2-binding RNA aptamers C3 and C5 (Section 5.2).
Lastly, the ability of aptamers C3 and C5 to control intracellular kinase activity is evaluated (Section
5.3).
5.1 The co-crystal structure of aptamer C13 and GRK2
Specific GRK2 inhibitors are essential for therapeutic applications and chemical biology research.
At the moment, such inhibitors are rare (Section 3.4.1.1). An ATP-competitive RNA aptamer,
termed C13, represents one of the most potent and specific inhibitors of GRK2 [209].
In order to understand how this aptamer can derive its high specificity, the molecular deter-
minants of the C13-GRK2 complex were investigated. GRK2 participates together with arrestins
in the regulation of G protein-coupled receptors [211, 212]. Since aberrant GRK2 signaling has
been shown to contribute to the onset or progression of human pathologies, such as cardiovascular
diseases [214, 223], unraveling the molecular interaction can aid in the development of novel drug
candidates.
In order to elucidate the molecular determinants contributing to the specificity of aptamer C13,
co-crystal structures of the C13-GRK2 complex were obtained in collaboration with the lab of Prof.
Dr. John Tesmer, University of Michigan. Valerie Tesmer determined all crystal structures that
are shown for the C13-GRK2 complex in this chapter. This structural data was supported by bio-
chemical binding assays that were performed in parallel during this thesis.
Additional information about the C13-GRK2 complex was published in [315].
5.1.1 Structural determinants of GRK2 binding and selectivity in the
C13 aptamer
Full-length aptamer C13 and the truncated variant C13.51 revealed an a nity of 78.2 ± 2.6 nM and
101.2 ± 7.2 nM for GRK2 in filter retention assays, respectively [209]. The KD values represents
the equilibrium binding constant of the aptamer-protein complex. All filter retention assays were
performed at 37 C in selection bu↵er (PBS, 3mM MgCl2).
To determine the regions of C13 that are important for GRK2 binding and to shorten the
RNA sequence for crystallographic experiments, truncated versions based on the C13.51 variant of
the aptamer were synthesized and tested for their ability to bind to GRK2 or other GRK family
members (Figure 5.1).
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The interaction of GRK2 with truncated C13 variants was measured with flow cytometry using a
bead protein-RNA interaction assay. In this assay, GRK2 was biotinylated, coupled to streptavidin-
coated beads and incubated with increasing concentrations of 5´- Alexa 488-labeleld RNA at 4 C.
The beads were then passed through a flow cytometry and the amount of fluorescence bound to
the beads was quantified to calculate a KD value.
The half maximal inhibitory concentration (IC50) values for C13 variants were determined by
measuring the transfer of  -32P from ATP to rhodopsin at room-temerapture. Rhodopsin is a
natural substrate for GRK family members [316]. These experiments were kindly performed by V.
Tesmer (Tesmer lab, University of Michigan).
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Figure 5.1: RNA aptamer C13 and truncated variants. Proposed secondary structure model of
RNA aptamer C13 (A) and its truncated variant C13.51 (B) as described in [209]. Truncated variants
of C13.51, namely C13.28 (C) and C13.18 (D) were employed for structural assays. Nucleotde numbers
were taken from full-length C13.
Table 5.1: Binding and inhibitory properties of C13 variants.
Variants KD [nM] Temperature [ C] Activity/ IC50 [nM] Temperature [ C]
C13* 78.2 ± 2.6 37 4.1 nM ± 1.2 23
C13.51* 101.2 ± 7.2 37 n.d. 23
C13.28 1.2 ± 0.6 4 11 ± 4 23
C13.18 35 ± 5 4 220 ± 40 23
* Taken from Mayer et al. [209], n.d.: not described
30
5.1. The co-crystal structure of aptamer C13 and GRK2
One truncated variant of C13.51, C13.28, was designed by shortening the stem of the original
aptamer to only four Watson-Crick base pairs (Figure 5.1C). C13.28 had 60-fold higher a nity for
GRK2 than C13 (Table 5.1). This can be explained by di↵erences in the assay setups, in particular
the lower temperature which was used during the bead-based flow cytometry assays.
In addition, C13.28 inhibited GRK2 activity with identical potency as C13 (IC50 value 11 ± 4 nM,
Table 5.1). C13.28 also exhibited similar specificity properties as C13. It inhibited GRK6 activity
(IC50 210 ± 10 nM) and GRK1 activity (IC50 590± 160 nM) with more than 60 times lower potency
than C13.
C13.28 was further truncated down to 18 nucleotides (Figure 5.1D). The resulting aptamer,
C13.18, lacked a terminal stem and two residues from the 5´end of the nucleotide variable region.
C13.18 revealed a 35-fold lower a nity for GRK2 binding than C13.28 (Table 5.1).
In summary, these data indicate that these 18 nucleotides within the selected sequence of C13
are key for binding and inhibiting GRK2. The aptamers terminal stem seems to be required to
maintain its high potency.
5.1.2 C13 variants target the active site of GRK2
The structural models of the C13-GRK2 complexes were determined with C13.28 and C13.18. The
co-crystal structure of the C13.18-GRK2 complex was determined at a 3.5 Angstrom resolution
(Figure 5.2A):
Figure 5.2: C13.18 targets the active site of GRK2. A) C13.18 stabilizes a unique conformation
of the GRK2 kinase domain. The small lobe of the kinase domain in structures of apo-GRK2 (green;
PDB entry 2BCJ5) and C13.18-bound GRK2 (yellow) were superimposed to show the 8  rotation of the
large lobe. B) Proposed secondary structure of C13.18 based on the C13 aptamer. Nucleotides A49-C52
were modeled into the active site of GRK2 as described in [315] and are marked in cyan. C) C13.18
mimics ATP-binding within the kinase domain of GRK2. Nucleotides A49-C52 of C13 are marked in
cyan. ATP is shown in magenta.
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The RNA aptamer forms extensive interactions with the kinase domain which bury about 1,140
Angstrom2 of accessible surface area. The C13-GRK2 structure revealed that C13.18 binds into a
cleft formed between the large and small lobe of the kinase domain where the aptamer stabilizes a
unique conformation. In this conformation, the lobes of the kinase domain di↵er by 8  relative to
those in previously described structures of GRK2 and ATP [317, 318].
Electron density was obtained for nucleotides 47 to 52 of the C13.18 aptamer within the active
site of GRK2. As can be seen in Figures 5.2B,C, adenine 51 (A51) of C13.18 binds deep into the
active site of GRK2 where it overlaps with the AMP moiety of ATP. Moreover, the aptamer seems
to recapitulate specific contacts made by ATP within the active site, including hydrophobic contacts
to the base and hydrogen bonds to the ribose and adenine ring. Furthermore, the 5´-phosphate of
uracil 50 (U50) was shown to replace the  -phosphate group of ATP. A bridging magnesium ion
was modeled between the 5´-phosphate of U50 and Asp335 of GRK2. This magnesium ion might
help in neutralizing negative charges.
The overall structure of the nucleotides interacting within the active site of GRK2 seems to
be stabilized by hydrogen bonds between N4 of C52 and the 2´-OH of A49 and between the 5´-
phosphate of C52 and the 2´-OH of U50.
5.1.3 Nucleotides A49-G53 of C13 are essential for GRK2 binding
The importance of nucleotides A49 - C52 for GRK2 binding was validated with additional as-
says. Therefore, point mutations at positions A49, U50, A51, C52 and G53 were introduced into
full-length C13 by site-directed mutagenesis (Figure 5.3A). These point mutations were verified by
sequencing and analyzed for binding to GRK2 in filter retention assays. In this assay, ↵-32P labeled
RNA is incubated with increasing GRK2 concentrations in binding bu↵er (PBS, 3 mM MgCl2, 1
mg/ml Heparin). The amount of radioactively labeled RNA retained on GRK2 was detected and
quantified for KD value determination by assuming a 1:1 binding model.
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Figure 5.3: Nucleotides A49-G53 are essential for GRK2 binding. A) In accordance with
Figure 5.2C, point mutations in C13 nucleotides A49-G53 were generated by site-directed mutagenesis.
Nucleotides 1-40 and 69-101 of aptamer C13 are omitted for clarity in this picture. B) Filter retention
assay of C13 and point mutants binding to GRK2. The amount of radioactively labeled RNA bound
to GRK2 is plotted against the protein concentration. KD values are listed in Table 5.2. Experiments
were performed at least twice (mean ± SEM).
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Table 5.2: KD values [nM] of C13 variants for GRK2 as determined from Figure 5.3B.
Variant KD [nM]
C13 126.3 ± 15.3
C13 U50G 108.2 ± 20.7
all others n.d.
n.d.: no binding detectable
As can be seen in Figure 5.3B and Table 5.2, the full-length aptamer C13 revealed an a nity
of 126 ± 15.3 nM for GRK2 in filter retention assays, consistent with previous data [209]. Most
strikingly, the C13 point mutant U50G bound with similar a nity to GRK2 as C13 itself (Figure
5.3B, Table 5.2).
As shown in Figure 5.2C, the nucleotide at position 50 contributes its 5´-phosphate to GRK2
binding and does not form specific interaction to GRK2 or within the C13.18 structure, explaining
why the uracil base could be exchanged easily with a guanine without a loss of a nity.
In contrast to U50G, point mutation at adenine 51 to cytosine completely diminished the binding
to GRK2 in filter retention assays. According to the structural model (Figure 5.2C), the adenine
base occupies the adenine-binding site within the kinase domain. A smaller cytosine base does not
seem to allow for structural substitution.
Mutations of A49, C52 and G53 completely abolished aptamer binding in filter retention assays,
most likely by changes in the aptamer fold or loss of hydrogen interaction within the nucleotide
sequence.
This data further support that nucleotides interacting within the active site are essential for
GRK2 binding.
5.1.4 Aptamer C13 forms extensive interactions both within and outside
of the active site of GRK2
The co-crystal structure of the C13.18-GRK2 complex (Figure 5.4A) implicated that the C13 nu-
cleotides A49 - C52 could engage in electrostatic interactions with the active site residues His280
and Asp335 (Section 5.1.2). To further delineate the interaction of C13 with the active site residues
His280 (H280) and Asp335 (D335), the residues were individually mutated to alanine and analyzed
for C13 binding (Figure 5.4B).
The binding data are summarized in Figure 5.4B and Table 5.3. Mutating His280 to alanine
droped the a nity of C13 for GRK2. H280 likely interacts electrostatically with the aptamer. A
less polar amino acid does not seem to able to replace this interaction.
In contrast, the interaction of C13 with active site mutant GRK2-D335A was barely detectable,
highlighting the necessity of Aps335 for the coordination of the bridging magnesium ion. This
magnesium ion might be crucial for neutralizing negative charges.
These data further support the important role of active site residues His280 and Asp335 for the
interaction with aptamer C13 within the active site, consistent with the structural model in Section
5.1.2.
The 12 unresolved residues of C13.18 were projected into a cavity outside of the active site,
where they likely interact electrostatically with positively charged residues that line the cavity
(Figure 5.4A). Inside this cavity, the basic residues of the ↵F-↵G-loop region might interact with
the phosphodiester backbone of nucleotides 56-63 of GRK2.
In order to refine this model, the basic residues in the ↵F-↵G-loop region (Arg392, His394, Lys395,
Lys397, Lys399, and His400) were simultaneously mutated to alanine (GRK2 FG-6A) and analyzed
for C13 binding.
These binding experiments are summarized in Figure 5.4B and Table 5.3 and show that C13
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Figure 5.4: Structural determinants of GRK2 involved in mediating the binding to C13. A)
Interactions of the C13.18 aptamer within the active site of GRK2. The position of the ↵F-↵G-loop and
↵G-helix in apo-GRK2 (amino acids 391–410; PDB entry 2BCJ) is shown in green at half transparency.
The blue wire cage shown corresponds to an electron density map around residues 47-CCAUAC-52 of
C13.18. Carbons atoms are gray for C13.18, and yellow for the kinase domain. Nitrogens are in cyan,
oxygens are red, phosphates are orange and magnesium ions are black. Intramolecular hydrogen bonds
in the RNA are dashed lines. The 12 C-terminal nucleotides of the aptamer are disordered, but extend
into a crystal contact lined with positively charged amino acids. B) GRK2 active site residues H280 or
D335 as well as 6 residues of the basic ↵F-↵G-loop (FG-6A) were mutated to alanine. The a nity of C13
to GRK2 wildtype (”wt”) or the GRK2 mutants was analyzed by filter retention assay. Experiments
were performed at least twice (mean ± SEM). KD values are listed in Table 5.3.
Table 5.3: KD values of C13 and GRK2 variants [nM] as determined from Figure 5.3B.
Variant KD [nM]
GRK2 126.3 ± 15.3
H280 > 1000
D335 > 1000
FG-6A > 1000
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forms interactions outside of the active site. Mutations in the basic ↵F-↵G-loop of GRK2 (GRK2-
FG-6A) outside of the active site showed a strong drop in a nity for C13. This further supports
the notion that the basic ↵F-↵G-loop interacts with the phosphodiester backbone of unmodeled
nucleotides 56 – 63 of C13.
Taken together, the binding data and co-crystal structures presented in this chapter indicate
that C13 stabilizes a unique inactive conformation of GRK2 through multiple interactions, both
within and outside of the kinase domain.
5.2 In vitro characterization of novel Erk2 - recognizing ap-
tamers C3 and C5
This section extends the concept of aptamers as selective protein kinase inhibitors to the MAP kinase
Erk2. Erk1/2 are versatile protein kinases that are associated with many human pathologies, such
as cancer [246, 247] and neurodegerative diseases [302].
The ATP-competitive RNA aptamer TRA represented one of the most promising Erk2 in-
hibitors. In vitro, it blocks the activity of the MAP kinase Erk2 with high a nity and specificity.
However, the binding of TRA to Erk2 was shown to be a↵ected in a PBS bu↵er supplemented with
3 mM MgCl2 [314]. Since this sensitivity to ionic strength will likely hamper the application of
TRA in cell-based studies, two novel Erk2-recognizing aptamers, C3 and C5, were selected in a
high salt containing bu↵er prior to this thesis (Sections 3.4.2.5, 5.2.1.3).
In order to evaluate the aptamers dependency on cations for future applications, the interaction
of TRA as well as the novel Erk2-recognizing aptamers C3 and C5 are tested under distinct ionic
bu↵er conditions (Sections 5.2.1.1, 5.2.1.3).
Furthermore, to assess the potential of C3 and C5 as research tools, their specificity is charac-
terized (Section 5.2.3).
The last part of this section identifies the modes of actions and putative binding sites of C3 and
C5 (Section 5.2.4).
5.2.1 Binding studies
5.2.1.1 Characterization of the ionic strength dependence of TRA binding
Insensitivity to cationic strength could play an important role for the successful intracellular ap-
plication of aptamers. Previous experiments implicated that the binding of the Erk2- recognizing
aptamer TRA was a↵ected in a high salt bu↵er. The bu↵er used for these experiments was PBS,
pH 7.4, supplemented with 3 mM MgCl2 [314]. PBS is a phosphate bu↵er which contains 2.7 mM
KCl and 130 mM NaCl.
TRA was selected in the absence of monovalent cations in 10 mM Hepes bu↵er, pH 7.4, supple-
mented with 10 mM MgCl2. To further delineate the cation sensitivity of TRA, it was investigated
if monovalent cations or lower magnesium concentration might cause TRA´s loss of interaction with
Erk2 in PBS bu↵er.
Filter retention assays were performed with ↵-32P labeled TRA and increasing concentrations
of inactive Erk2 in Hepes or PBS bu↵er with the varying Mg2+, Na+, or K+ concentrations (Figure
5.5). The pH values of the bu↵ers were tested and did not di↵er.
The amount of radioactively labeled RNA bound to Erk2 was detected and quantified. A four-
parameter logistic fit was applied for KD value determination. This fit allows for the determination
of both the KD value and the Hill coe cient. The Hill coe cient quantifies the steepness of a
binding curve and may give information on the number of binding sites on a macromolecule. If one
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molecule binds with positive cooperativeness to the target, the Hill coe cient should be close to a
value of 1 (ideally between 0.8 and 1.5) [319].
First, it was investigated if the observed loss of a nity in PBS bu↵er was caused by the low
magnesium concentration. To analyze this, the binding of TRA to inactive Erk2 was tested in
Hepes bu↵er with distinct MgCl2 concentrations (Figure 5.5).
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Figure 5.5: KD value determination of TRA in Hepes bu↵er supplemented with indicated
MgCl2 concentrations. The amount of radioactively labeled TRA bound to inactive Erk2 is plotted
against the Erk2 concentration. All experiments were performed at least twice (mean ± SEM). KD
values are listed in Table 5.4. w/o = without additional MgCl2.
Table 5.4: KD values [nM] and Hill coe cients of TRA binding to Erk2 in Hepes bu↵er with indicated
MgCl2 concentrations as determined from Figure 5.5.
MgCl2 KD [nM] Hill coe cient
10 mM 487.6 ± 52.7 2.1 ± 0.4
3 mM 421.1 ± 82.5 1.5 ± 0.3
1 mM > 1000
0 mM > 1000
As can be seen in Figure 5.5 and Table 5.4, TRA binds with an a nity of 488 ± 52.7 nM to Erk2
in its selection bu↵er (10 mM Hepes, pH 7.4, supplemented with 10 mM MgCl2). The observed
KD value is about 5-times higher than the reported KD value of TRA´s progenitor, the family II
aptamer [210]. This di↵erence might be explained by di↵erent protein preparations.
The KD value did not change when the MgCl2 concentration in Hepes bu↵er was lowered from
10 to 3 mM (KD 421.1 ± 82.5 nM). Therefore, the previously observed loss of a nity in PBS bu↵er
was not caused by the lower magnesium concentration (3 mM) used for the binding assay but likely
results from the presence of monovalent cations in PBS bu↵er.
The a nity of TRA for Erk2 in Hepes bu↵er decreased when the magnesium concentration was
lowered to 1 mM or when magnesium was left out (Figure 5.5).
Strikingly, the Hill coe cients of TRA were observed to be higher than 1. This may indicate
that more than one molecule binds with positive cooperativeness to Erk2 [319].
Next, the binding of TRA was analyzed for monovalent cation dependence. Thus, filter reten-
tion assays in Hepes bu↵er, supplemented with 10 mM MgCl2, and with the addition of KCl or
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NaCl concentrations identical to those present in PBS bu↵er, were performed (Figure 5.6).
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Figure 5.6: KD value determination of TRA in Hepes bu↵er supplemented with 10 mM
MgCl2 and additional 130 mM NaCl or 2.7 mM KCl. The amount of radioactively labeled
TRA bound to inactive Erk2 is plotted against the Erk2 concentration.The binding curve of TRA in
the absence of monovalent cations is the same as in Figure 5.5. All experiments were performed at least
three times (mean ± SEM). w/o = without additional KCl or NaCl.
Table 5.5: KD values [nM] and Hill slopes of TRA binding to Erk2 in Hepes bu↵er, 10 mM MgCl2,
and NaCl or KCl as determined from Figure 5.6.
Salt KD [nM] Hill coe cient
w/o 487.6 ± 52.7 2.1 ± 0.4
130 mM NaCl > 1000
2.7 mM KCl > 1000
w/o: without additional salt
TRA binds with an a nity of 488 ± 52.7 nM to Erk2 in 10 mM Hepes, pH 7.4, supplemented
with 10 mM MgCl2 (Figure 5.6, Table 5.5). The addition of either 130 mM NaCl or 2.7 mM KCl
dropped the a nity of TRA for Erk2. Hence, TRA seems to be sensitive to the presence of mono-
valent cations tested (sodium, potassium).
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Consequently, it was investigated how the presence of both potassium and sodium ions in PBS
bu↵er a↵ects the binding of TRA to Erk2 (Figure 5.7).
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Figure 5.7: Binding assays with TRA in PBS bu↵er with indicated MgCl2 concentrations.
The amount of radioactively labeled TRA bound to inactive Erk2 is plotted against the Erk2 con-
centration. All experiments were performed at least twice (mean ± SEM). w/o = without additional
MgCl2.
Binding assays in PBS bu↵er further underline TRA´s sensitivity to ionic strength for Erk2
binding (Figure 5.5A, Table 5.4). The addition of 10 mM MgCl2, the magnesium concentration
which is identical to the concentration in TRA´s selection bu↵er (10 mM MgCl2), could not rescue
the interaction of TRA and Erk2. When the magnesium concentration was lowered further, no
binding of TRA to Erk2 was detected.
Taken together, these data show that the binding of TRA to Erk2 is sensitive to the presence
of monovalent cations tested (potassium and sodium). Furthermore, decreasing magnesium ion
concentrations below 3 mM also a↵ects the interaction of TRA and Erk2. Since the K+ ion con-
centration is about 70-times higher in the cytoplasm and the concentration of free magnesium ions
is reported to be approximately 1 mM [3], TRA could likely not be used within cells.
5.2.1.2 KD value determination of aptamers C3 and C5
As mentioned before, two di↵erent selection strategies were performed to identify aptamers that
would target Erk2 under more physiologicalyl relevant conditions (Section 3.4.2.5). PBS, sup-
plemented with 3 mM MgCl2, was chosen as the selection bu↵er. This bu↵er has been shown
in previous experiments to give rise to aptamers that are adaptable to intracellular applications
[182, 183].
A reselection of a doped library based on the sequence of the TRA aptamer was performed
against active Erk2 and yielded the aptamer C5 (Figure 3.15B). To address an epitope that is
present in inactive Erk2, a second selection was performed with a completely randomized library
against inactive Erk2. This SELEX strategy yielded the aptamer C3 (Figure 3.15C).
The active conformation of Erk2 was bound by TRA with 10-fold higher a nity than inactive
Erk2 [210]. Since it is very likely that C5 shares these properties, KD values were determined
for both active and inactive Erk2 (Figure 5.8A). In order to identify if C3 preferentially targets
the active or inactive conformation of Erk2, filter retention assays were performed with both Erk2
proteins (Figure 5.8B). The KD values of C3 and C5 were determined in selection bu↵er (PBS, 3
mM MgCl2).
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Figure 5.8: KD value determination of C3 and C5. Binding curves of C5 (A) or C3 (B) for active
and inactive Erk2. The amount of radioactively labeled RNA bound is plotted against the concentration
of active (pp-Erk2) or inactive Erk2 (Erk2). KD values are listed in Table 5.6. All experiments were
performed in PBS bu↵er, supplemented with 3 mM MgCl2 (n=2, mean ± SEM).
Table 5.6: KD values and Hill coe cients (h) of C5 and C3 according to Figure 5.8.
Aptamer KD Erk2 [nM] h Erk2 KD pp-Erk2 [nM] h pp-Erk2
C5 113.7 ± 26.1 1.5 ± 0.1 10.3 ± 1.1 2.1 ± 0.4
C3 73 ± 18.2 1.2 ± 0.3 28.6 ± 0.3 2.4 ± 0.3
Erk2: inactive Erk2, pp-Erk2: active Erk2
The results are summarized in Figure 5.8 and Table 5.6 and show that aptamer C5 binds with KD
values of 10.3 ± 1.1 nM to active Erk2 and 113.7 ± 26.1 nM to inactive Erk2, respectively. The
10-fold higher increase in a nity for active Erk2 is in accordance with the selection scheme and
likely reflects the importance of the activation status of Erk2 recognitizing C5.
C3 binds with an a nity of 28.6 ± 0.3 nM to active Erk2 and 73.4 ± 18.2 nM to inactive Erk2
(Figure 5.8B, Table 5.6). The similar a nity of C3 for active and inactive Erk2 suggests that C3
targets an epitope that is present in both the active and inactive conformation of Erk2.
Notably, the saturation of the binding curves of C5 and C3 for Erk2 were lower that the satu-
ration of the binding curves for inactive Erk2. These di↵erences might result from distinct protein
preparations. Inactive Erk2 was produced in-house whereas active Erk2 was purchased.
The Hill coe cients of C3 and C5 for inactive Erk2 were close to 1 (Table 5.6). This indicates
that indeed a single aptamer binds to one Erk2 protein. Strikingly, the Hill coe cients of the
aptamers binding curve for active Erk2 shifted above 2. The Hill slopes of the binding curves of
C3 and C5 under the tested conditions indicate that more than one aptamer could bind to Erk2.
However, this finding needs to be evaluated further because Hill slopes >> 1 may also arise if the
protein concentrations used for the binding assays by far exceeds the KD value [319].
5.2.1.3 Cation dependence of aptamers C3 and C5
The binding of C5´s progenitor TRA was shown to be greatly impaired in the presence of monovalent
cations (Section 5.2.1.1). Since the long-term goal of this study was to apply the novel Erk2-binding
aptamers C5 and C3 as inhibitors in a cell cultures studies, it was crucial to determine if the
aptamers binding to Erk2 could be a↵ected by ionic strength.
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Consequently, the dependence of aptamer C3 and C5 on magnesium, sodium, or potassium ions
for Erk2 binding was analyzed in distinct bu↵ers. Since the aptamers were selected in PBS bu↵er,
it is obvious that C3 and C5 would tolerate the presence of monovalent cations that are present in
PBS bu↵er (130 mM MaCl, 2.7 mM KCl). Therefore, first it was investigated if binding of C3 and
C5 could be sensitive to magnesium ions by supplementing PBS bu↵er with varying magnesium
concentrations Figure 5.9).
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Figure 5.9: Binding assays in PBS bu↵er with varying MgCl2 concentrations. The amount
of radioactively labeled RNA bound to inactive Erk2 is plotted against the Erk2 concentration. Filter
retention assays of C5 (A) or C3 (B) binding to Erk2 in PBS bu↵er supplemented with varying MgCl2
concentrations. KD values are listed in Table 5.7. Experiments were performed at least three times
(mean ± SEM). w/o: without MgCl2.
Table 5.7: KD values [nM] and Hill coe cients (h) of C5 and C3 binding to Erk2 in PBS bu↵er with
indicated MgCl2 concentrations as determined from Figure 5.9.
MgCl2 KD C5 [nM] h C5 KD C3 [nM] h C3
10 mM 122.2 ± 13.3 2.2 ± 0.3 94.6 ± 12.2 2.0 ± 0.4
3 mM 113.7 ± 27.2 1.5 ± 0.3 74.7 ± 19.6 1.2 ± 0.3
1 mM 210.1 ± 19 2.5 ± 0.5 91.9 ± 15.6 1.3 ± 0.2
0 mM n.d. 81.2 ± 11.4 1.5 ± 0.2
n.d.: not detectable
As summarized in Figure 5.9A and Table 5.7, C5 revealed high tolerance to varying magnesium
concentrations. The aptamer bound with similar KD values to Erk2 when 1, 3, or 10 mM MgCl2
were present in PBS bu↵er. In the absence of magnesium, the interaction of C5 and Erk2 was
barely detectable at high Erk2 concentrations. Whether the loss of a nity of TRA or C5 at low
magnesium concentration is due to e↵ects on protein or aptamer folding or on the interaction of
both needs to be investigated further.
The results of the experiments for C3 are summarized in Figure 5.9B and Table 5.7. Binding
tests in PBS bu↵er with di↵erent MgCl2 concentrations revealed that C3 exhibits similar a nities
of about 90 nM in PBS bu↵er regardless of the magnesium concentration (Figure 5.9B). The lack
of dependency on Mg2+ ions for Erk2-binding in PBS bu↵er is best reflected in the absence of
magnesium. Most notably, C3 was still able to bind to Erk2 without alterations in a nity.
40
5.2. In vitro characterization of novel Erk2 - recognizing aptamers C3 and C5
Next, it was evaluated if the aptamers would tolerate the absence of monovalent cations. Thus,
binding assays were performed in Hepes bu↵er (Figure 5.10).
1 10 100 1000
0
20
40
60
80
conc Erk2 [nM]
am
ou
nt
 C
3 
bo
un
d 
[%
] 
w/o
1 mM 
3 mM 
10 mM 
A B
1 10 100 1000
0
20
40
60
80
conc. Erk2 [nM]
am
ou
nt
 C
5 
bo
un
d 
[%
]
w/o
1 mM
3 mM 
10 mM 
Figure 5.10: Binding assays in Hepes bu↵er with varying MgCl2 concentrations. The amount
of radioactively labeled RNA bound to Erk2 is plotted against the Erk2 concentration. Filter retention
assays of C5 (A) or C3 (B) binding to inactive Erk2 in Hepes bu↵er supplemented with varying MgCl2
concentrations. KD values are listed in Table 5.8. Experiments were performed at least three times
(mean ± SEM). w/o: without additional MgCl2. The experiments shown in A) and B) were performed
by D. Minich during a lab rotation.
Table 5.8: KD values [nM] of C5 and C3 binding to Erk2 in Hepes bu↵er supplemented with indicated
MgCl2 concentrations as determined from Figure 5.10.
MgCl2 KD C5 [nM] h C5 KD C3 [nM] h C3
10 mM 232.9 ± 29.5 1.8 ± 0.3 109.4 ± 25.3 1.1 ± 0.2
3 mM 142.4 ± 10.6 1.7 ± 0.2 141.7 ± 26.6 1.0 ± 0.1
1 mM 522.4 ± 194.9 1.3 ± 0.3 346 ± 117.9 1.6 ± 0.6
0 mM > 1000 > 1000
Figure 5.10A and Table 5.8 show that C5 binds to Erk2 with an a nity of 142.4 ± 10.6 nM
in Hepes bu↵er, supplemented with 3 mM MgCl2. The KD values of C5 in Hepes bu↵er and PBS
bu↵er (113.7 ± 27.4) are nearly identical. Moreover, aptamer C5 bound equally well to Erk2 when
3 or 10 mM MgCl2 were present in Hepes bu↵er. This data indicate that C5 is able to tolerate the
absence of monovalent cations (sodium and potassium) in the presence of certain magnesium ion
concentrations.
However, the binding of C5 in Hepes bu↵er (Figure 5.10A, Table 5.8) displays higher constraints
to magnesium than the interaction of C5 with Erk2 in PBS bu↵er (Figure 5.9A). Its KD value de-
creased when the magnesium concentration was reduced below 3 mM.
In Hepes bu↵er, C3 bound with similar a nities in the presence of magnesium concentrations
ranging from 3 to 10 mM (Figure 5.10A, Table 5.8). Similar KD values were observed for PBS bu↵er
(Figure 5.9B). Like C5, the interaction of C3 and Erk2 seems to tolerate the absence of monovalent
cations in the presence of magnesium ions. However, the a nity of C3 decreased three-fold when
the magnesium concentration was lowered to 1 mM. When magnesium was left out completely, the
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a nity of C3 for Erk2 dropped even further. This sensitivity to magnesium ion concentrations
was not observed in PBS bu↵er (Figure 5.9B) and indicates that the interaction of Erk2 and C3 is
enhanced in the presence of monovalent cations.
Strikingly, the saturation of the binding curves C3 for Erk2 in Hepes bu↵er decreased when
magnesium concentrations were reduced. This e↵ect might result from distinct RNA preparations
used for the assays.
In turn, the binding of C3 or C5 to Erk2 was further analyzed with binding studies in Hepes
bu↵er, supplemented with 10 mM MgCl2, and additional 2.7 mM KCl or 130 mM NaCl as supplied
in PBS bu↵er (Figure 5.11, Table 5.9).
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Figure 5.11: Binding assays in Hepes bu↵er, supplemented supplemented with 10 mM
MgCl2 and 2.7 mM KCl or 130 mM NaCl. The amount of radioactively labeled RNA bound to
inactive Erk2 is plotted against the Erk2 concentration. Filter retention assays of C5 (A) or C3 (B)
binding to inactive Erk2 in Hepes bu↵er supplemented with 10 mM MgCl2 and 2.7 mM KCl or 130 mM
NaCl. KD values are listed in Table 5.9. Experiments were performed at least three times (mean ±
SEM). w/o: without additional KCl or NaCl.
Table 5.9: KD values [nM] of C5 and C3 binding to Erk2 in Hepes bu↵er, 10 mMMgCl2, and additional
KCl or NaCl as determined from Figure 5.10.
Salts KD C5 [nM] h C5 KD C3 [nM] h C3
w/o 232.5 ± 31 1.8 ± 0.3 109.1 ± 23.9 1.1 ± 0.2
130 mM NaCl 140.8 ± 9.7 2.2 ± 0.3 66.6 ± 7.3 1.9 ± 0.3
2.7 mM KCl 159.8 ± 19 1.8 ± 0.3 221.6 ± 65.6 1.4 ± 0.4
w/o: without additional KCl or NaCl
In accordance with the selection scheme, the addition of NaCl or KCl to Hepes bu↵er did not a↵ect
the a nities of C5 or C3 for Erk2 in the presence of magnesium ions (Figure 5.11, Table 5.9).
Taken together, the SELEX strategy in high salt containing PBS bu↵er has given raise to
aptamers that are adaptable to distinct ionic conditions. In summary, both C5 and C3 require
monovalent cations and magnesium ions for Erk2 binding. They tolerate varying magnesium con-
centrations and the absence of monovalent cations under most tested conditions. Aptamer C5
requires at least 1 mM magnesium to bind to Erk2. Its interaction with Erk2 at low magnesium
42
5.2. In vitro characterization of novel Erk2 - recognizing aptamers C3 and C5
concentrations is enhanced in the presence of monovalent cations. In contrast, the interaction of
C3 and Erk2 seems to be less dependent on cation identity. C3 requires the presence of monovalent
cations for Erk2 binding to tolerate the absence of magnesium ions. In the absence of monova-
lent cations, however, the binding of C3 can only be rescued by higher magnesium concentrations.
Hence, the aptamers distinct properties to ionic strength indicates that cations play di↵erent roles
to the interaction of C3 with Erk2 as compared to C5 and Erk2.
The Hill slopes of the binding curves of C3 and C5 under the tested conditions indicate that
more than one aptamer could bind to Erk2. However, this finding needs to be evaluated further
because Hill slopes >>1 may also arise if the protein concentrations used for the binding assays by
far exceed the KD value [319].
In the last step, it was investigated if the aptamers tolerance to ionic strength could also be
assigned to a bu↵er system which mimics cytosolic cation concentrations to assess the potential
for C3 and C5 for later cellular applications. Therefore, their a nities for Erk2 were determined
in a phosphate bu↵er which mimics cytosolic cation concentrations (ICB: 16 mM KCl, 130 KCl
and 1 mM MgCl2, Figure 5.12) [320]. In this bu↵er, the sodium and potassium concentrations are
reversed compared to PBS bu↵er.
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Figure 5.12: Binding assays in a cytosolic phosphate bu↵er. The amount of radioactively
labeled RNA is plotted against the Erk2 concentration. Filter retention assays of C5 (A) or C3 (B) in
phosphate bu↵er which mimics cytosolic cation concentrations (16 mM KCl, 130 KCl and 1 mM MgCl2)
or PBS bu↵er supplemented with 3 mM MgCl2. Experiments were performed once in duplicates (mean
± SEM). ICB: cytosolic cation concentrations, PBS: PBS bu↵er with 3 mM MgCl2.
Table 5.10: KD values and Hill coe cients (h) of C5 and C3 according to Figure 5.12.
Bu↵er KD C5 [nM] h C5 KD C3 [nM] h C3
ICB 175 ± 9.5 2.6 ± 0.3 167.5 ± 29.5 2.3 ± 0.7
PBS 330 ± 11.5 2 ± 0.1 300 ± 28 2.5 ± 0.5
Remarkably, both C5 and C3 bound with identical a nity to Erk2 in phosphate bu↵er with
cytoplasmic-based cation concentrations and selection bu↵er (Figure 5.12, Table 5.10). Thus, the
aptamers represent promising candidates for cellular assays.
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5.2.2 Validation of non-binding point mutants of C5
Once determined, the secondary structure of an aptamer can be used to design a negative control
sequence in the form of a non-binding point mutant. Since the precise secondary structure of
aptamer C5 has not been determined yet, structural and mutational analysis based on TRA were
utilized to identify non-binding point mutants of C5.
Seiwert et al performed extensive mutational analysis on TRA and identified point mutations
that either reduced or diminished its inhibitory activity [210]. By slightly changing the sequence
of one strand in the putative stem of TRA (mutation A1, Figure 5.13A), they demonstrated a
complete loss of TRAs inhibitory activity. A mutation in the lower bulge of TRA was also shown
to strongly a↵ect TRA´s inhibitory activity (mutation B2, Figure 5.13A).
In C5, these nucleotides are conserved and can be found at the same position as in TRA, high-
lighting their importance for Erk2 binding (Figure 5.13B). Therefore, it was very likely that similar
point mutations would a↵ect the binding of aptamer C5. Thus, analog point mutants of aptamer C5
were designed. These point mutants, termed ”C5 A1” and ”C5 B2”, contain two point mutations
in either the stem or the lower bulge region of aptamer C5. The binding of the C5 point mutants
to Erk2 was analyzed in selection bu↵er (PBS, 3 mM MgCl2).
As can be seen in Figure 5.13B, no interaction of point mutants C5 A1 or C5 B2 with Erk2 was
detected. Hence, this data indicates that similar structural properties might be shared by aptamer
C5 and its parental aptamer TRA. Mutations at the same positions reduced both aptamers a nity
or inhibitory properties.
The point mutants or a scrambled control RNA of C5 (”C5sc”) were used as negative control
sequences for C5. A scrambled control sequence was used as a negative control for C3, too. None
of these sequences revealed any a nity for Erk2 (Section 10.1).
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Figure 5.13: Validation of non-binding point mutants of aptamer C5. A) Proposed secondary
structures of the RNA aptamers TRA and C5. Point mutations are annotated. B) Binding of aptamer
C5 and point mutants C5 A1 and C5 B2 to inactive Erk2 in filter retention assays. Experiments were
performed twice (mean ± SEM).
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5.2.3 Specificity profile
Low molecular weight kinase inhibitors often interact with multiple members of a protein kinase
family or target kinases from distinct subfamilies [91, 321]. The availability of more specific protein
kinase inhibitors would be extremely useful in helping to delineate the physiological roles of these
enzymes [87]. However, the identification of truly selective inhibitors has remained challenging since
protein kinases represent a large family of approximately 520 enzymes that share high homology
within their active site [7].
To investigate if the aptamers C3 and C5 interact with distinct members of the MAP kinase
family, filter retention assays were performed with Erk1 (Erk1/2 MAPK family), p38↵ (p38 MAPK
family), and JNK2↵ (JNK/SAPK MAPK family).
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Figure 5.14: Specificity tests with di↵erent MAP kinases. Filter retention assays of A) C5 or
B) C3 binding to di↵erent members of the Erk1/2, p38 or JNK MAP kinase families in PBS bu↵er,
supplemented with 3 mM MgCl2. The amount of radioactively labeled RNA is plotted against the
protein concentration. KD values are listed in Table 5.11. Experiments were performed at least twice
(mean ± SEM). KD values are listed in Table 5.11. Erk: extracellular signal-regulated kinase, JNK:
c-Jun N-terminal kinases.
Table 5.11: KD values and Hill coe cients (h) determined from Figure 5.14
MAPK KD C5 [nM] h C5 KD C3 [nM] h C3
Erk2 69.3 ± 6.8 1.8 ± 0.3 86.1 ± 15.2 2.2 ± 0.7
Erk1 97.6 ± 8.3 1.5 ± 0.2 120.3 ± 12.6 1.9 ± 0.3
p38↵ n.d. n.d.
JNK2↵ n.d . n.d.
n.d.: not detectable, MAPK: MAP kinase Erk: extracellular
signal-regulated kinase, JNK: c-Jun N-terminal kinases.
Both aptamers demonstrated a remarkable ability to discriminate between di↵erent structurally
similar MAP kinases (Figure 5.14). C3 and C5 revealed identical a nities for Erk2 and Erk1 (KD
values are listed in Table 5.11). This is not surprising because Erk1 and Erk2 share about 84%
sequence identity (Figure 5.15) [257]. However, the saturation of binding curves of C5 for Erk1 and
Erk2 di↵ered by two-fold. This likely results from di↵erent protein preparations.
More importantly, no binding of C3 or C5 to p38↵ or JNK2↵ was detected which argues for a
high degree of specificity (Figure 5.14 ). p38↵ and JNK2↵ MAP kinases share about 45% sequence
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identity with Erk1/2 (Figure 5.15).
Erk2            MAAAAAAGAG-----------------PEMVRGQVFDVGPRYTNLSYIGEGAYGMVCSAY 
Erk1            MAAAAAQGGGGGEPRRTEGVGPGVPGEVEMVKGQPFDVGPRYTQLQYIGEGAYGMVSSAY 
p38a            MSQERPTFYR------------------QELNKTIWEVPERYQNLSPVGSGAYGSVCAAF 
JNK2a           MSDSKCDSQFYS----------------VQVADSTFTVLKRYQQLKPIGSGAQGIVCAAF 
                 
 
Erk2            DNVNKVRVAIKKIS-PFEHQTYCQRTLREIKILLRFRHENIIGINDIIR-APTIEQMKDV 
Erk1            DHVRKTRVAIKKIS-PFEHQTYCQRTLREIQILLRFRHENVIGIRDILR-ASTLEAMRDV 
p38a            DTKTGLRVAVKKLSRPFQSIIHAKRTYRELRLLKHMKHENVIGLLDVFTPARSLEEFNDV 
JNK2a           DTVLGINVAVKKLSRPFQNQTHAKRAYRELVLLKCVNHKNIISLLNVFTPQKTLEEFQDV 
 
 
Erk2            YIVQDLMETDLYKLLKTQHLSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLLNTTC 
Erk1            YIVQDLMETDLYKLLKSQQLSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLINTTC 
p38a            YLVTHLMGADLNNIVKCQKLTDDHVQFLIYQILRGLKYIHSADIIHRDLKPSNLAVNEDC 
JNK2a           YLVMELMDANLCQVIH-MELDHERMSYLLYQMLCGIKHLHSAGIIHLKPSNIVVKSDCDC 
 
 
Erk2            DLKICDFGLARVADPDHDHTGFLTEYVATRWYRAPEIMLNSKGYTKSIDIWSVGCILAEM 
Erk1            DLKICDFGLARIADPEHDHTGFLTEYVATRWYRAPEIMLNSKGYTKSIDIWSVGCILAEM 
p38a            ELKILDFGLARHTDDEMTG------YVATRWYRAPEIMLNWMHYNQTVDIWSVGCIMAEL 
JNK2a           TLKILDFGLARTACTNFMMTP----YVVTRYYRAPEVILG-MGYKENVDIWSVGCIMAEM 
                  
 
Erk2            LSNRPIFPGKHYLDQLNHILGILGSPSQEDLNCIINLKARNYLLSLPHKNKVPWNRLFP- 
Erk1            LSNRPIFPGKHYLDQLNHILGILGSPSQEDLNCIINMKARNYLQSLPSKTKVAWAKLFP- 
p38a            LTGRTLFPGTDHINQLQQIMRLTGTPPAYLINRMPSHEARNYIQSLTQMPKMNFANVFI- 
JNK2a           VLHKVLFPGRDYIDQWNKVIEQLGTPSAEFMKKLQ-PTVRNYVENRPKYPGIKFEELFPD 
 
 
Erk2            -----------NADSKALDLLDKMLTFNPHKRIEVEQALAHPYLEQYYDPSD-EPIAEAP 
Erk1            -----------KSDSKALDLLDRMLTFNPNKRITVEEALAHPYLEQYYDPTD-EPVAEEP 
p38a            -----------GANPLAVDLLEKMLVLDSDKRITAAQALAHAYFAQYHDPDD-EPVADP- 
JNK2a           WIFPSESERDKIKTSQARDLLSKMLVIDPDKRISVDEALRHPYITVWYDPAEAEAPPPQI 
 
 
Erk2            FKFDMELDDLPKEKLKELIFEETARFQPGYRS---------------------------- 
Erk1            FTFAMELDDLPKERLKELIFQETARFQPGVLEAP-------------------------- 
p38a            YDQSFESRDLLIDEWKSLTYDEVISFVPPPLDQEEMES---------------------- 
JNK2a           YDAQLEEREHAIEEWKELIYKEVMDWEERSKNGVVKDQPSDAAVSSNATPSQSSSINDIS 
 
 
Erk2            --------------------------- 
Erk1            --------------------------- 
p38a            --------------------------- 
JNK2a           SMSTEQTLASDTDSSLDASTGPLEGCR!
Kinase domain
Kinase domain
Kinase domain
Kinase domain
Kinase domain
Figure 5.15: Amino acid sequences of Erk2, Erk1, p38↵, and JNK2↵. Identical amino acids
are marked in green or purple. Conserved residues for ATP-binding are shown in red.
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A further important point that was clearly shown in studies with small molecule kinase in-
hibitors was the fact that the specificity of a protein kinase inhibitor cannot be gauged simply by
comparing its e↵ects on the protein kinases to which it is most closely related [87]. For some kinase
inhibitors, impressive selectivity against a panel of closely related kinases can suggest a high degree
of specificity against the kinome [322, 323], whereas for other kinase inhibitors, specificity within
a kinase subfamily does not necessarily predict overall selectivity [91]. Therefore, the specificity
tests of the aptamers were extended towards other kinases belonging to distinct kinase groups as
described by Manning et al [7].
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Figure 5.16: Specificity tests with a panel of 10 kinases belonging to distinct groups.
Filter retention assay of C3 or C5 binding to Erk2 and distinct kinases belonging to di↵erent kinase
superfamilies as described by Manning et al [7]. The amount of radioactively labeled RNA bound to
inactive Erk2 was set to 100%. The amount of bound radioactively labeled RNA was normalized onto the
amount of radioactively labeled C3 or C5 bound to Erk2. Assays were performed at least twice (mean
± SEM) in PBS bu↵er, supplemented with 3 mM MgCl2. Erk2: extracellular signal-regulated kinase 2,
MKK1: Mitogen-activated protein kinase kinase 1, RSK2: 90 kDa ribosomal S6 kinase, PKB : protein
kinase B , GRK2: G protein-coupled receptor kinase 2, VRK1: Vaccina-related kinase 1, CK1: casein
kinase 1, DRAK1: DAP kinase-related apoptosis-inducing protein kinase 1, AAK1: AP2 associated
protein kinase 1, NEK1: NimA related kinase 1, TOPK: Lymphokine-activated killer T-cell-originated
protein kinase.
The results of these assays are summarized in Figure 5.16 and demonstrate that neither C3 nor
C5 interacted with any other investigated kinases at concentrations 10-fold above the determined
KD-value with which Erk2 is bound. Taken together, these data indicate that aptamers C3 and C5
may be highly specific for Erk1/2 against the remainder of the kinome.
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5.2.4 Investigation of the modes of action of C3 and C5
Subsequently, binding and functional assays were performed to assess the potential of the aptamers
C3 and C5 as research tools.
5.2.4.1 ATP competition assays
The ancestor of C5, aptamer TRA, was described to compete with ATP for Erk2 binding [210].
Consequently, it was investigated if binding of C5 could be a↵ected by ATP, too. Therefore, the
binding of radioactively labeled C5 bound to 250 nM inactive Erk2 was measured in the presence
of increasing concentrations of ATP and analyzed by filter retention analysis. UTP was used as
negative control.
The equilibrium dissociation constant (Ki) of the complex was quantified by measuring the
competition of ATP or UTP for C5 binding. To estimate the reliability of the Ki calculation, the
95 % confidence intervals (CI) are given. Confidence intervals indicate the concentration range that
contains the true mean of the population with a likelihood of 95 %.
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Figure 5.17: C5 competes with ATP for binding to Erk2. Filter retention analysis of radioac-
tively labeled C5 (A) or C3 (B) binding to inactive Erk2 in the presence of 0 - 10,000 µM ATP or UTP
in PBS bu↵er, supplemented with 3 mM MgCl2. The amount of radioactively labeled RNA bound to
inactive Erk2 without ATP was set to 100% (n = 4, mean ± SEM).
ATP strongly competed with the binding of aptamer C5 in a concentration dependent manner
with an Ki of 980 µM (CI 753.6 to 1295, Figure 5.17A). In accordance with data from the literature,
the determined Ki value lies in the same range as the KD value of Erk2 for ATP (700 - 1600 µM)
[245]. About 10 times higher concentrations of UTP also induced a reduction of C5 binding to
Erk2, most likely through unspecific interactions with the ATP-binding site of Erk2 or the RNA
itself. The Ki value of UTP is 7900 µM. However, a CI ranging from 2444 to 25545 indicates that
this value is not accurate.
In order to find out if aptamer C3 also interferes with ATP for binding to Erk2, similar com-
petitive binding experiments were performed. These experiments demonstrated that the binding
of aptamer C3 to Erk2 is also a↵ected by ATP (Figure 5.17B). In contrast to C5, a complete
competition of the binding of aptamer C3 could not be monitored.
To validate that complete competition of C3 can indeed be observed in this experimental setup,
the binding of radioactively labeled C3 RNA was analyzed in the presence of increasing concen-
tration of unlabeled C3 or control RNA (Section 10.2). Complete reduction of C3 binding was
observed by increasing concentrations of C3 RNA but not with control RNA.
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This data indicates that the observed reduction in binding of C3 (Figure 5.17B) might result
from electrostatic interactions between ATP and C3. Additionally, ATP could also a↵ect C3 binding
indirectly via an allosteric mechanism.
5.2.4.2 Erk2 activity assays
Aptamers that target the ATP-binding site were described to interfere with kinase activity [209,
210, 324]. In the next step, the aptamers impact on Erk2 kinase activity was evaluated. To achieve
this, 60 nM active Erk2 was incubated with substrate proteins and increasing concentrations of C3,
C5, control RNA or the commercially available ATP-competitive inhibitor FR180204. Erk2 activity
was measured by transfer of  -32P from ATP to the artificial substrate protein myelin basic protein
(MBP, 10 µM, Figure 5.18A,B).
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Figure 5.18: Erk2 activity assays. A) Schematic representation of the Erk2 activity assay. Erk2
is incubated with ATP and myelin basic protein as target protein. Inhibition of Erk2 activity results
in a decrease in substrate phosphorylation. B) Erk2 activity assays with MBP as substrate. Data were
normalized to the same concentration of control RNA. MBP assays were performed four times (mean
± SEM). MBP: Myelin basic protein, ADP+P: adenosine triphosphate (ATP).
Figure 5.18B shows that aptamer C5 inhibits Erk2 activity to a similar extent as the ATP-
competitive inhibitor FR180204 [310]. However, the concentration of FR180204 needed to inhibit
Erk2 activity in the kinase assay was 10 times higher than its reported IC50 value of 510 nM
[325]. This di↵erence likely results from lower ATP concentrations that were utilized by Ohori and
co-workers (2.5µM in [325] vs. 100 µM in this assay).
Aptamer C3, on the other hand, did not show any inhibitory activity towards Erk2.
MBP was used as substrate for Erk2 during most of the kinase assays. However, all nucleic
acids showed high background binding to MBP (Section 10.3.1). Most likely, this reflects MPB´s
ability to sequester RNA through nonspecific electrostatic interactions due to its high isoelectric
point (pI) of 11 [210].
In order to validate that the inhibition of substrate phosphorylation is solely assigned to direct
inhibition of Erk2 by the aptamers, a GST-Elk1 fusion protein (1 µM) was used as a substrate for
Erk2 (Figure 10.3). The fusion protein contains amino acids 307–428 of Elk1, which is a natural
substrate for Erk2 [326]. No background interaction between GST-Elk1 and any RNA was observed
(Section 10.3.1).
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Figure 5.19: Erk2 activity assays. Erk2 activity assays with Elk-1 as substrate. Data were nor-
malized to samples without RNA. Kinase assays were performed four times (mean ± SEM).
By using Elk1 as the substrate for Erk2 in the kinase assays, similar results were obtained as
when MBP was used as substrate (Figure 5.19). Both aptamer C5 and FR180204 inhibited Erk2
activity. Aptamer C3, on the other hand, did not reveal any impact on kinase activity, even at
concentrations of 25 µM.
The evidence given in this section demonstrate that aptamer C5 targets Erk2 in a similar mode
of action as its ancestor TRA. C5 prevented ATP from binding to Erk2 and inhibited Erk2 activity.
In summary, these data indicate that C5 may target the active site of Erk2. Aptamer C3 associated
with Erk2 in the presence of ATP and did not have any impact on Erk2 kinase activity. Hence, it
seems to recognize a di↵erent epitope on the kinase structure.
5.2.4.3 The putative binding site of C3 comprises the MAP kinase insert of Erk2
After having shown that C3 likely does not target the active site of Erk2, it was investigated if the
putative binding site of the aptamer comprises another functional domain of Erk2 (Figure 5.20A).
Erk2 contains several docking domains that have been shown to mediate the interaction with its
substrate proteins, activating kinases and inactivating phosphatases [245].
One of these domains is the so-called “D-site recruitment site” (DRS). The DRS is located
opposite to the catalytic cleft and consists of several negatively charged residues (Asp 316/319) and
a hydrophobic groove [245].
Another functional domain is the MAP kinase insert, which is located in close proximity to
the activation lip. The MAP kinase insert is a 31-amino acid insertion that can only be found in
MAP kinases and cyclin dependent kinases. Its sequence is unique for one subfamily and provides
additional functional specificity [245].
To elucidate whether the DRS or MAP kinase insert region are involved in mediating the binding
of C3 or C5 to Erk2, the impact of Erk2 point mutations D319N (DRS) [327], or N236K, Y261N,
and S264P42 (adjacent to or located within the MAP kinase insert) [328] were quantitatively ana-
lyzed on the aptamers binding with filter retention assays (Figure 5.20). Prior to any experiment,
the purity of the recombinant proteins was determined to be >90% by SDS-PAGE analysis and
Coomassie staining (Section 10.4).
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Figure 5.20: Aptamer C3 recognizes the MAP kinase insert of Erk2. A) Overall structure
of inactive Erk2 (PDB 1ERK) depicted as cartoon ribbon. The ATP-binding loop, the activation loop
and the MAP kinase insert region are shown in green, cyan and light purple, respectively. Mutated
amino acids tested for aptamer binding are marked and colored. B) In this filter retention assay, the
amount of radioactively labeled C3 RNA bound is plotted against the protein concentration. C) Binding
of C5 to wildtype Erk2 (“wt”) and Erk2 point mutants. KD values are listed in Table 5.12. Data in
B,C represent at least three independent measurements (mean ± SEM). Experiments were performed
in selection bu↵er (PBS, 3 mM MgCl2).
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Table 5.12: KD values and Hill coe cients (h) determined from Figure 5.20
Protein KD C5 [nM] h C5 KD C3 [nM] h C3
wild-type 129.7 ± 9.4 2.2 ± 0.3 106.4 ± 7.5 2.4 ± 0.3
N236K 140.8 ± 13 2.2 ± 0.4 89.2 ± 10.4 1.8 ± 0.3
Y261N 179.4 ± 18.5 2.2 ± 0.4 >1000
S264P 109.9 ± 15.4 1.8 ± 0.4 n.d.
D319N 132.2 ±25.7 1.9 ± 0.6 49.4 ± 4.1 1.9 ± 0.3
n.d.: not detectable
As shown in Figure 5.20B and Table 5.12, the Erk2 DRS mutant D319N interacted with aptamer
C3 with the same a nity as Erk2 wild-type protein, indicating that the DRS is mostly not involved
in the Erk2-recognition by C3.
The Erk2 point mutation N236K is located adjacent to the MAP kinase insert region. A
mutation at position N236 did not a↵ect the binding of C3 at all (Figure 5.20B, Table 5.12).
In contrast, the MAP kinase insert mutant S264P exhibited dramatically decreased interactions
with C3 and the mutant Y261N completely failed to interact with C3 (Figure 5.20B, Table 5.12).
Thus, the MAP kinase insert seems to be essential in the interaction of aptamer C3 and Erk2.
These binding experiments further support the notion that aptamer C3 recognizes a di↵erent
epitope on the kinase structure than the ATP-competitive aptamer C5. Point mutations in the
DRS or MAP kinase insert of Erk2 did not change the a nity of C5 to Erk2 (Figure 5.20BC, Table
5.12). This provides additional evidence that the binding site of C5 comprises the active site of Erk2.
5.2.4.4 Erk2 activation assays
The MAP kinase insert was described to contribute to diverse kinase-dependent and -independent
functions of Erk2 [329]. However, most of these studies used overexpression or knockdown strategies.
A domain-specific inhibitor, targeting only the MAP kinase insert region, would be invaluable as
tool to study the precise function of this domain in cellular processes. At present, no small molecule
inhibitor for the MAP kinase insert of Erk2 is available.
The MAP kinase insert region has been connected to the activation of Erk2 by its upstream
kinase Mek1 [295]. Mek1 and the closely related kinase Mek2 are dual-specific kinases that phos-
phorylate a tyrosine (Y187) and a threonine (T185) residue in the activation loop of Erk1 or Erk2
[259, 330]. These phosphorylation events then induce a conformational change upon which Erk
gains its full catalytic activity [290, 331].
To elucidate the potential of C3 as a domain-specific inhibitor, its impact on Erk2 activation
and consecutive substrate phosphorylation was analyzed in an activation-based kinase assay (Figure
5.21A). For this assay, a constitutively active mutant of Mek1, named Mek1 G7B [332], was em-
ployed as the Erk2 activator and MBP as the substrate protein. By performing the kinase assay in
the presence of  -32P -ATP, the impact of C3 and C5 on Erk2 activation and substrate phosphory-
lation could be monitored by   -32P incorporation into Erk2 and MBP. Subsequently, incorporation
of -32P into Erk2 and MBP was quantified by SDS-PAGE gel analysis and autoradiography. For
this kinase assay, 1 µM Mek1 G7B, 1 µM Erk2, and 10 µM MBP were used.
At concentrations used for this assay, C3 and C5 showed background binding to both MBP and
Mek1 G7B (Section 10.3.1), but did not target Mek1 G7B activity directly (Section 10.3.2). Hence,
any observed e↵ects are likely not due to unspecific e↵ects and reflect inhibited Erk2 kinase activity
after impaired Erk2 activation.
53
5. RESULTS
0.5 1.0 5.0 10.0
0.0
0.5
1.0
conc. [µM]
re
l. 
Er
k2
 a
ct
iv
at
io
n
C3
C5
0.5 1.0 5.0 10.0
0.0
0.5
1.0
conc. [µM]
re
l. 
M
BP
 p
ho
sp
ho
ry
la
tio
n
C3
C5
C5
B2 C3 C5
A
B C
Erk2
MBP
Figure 5.21: Erk2 activation assay. A) Schematic representation and autoradiography of a rep-
resentative Erk2 activation assay. Incorporation of  -32P into Erk2 and MBP was monitored after
addition of 5 µM RNA. A constitutively active Mek1 (Mek1 G7B) was employed as the Erk2 activator
and MBP was used as the substrate. B) Erk2 activation quantified from the phosphorylation of Erk2.
C) Erk2 activity quantified from the phosphorylation of MBP. Data were normalized onto control RNA.
Experiments were performed at twice (mean ± SEM). MBP: Myelin basic protein, ADP+P: adenosine
triphosphate (ATP).
The addition of increasing amounts of C3 resulted in strong inhibition of Erk2 phosphorylation
and, thus, activation (Figure 5.21B). At a concentration of 1 µM, which reflects 10 times its KD
value for Erk2, aptamer C3 inhibited Erk2 activation completely. Furthermore, C3 reduced Erk2
substrate phosphorylation (Figure 5.21 C), albeit at elevated concentrations (Figure 5.21C). Hence,
the inhibition of substrate phosphorylation likely reflects inhibited Erk2 kinase activity after im-
paired Erk2 activation.
Adding increasing concentrations of the ATP-competitive aptamer C5 also resulted in the in-
hibition of Erk2 activation. It required 10 µM C5 to completely inhibit the activation of Erk2
by Mek1 (Figure 5.21B). Moreover, C5 reduced Erk2 substrate phosphorylation (Figure 5.21C). It
was observed that higher concentrations of C5 were needed to inhibit Erk2 activity than in the
Erk2 activity assay (Section 5.2.4.2). This di↵erence was likely caused by distinct kinase concen-
trations that were utilized (Erk2 activity assay: 60 nM Erk2; Erk2 activation assay: 1000 nM Erk2).
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5.2.5 Summary
Taken together, the data presented in this section imply that the two aptamers bind to di↵erent sites
on Erk2 and exhibit di↵erent modes of action in respect to kinase activity disturbance. Aptamer
C5 recognizes Erk2 in an ATP-dependent manner and directly a↵ects Erk2 kinase activity.
The putative binding site of C3 comprises the MAP kinase insert of Erk2. In contrast to C5,
aptamer C3 does not target Erk2 activity itself. Instead, C3 demonstrated the ability to inhibit
Erk2 kinase activity in an ATP- and substrate independent manner. This implicates that C3 could
provide a valuable tool to study the function of the MAP kinase insert.
Both aptamers represent promising tools for the functional interference of Erk2 activity inside
cells. Therefore, their e↵ect on intracellular Erk1/2 MAP kinase signaling was investigated next.
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Figure 5.22: C3 and C5 exhibit di↵erent modes of action. Schematic representation of the
di↵erent modes of action of C3 and C5.
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5.3 Investigation of RNA aptamers as intracellular protein
kinase inhibitors
Several lines of evidence support the conclusion that aptamers C3 and C5 might be applicable as
Erk1/2 inhibitors in a cellular environment.
First, they bound to Erk2 under cytosolic ion conditions (Section 5.2.1.3). Second, C3 and C5
revealed remarkable specificity for Erk1/2 MAP kinases (Section 5.2.3). And lastly, C3 and C5
were able to interfere with distinct Erk2 functions in vitro (Section 5.2.4).
The following sections describe the elucidation of the aptamers putative inhibitory e↵ects on
Erk1/2 MAP kinase signaling. Therefore, the use of expression vectors and transfection or microin-
jection of in vitro transcribed RNA, was investigated to facilitate the delivery of the aptamers or
control sequences into the cells.
5.3.1 C3 and C5 recognize endogenous Erk1/2
The selections of aptamers C3 and C5 were performed against recombinant Erk2 protein of rat origin
[314]. Human and rat Erk2 di↵er in only two amino acids. Nevertheless, it had to be validated that
C3 and C5 are able to interact with endogenous human Erk1/2 before applying them as inhibitors
inside cells. Therefore, aptamer-protein pull-down assays were performed.
The scheme in Figure 5.23 explains the principle of this experiment. Briefly, biotinylated variants
of C3, C5, or control RNA were coupled to Streptavidin-coated magnetic beads. These matrices were
incubated with protein preparations from H460 cells. H460 cells are a human lung adeno carcinoma
- derived cell line. After incubation, the a nity matrices were washed and bound proteins were
detected by SDS-PAGE and immunoblot analysis.
lyse
collect cells
add biotinylated 
RNA coupled to 
magnetic beads
remove unbound
 proteins elute
Figure 5.23: Pulldown Assay. Schematic representation of the RNA-protein pulldown assay. Picture
of the SDS-PAGE chamber was taken from [333].
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The interaction of C3 and C5 with endogenous proteins was elucidated for Erk1/2, p38↵ and
JNK1↵/  MAP kinases. The results are summarized in Figure 5.24 and show that both C3 and
C5 interact with endogenous Erk1/2. Faint bands were observed for unloaded beads or control
sequences. These bands might result from unspecifically bound Erk1/2 that were co-precipitated
from cell lysate and subsequently detected with Erk1/2-specific antibodies.
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Figure 5.24: C3 and C5 interact with endogenous Erk1/2. Endogenous Erk1/2 were detected
when C3 or C5 were used as an a nity matrix. Only background binding of Erk1/2 to control RNA
and empty beads was observed. No binding of p38 or JNK1 to C3, C5 or controls were detected.
Moreover, no binding of C3 or C5 to endogenous p38↵ or JNK1↵/  MAPK was detected. These
experiments demonstrate that the derivation of aptamers with the potential to interact in a highly
specific manner with endogenous proteins is feasible.
5.3.2 Intracellular expression of C3 and C5
The application of functional RNA intramers can be mediated through two types of molecules: in
vitro transcribed aptamers or aptamer expression plasmids (Section 3.3.3). Plasmid expression is
probably the most common approach to deliver RNA aptamers into cells [168]. Thereby, aptamers
can be continuously synthesized by the host cell and inhibitory e↵ects should prevail for a long
period of time. Consequently, an intracellular expression system was employed to evaluate the
aptamers potential as tools to modulate intracellular Erk1/2 activity.
5.3.2.1 Design of the aptamer expression vector
Inhibitory RNA aptamers have been expressed successfully inside eukaryotic cells, such as yeast and
multi-cellular organisms, by using polymerase II or polymerase III based RNA expression vectors
[181, 192, 334, 335]. A simple and reliable method for expressing RNA aptamers in mammalian cells
was described by Mi and co-workers [181]. Briefly, they adopted a vector that delivers a H1 RNA
polymerase III promoter for high levels of RNA expression [336]. The advantage of this approach
is that RNA transcription starts accurately at the initial base of inserted sequences. Transcription
terminates with the addition 6 thymidine residues and the RNA constructs contain two-four uridines
(U) at the 3´- end.
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A congruent strategy was employed to design an expression vector for expressing the Erk2-
recogizing aptamers C3 and C5 inside eukaryotic cells (Figure 5.25). Since Erk1/2 concentrations
are very high inside cells (1 µM, [337]), a vector was chosen that employed a U6 small nuclear (U6)
RNA polymerase III promoter instead of a H1 promoter. Studies with shRNA have shown that U6
promoters often yield higher RNA expression levels that H1 promoters [338, 339].
Similar to the H1 Polymerase III vector, RNA transcription is supposed to start at the initial
base of inserted sequences and terminates with the addition of two to four uridines at the 3‘- end.
The ability of C3 and C5 to bind to Erk2 with three uridines at the 3‘- end was verified before
cellular experiments were performed (Section 10.5).
In addition, the expression vector allowed the co-cistronic expression of Green Fluorescent Pro-
tein (GFP) under the control of a Polymerase II promoter. GFP expression from a RNA polymerase
II promoter and RNA expression from a U6 polymerase III promoter enables the analysis and reli-
able correlation between observed signals and transfection e ciency.
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Figure 5.25: Design of the aptamer expression vector. Two complementary oligonucleotides
containing full length C3, C5, or control sequences and six thymidines to terminate transcription were
ligated into an expression vector downstream of a U6 gene-based RNA Polymerase III promoter. Upon
transcription, three additional uridines are present at the 5´ end of the RNA. Furthermore, the expres-
sion vector contained a GFP gene under the control of a Polymerase II promoter. Modified from [181].
GFP: green fluorescent protein, Pol II: Polymerase II promoter, Pol III: Polymerase III promoter.
58
5.3. Investigation of RNA aptamers as intracellular protein kinase inhibitors
5.3.2.2 E↵ects of small molecule inhibitors on the SRE luciferase reporter gene assay
The experiments were conducted in HEK 293 cells. HEK cells are originally derived from human
embryonic kidney cells grown in tissue culture. Since the transfection of e ciency of the RNA
expression vectors was about 50% 24 hours after transfection (Section 10.5), putative inhibitory
e↵ects were not investigated by monitoring the e↵ects on Erk1/2 target protein phosphorylation.
Instead, it was chosen to co-transfect a plasmid encoding for a reporter gene to ensure that Erk1/2
signaling was quantified only in cells that were transfected with the RNA expression vectors. To
this end, the SRE luciferase reporter gene assay was utilized (Figure 5.26) [188].
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Figure 5.26: Schematic representation of the SRE luciferase reporter gene assay. Upon
activation, Erk1/2 translocate into the nucleus and phosphorylate serum response transcription factors
(SRFs [340]). Binding of SRF to the serum response element (SRE) then induces Luciferase expression.
Firefly luciferase then catalyzes a light-emitting reaction which is proportional to Erk1/2 activity. The
light-emitting reaction can be quantified in cell lysate. The small molecule U0126 blocks the activation
of MEK by Raf whereas FR180204 blocks Erk1/2 activity in an ATP-dependent manner. Both inhibitors
should decrease the luciferase signal. RTK: receptor tyrosine kinase, EGF: epidermal growth factor
This reporter gene assay enables the measurement and quantification of the firefly luciferase
bioluminescence reaction respective to Erk1/2 activity (Figure 5.26): Upon activation, Erk1/2
translocate into the nucleus where they phosphorylate diverse targets, including the ternary com-
plex transcription factor Elk-1 [341]. Elk-1 forms a complex with the serum response transcription
factor (SRF) over the SRE and activates gene expression [342]. Elk-1 is phosphorylated by Erk1/2,
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resulting in increased DNA binding, ternary complex formation, and transcriptional activation of
the firefly luciferase gene [343, 344]. Firefly luciferase then catalyzes a light-emitting reaction [345].
This reaction is proportional to endogenous Erk1/2 activity and can be quantified in cell lysate.
First, it was investigated if direct inhibition of growth factor induced Erk1/2 signaling by the
aptamers would be detectable with this reporter gene assay (Figure 5.26). To this end, two small
molecule inhibitors were employed. FR180204 blocks Erk1/2 activity in an ATP-dependent manner
[310]. U0126 is a non-ATP competitive Mek1/2 inhibitor that prevents the activation of MEK by
Raf, and thus, inhibits Erk1/2 activation [346, 347]. Hence, the two inhibitors serve as references
if inhibition of Erk1/2 activity by C5 or Erk1/2 activation by C3 could be observed.
To monitor inhibitory e↵ects on Erk1/2 signaling, the SRE luciferase reporter plasmid and the
RNA expression vectors were transfected at a ratio of 1:2.5 into HEK 293 cells. After transfection,
the cells were incubated for 24 hours with the MEK1/2 inhibitor U0126 (2.5 µM), the Erk1/2
inhibitor FR180204 (10 µM), or solvent (0.4% DMSO). Afterwards, cells were starved for 4 hours
(basal medium without fetal bovine serum) and stimulated with EGF for 2 hours. Then, cells were
lysed and luciferase activity was detected. The GFP intensity was used to normalize the reporter
gene activity.
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Figure 5.27: E↵ects of small molecule inhibitors on the SRE luciferase reporter gene assay
in HEK 293 cells. This diagram shows the relative luciferase expession after co-transfection of the
SRE luciferase reporter plasmid and the indicated vectors. After transfection, HEK 293 cells were
treated with U0126 [2.5 µM], FR180204 [10 µM], or solvent [0.4% DMSO] for 24 hours, serum-starved
and stimulated with EGF. The data are normalized with the unstimulated, empty vector transfected
control cells set as 1 (mean ± SEM).
As shown in Figure 5.27, co-transfection of the SRE luciferase reporter plasmid and the empty
control plasmid caused a readily detectable increase in luciferase activity. Incubation with the
MEK1/2 inhibitor U0126 or Erk1/2 inhibitor FR180204 completely blocked luciferase expression.
Hence, this reporter gene assay represents a suitable method to evaluate the putative inhibition of
Erk1/2 activity by C5 or Erk1/2 activation by C3, respectively.
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5.3.2.3 E↵ects of C3 and C5 on the SRE luciferase reporter gene assay
The e↵ect of the RNA aptamers was investigated after co-transfection of the SRE luciferase reporter
and the RNA expression vectors, which facilitated the expression of the aptamers C3 or C5, or the
control sequences C5 B2, C3sc, or C5sc (Section 5.2.2). After transfection, HEK 293 cells were
incubated for 24 hours and processed as described above.
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Figure 5.28: E↵ect of C3 and C5 on the SRE luciferase assay after 24 hours incubation.
This diagram shows the relative luciferase expession after co-transfection of the SRE luciferase reporter
plasmid and the indicated vectors. After transfection, HEK 293 cells were incubated for 24 hours,
serum-starved, and stimulated with EGF. The data are normalized with the unstimulated, empty vector
transfected control cells set as 1 (n =3, mean ± SEM). Expression of the control sequence C5sc induced
a significant alteration of the luciferase signal whereas all other RNA expression vectors showed no
inhibitory e↵ects. Comparison was made by the use of the Kruskal-Wallis test with multiple comparison
post-test. * indicates p-value < 0.05, n.s. not significant. Empty: empty control vector.
It was again possible to detect an increase in luciferase activity after transfection and EGF
stimulation (Figure 5.28). Strikingly, the co-transfection of the control sequence C5sc resulted in a
significant attenuation of the luciferase signal compared to the empty control vector (p = 0.0183,
Kruskal-Wallis test with multiple comparison post-test).
Since C5sc does not bind to Erk1/2 (Section 10.1), these e↵ects might be mediated either by
a decrease in protein expression or o↵-target e↵ects which interfere with Erk1/2 signaling. HEK
293 cells that were transfected with C5sc expression plasmids revealed a decrease in luciferase
activity but did not show alterations in GFP expression levels (see Section 10.5 for a representative
experiment). This implicates that the expression of C5sc a↵ects the Erk1/2 MAP kinase pathway
through o↵-target e↵ects.
Notably, neither the expression of C3 nor C5 resulted in a decrease in luciferase expression after
24 hours (Figure 5.28). Thus, the incubation time of the RNA expression vectors was prolonged
from 24 hours up to 72 hours. As can be seen in Figure 5.29, no inhibitory signal of C3 or C5 was
observed after incubation periods of 36, 48, 60, or 72 hours. Surprisingly, no e↵ects by C5sc were
observed either.
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Figure 5.29: Luciferase assays 36-72 hours. These diagram show the relative luciferase activity af-
ter co-transfection of the SRE luciferase reporter plasmid with the indicated vectors. After transfection,
HEK 293 cells were incubated for A) 36, B) 48, C) 60, or D) 72 hours, serum-starved and stimulated
with EGF. The data are normalized with the unstimulated, empty vector transfected control cells set as
1. The RNA expression vectors showed no inhibitory e↵ects on Erk1/2 signaling. Comparison (36 hours
only) was made by the use of the Kruskal-Wallis test with multiple comparison post-test. Experiments
were performed at least twice (mean ± SEM). Empty: empty control vector.
Taken together, these data demonstrate that C3 and C5 do not a↵ect intracellular Erk1/2 ac-
tivity under the tested conditions. Although the cellular RNA concentration and stability remain
to be investigated, the fact that C5sc showed activity after 24 hours supports the notion that the
RNA aptamers were indeed transcribed inside the cell. Therefore, two reason why the aptamers did
not show inhibitory activity in this assays could have been a lack of stability as well as retention in
cellular compartments. In turn, this could have prevented the aptamer´s access to Erk1/2.
5.3.3 Investigation of putative direct e↵ects on Erk1/2 MAP kinase sig-
naling after RNA transfection
In order to better control the cellular localization, the delivery strategy was changed in subsequent
experiments to facilitate the modulation of Erk1/2 activity in the cytoplasm. Instead of utilizing a
RNA expression vector, in vitro transcribed aptamers were directly transfected into the cells. This
strategy has previously been applied to modulate Erk1/2 MAP kinase signaling with aptamer M69
in H460 cells [188, 189]. The target of aptamer M69 are cytohesin guanine nucleotide exchange
factors, which are localized in the cytoplasm [183].
The transfection of exogenously synthesized aptamers o↵ers several additional advantages: For
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their synthesis, the RNAs do not rely on the host cells transcription machinery and can be tested
for binding and functionality before application inside cells. Moreover, in vitro transcribed RNAs
can easily be modified to improve stability, and to introduce chemical functionalities (Section 3.3.2).
5.3.3.1 Transfection e ciency of RNA aptamers
Since previous aptamer transfection experiments were conducted in H460 cells [188, 189], this cell
line was chosen for subsequent experiments. H460 cells are a non-small cell lung cancer cell line.
First, the transfection e ciency of this cell line was investigated. Thus, aptamers C3 or M69 were
5´-labeled with fluorescein and transfected for 5 hours. Transfection of the RNA aptamers took
place in medium without serum to prevent degradation by nucleases.
Afterwards, the cells were treated with RNAse to remove RNAs that bound to the cell surface,
and washed several times. The relative transfection e ciency was measured by detecting the fluo-
rescence signal of the cells by flow cytometry.
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Figure 5.30: Transfection e ciency. Cells were transfected with fluorescein - labeled C3 or M69
(labeled RNA), unlabeled RNA or treated with fluorescein -labeled RNA in the absence of transfection
reagent (untransfected RNA) for 5 hours. The relative transfection e ciency was measured by detecting
the fluorescence signal of the cells by flow cytometry. A) Histogram showing a representative FACS
experiment of H460 cells transfected with fluorescein labeled RNA. B) The bar diagram shows the
detected fluorescence signal 5 hours after transfection. The signal was normalized with non-transfected
control cells set as 1 (n = 2, mean ± SEM).
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The results of these experiments are summarized in Figure 5.30 and show that H460 cells can be
transfected with RNA aptamers in a concentration dependent manner. By utilizing RNA concentra-
tions above 50 nM, all cells could be addressed by lipofection and revealed a detectable fluorescence
signal (Figure 5.30B). The observed increase in the fluorescence signal results from internalized
RNAs. No increase in fluorescence signal was observed in cells that were transfected with unla-
beled RNA or incubated with fluorescein-labeled RNA without transfection reagent (Figure 5.30B).
Notably, the absolute intracellular RNA concentration was not quantified with this method. The
following table gives an estimation of the intracellular RNA concentration that could be achieved
by transfection.
Table 5.13: Estimation of the maximal intracellular RNA concentration that could be achieved by
transfection of 250 nM RNA.
Absolute transfection e ciency [%] Intracellular RNA concentration [nM]
15 5600
10 3750
5 1875
1 375
0.5 188
For the calculation, the following factors were taken into consideration: 75 pmol RNA in 300 µl
reaction volume, cell number: 20,000, cell volume: 10 11 liter [188].
The estimated transfection e ciencies are in accordance with other studies, which quantified the
total amount of transfected RNA in comparison to the original transfection mix for RNA aptamers
to be 12% [188] or 6% for siRNA [348]. Hence, these concentration should be su cient to monitor
the inhibition of Erk2 activity by C5 and Erk1/2 activation by C3, respectively.
5.3.3.2 E↵ect of small molecule inhibitors on Erk1/2 signaling in H460 cells
Under the tested assay conditions, all cells could be transfected in a concentration-dependent man-
ner with in vitro transcribed RNAs (see above). Therefore, putative e↵ects of the aptamers were
monitored by the quantification of intracellular Erk1/2 activation and downstream signaling via
SDS-PAGE and western blot analysis.
Erk1/2 activation was quantified by detecting the phosphorylation of its activation loop with
phosphospecific antibodies (Thr202/Tyr204, Thr 185/Tyr187). To analyze Erk1/2 activity in dis-
tinct cellular compartments, it was chosen to analyze the phosphorylation of two Erk1/2 substrates:
Elk-1 (p-Ser383) and p-90-RSK1 (p90, p-Thr356/Ser360). Elk-1 is a nuclear transcription factor
which becomes activated in the nucleus and p90-RSK1 is a kinase which becomes activated by
Erk1/2 in the cytosol (Figure 5.31).
Consequently, it was investigated if direct inhibition of growth factor induced Erk1/2 signaling
by the aptamers would be detectable in H460 cells. For this purpose, the two small molecule
inhibitors FR180204 and U0126, were employed (Figure 5.31). Again, FR180204 and U0126 served
as controls to verify if the inhibition of Erk1/2 activity by C5 or Erk1/2 activation of C3 would be
detectable with this assay.
To monitor intracellular Erk1/2 activation and downstream signaling after inhibitor treatment,
H460 cells were starved overnight (basal medium without fetal bovine serum). Cells were then
treated with FR180204, U0126, or solvent (0.5% DMSO). Afterwards, the cells were stimulated
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with EGF for 5 minutes, followed by cell lysis, SDS-PAGE, and immunoblot analysis. Actin served
as loading control.
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Figure 5.31: Erk1/2 signaling. The activation of intracellular Erk1/2 signaling is triggered by
the binding of EGF to a receptor-tyrosine-kinase. Subsequently, the activation of the Erk1/2-MAPK-
cascade is mediated by the small G-protein Ras. The activation of Erk1/2 results in the phosphorylation
of diverse nuclear transcription factors (e.g. Elk-1) or targets in the cytosol (e.g. p-90-RSK1). The
small molecule U0126 blocks the activation of MEK by Raf, whereas FR180204 blocks Erk1/2 activity
in an ATP-dependent manner. RTK: receptor tyrosine kinase, p90: p-90-RSK1.
.
The results of the MEK inhibitor U0126 are depicted in Figure 5.32.
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Figure 5.32: E↵ect of U0126 on Erk1/2 signaling in H460 cells. A) Representative immunoblot analysis of H460 cells treated with the
control compound U0126 or solvent and stimulated with EGF. Phosphorylation of the indicated proteins was determined by immunodetection using
phosphospecific antibodies. Actin served as loading control. B-D) These diagrams show relative phosphorylation levels of B) Erk1/2, C) p90 or D) Elk-1
after normalization for actin with EGF-stimulated cells set as 1 (n=3, mean ± SEM).
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In H460 cells, it was possible to detect an increase in Erk1/2 signaling after EGF stimulation,
which was found both in the level of Erk1/2 (Figure 5.32B) and of the substrate protein p90-RSK1
(Figure 5.32C). In contrast, Elk-1 activation was barely detectable (Figure 5.32D).
Treatment of H460 cells with the Mek inhibitor U0126 resulted in complete inhibition of Erk1/2
activation at a concentration of 2.5 µM (Figure 5.32B). This inhibitory e↵ect was also found on the
levels of the substrate proteins p90-RSK1 and Elk1 (Figure 5.32C,D).
When Erk1/2 activation was inhibited completely, phosphorylation of p90-RSK1 was reduced to
the baseline level of unstimulated cells (Figure 5.32C). Interestingly, Elk-1 phosphorylation seemed
to be more strongly reduced in U0126 treated cells that in unstimulated cells (Figure 5.32D). Since
Elk-1 is phosphorylated by additional kinases besides Erk1/2 [349], this e↵ect might be explained
by o↵-target e↵ects of the inhibitor.
These data indicate that inhibition of Erk1/2 activation and downstream signaling, in accor-
dance with the mode of action of aptamer C3, could be detected with this assay.
Treatment with ATP-competitive Erk1/2 inhibitor FR180204 also resulted in the inhibition of
substrate phosphorylation (Figure 5.33).
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Figure 5.33: E↵ect of FR180204 on Erk1/2 signaling in H460 cells. A) Representative im-
munoblot analysis of H460 cells treated with FR180204 or solvent and stimulated with EGF. Phospho-
rylation of the indicated proteins was determined by immunodetection using phosphospecific antibodies.
Actin served as loading control. B-C) These diagrams show relative phosphorylation levels of B) p90-
RSK1 or C) Elk-1 after normalization for actin with the EGF-stimulated cells set as 1 (n=2, mean ±
SEM).
At a concentration of 10 µM, p90-RSK1 phosphorylation was reduced to the same baseline level
that is found in unstimulated cells (Figure 5.33B) and Elk-1 phosphorylation decreased even further
than the phosphorylation level found in unstimulated cells (Figure 5.33B). This was also observed
for the Mek inhibitor U0126 (Figure 5.32).
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In total, the Erk1/2 inhibitor FR10204 seems to be less potent that U0126. Inhibition of
Erk1/2 activity was observed at a high concentrations (10 µM) whereas the addition of U0126
blocked downstream signaling at a concentration of 2.5 µM (Figure 5.33B,C).
Taken together, these data suggest that the inhibition of the Erk1/2 pathway with C5 could be
detectable by reduction of both Elk-1 and p90-RSK1 phosphorylation.
5.3.3.3 E↵ect of C3 and C5 on Erk1/2 signaling in H460 cells
In the next step, the aptamers e↵ect on Erk1/2 MAPK signaling was investigated. To this end, 250
nM C3 or C5 aptamer were transfected into H460 cells and inhibition of cellular Erk1/2 activity was
monitored. The transfection took place in the absence of serum to prevent both nuclease-mediated
degradation and activation of the signal transduction pathway. To activate Erk1/2 signaling, the
cells were stimulated with EGF for 5 minutes before cell-lysis.
By using these transfection conditions, intracellular RNA concentrations of up to 6 µM can be
expected (Section 5.3.3.1). This concentration has been su cient to monitor the inhibition of Erk2
activity by C5 (Section 5.2.4.2) and Erk1/2 activation by C3 (Section 5.2.4.4) in vitro.
C3sc was used as a control sequence for C3 and C5. In addition, the e↵ects of TRA and C5sc
on Erk1/2 MAP kinase signaling were also investigated.
TRA has previously been shown to lose its a nity for Erk2 in the presence of potassium ions
(Section 5.2.1.1). Since potassium ions are highly abundant within the cytosol, it was tested if the
predicted lack of activity in vitro could indeed be observed in vivo.
C5sc does not bind to Erk1/2 and revealed side e↵ects on Erk1/2 signaling in the luciferase
assay (Section 5.3.2.3), Subsequently, it was investigated which Erk1/2 targets could be a↵ected by
cross-talk as a response to the transfection of C5sc.
First, the RNA´s e↵ect on Erk1/2 activation was detected with phosphospecific antibodies (Sec-
tion 5.3.3.2). Heat shock cognate protein 70 (Hsc70) served as loading control.
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Figure 5.34: E↵ect of C3 and C5 on Erk1/2 activation in H460 cells. A) Representative
immunoblot analysis of H460 cells transfected with the indicated RNAs and stimulated with EGF.
Phosphorylation of the indicated proteins was determined by immunodetection using phosphospecific
antibodies. Hsc70 served as loading control. B) This diagram shows relative phosphorylation levels of
Erk1/2 after normalization for hsc70 (n=3, mean ± SEM).
The results of these experiments are depicted in Figure 5.34. Contrary to the inhibition of
Erk1/2 activation by C3 which was detected in vitro, no inhibition of cellular Erk1/2 activation
was observed (Figure 5.34). Moreover, neither C5 nor TRA revealed an inhibitory e↵ect on Erk1/2
activation.
C5sc also did not a↵ect Erk!/2 activation directly. This supports the notion that the observed
e↵ects in the luciferase assay might have arisen from cross-talk with another signal transduction
pathway.
Subsequently Erk1/2 activity was monitored by substrate phosphorylation of p90-RSK1 (p-90,
Thr356/ Ser360) and Elk-1 (p-Ser383) (Figure 5.35).
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Figure 5.35: E↵ect of C3 and C5 on substrate phosphorylation in H460 cells. A) Rep-
resentative immunoblot analysis of H460 cells transfected with 250 nM of the indicated RNAs and
stimulation with EGF. Phosphorylation of the indicated proteins was determined by immunodetection
using phosphospecific antibodies. Actin served as loading control. B-C) These diagrams show relative
phosphorylation levels of B) p90-RSK1 or C) Elk-1 after normalization for actin (mean ± SEM). B) C5sc
induces a significant upregulation of p90-RSK1 phosphorylation in comparison to C3sc. Comparison
was made with the ”Mann Whitney test. * indicates p value <0.05, n.s.: not significant.
Under these conditions, C3 and C5 transfected samples did not display any inhibitory e↵ects
on p90-RKS1 phosphorylation (Figure 5.35B).However, previous results have implicated that intra-
cellular expression of C5sc induces a downregulation of the Erk1/2 MAP kinase pathway (Section
5.3.2.3). Here, it could be observed that transfection of C5sc increased phosphorylation levels by
45% compared to C3sc (p=0.0159, Mann Whitney test). Hence, p90-RSK1 seems to be one of the
Erk1/2 targets a↵ected by the secondary e↵ects of C5sc.
TRA revealed sensitivity to the presence of monovalent cations in vitro). Surprisingly, transfec-
tion of TRA also induced an up-regulation of p90-RSK1 phosphorylation in comparison to C3sc,
C3, or C5 (Figure 5.35A).
Moreover, none of the transfected aptamers have shown an inhibitory e↵ect on Elk-1 phospho-
rylation. In contrast to their e↵ect on p90-RSK1 phosphorylation, C5sc and TRA did not promote
an increase in Elk-1 phosphorylation (Figure 5.35C).
In summary, neither C3 nor C5 induced a down-regulation of Erk1/2 activation or activity in
H460 cells. In order to verify that the lack of inhibitory e↵ect was not dependent on the cell line
used, the transfection experiments were repeated in A431 cells. In contrast to H460 cells, A431 do
not have an activating mutation in the Ras oncogene [350].
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5.3.3.4 E↵ect on Erk1/2 signaling in A431 cells
The putative e↵ect of the Erk2 aptamers was also investigated in A431 cells. A431 are human
squamous carcinoma cells and have successfully been employed before to investigate MAP kinase
signaling inhibitors [351, 352].
The cells were again transfected with 250 nM aptamers or control sequences and processed as
described for H460 cells (Section 5.3.3.3). Erk1/2 activity was again measured by phosphorylation
of the substrate proteins Elk-1 (p-Ser383) and p90-RSK1 (p-90, p-Thr356/Ser360). Actin served
as loading control.
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Figure 5.36: E↵ect of C3 and C5 in A431 cells. A) Representative immunoblot analysis of A431
cells transfected with the indicated RNAs and stimulated with EGF. Phosphorylation of the indicated
proteins was determined by immunodetection using phosphospecific antibodies. Actin served as loading
control. B-C) These diagrams show relative phosphorylation levels of B) p90-RSK1 or (C Elk-1 after
normalization for actin (n=2, mean ± SEM).
Neither C3 nor C5 transfected samples displayed any inhibitory e↵ect on p90 phosphorylation
(Figure 5.36B). Again, C5sc induced an increase in p90 phosphorylation by approximately 35%. In
H460 cells, this was also observed for TRA (Section 5.3.3.3).
None of the sequences interfered with Elk-1 phosphorylation (Figure 5.36C). This is again in
accordance with the data from H460 cells that did not demonstrate any inhibitory or stimulatory
e↵ect of C3, C5, or the control RNAs on Elk-1 phosphorylation (Section 5.3.3.3).
To this end, no explicit inhibitory e↵ect of C3 or C5 on Erk1/2 activity and, thus, substrate phos-
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phorylation was observed after RNA transfection into A431 cells.
5.3.3.5 Transfection of in vitro transcribed RNAs impairs cell viability
The non-targeting control sequences C5sc and C3sc, as well as TRA, have exerted distinct e↵ects on
the phosphorylation of the Erk1/2 substrate p90-RSK1 in two cell lines (Sections 5.3.3.3, 5.3.3.4).
This raised the questions whether the lipofection of in vitro transcribed RNAs exhibits even
more pronounced o↵-target e↵ects, which could impair the use of this technique for research appli-
cations. In order to answer this question, the RNAs e↵ects on cell proliferation was investigated.
The e↵ect of the control RNA and the aptamers on cell proliferation was analyzed transfected
H460 cells at di↵erent time-points (Figure 5.37). To achieve this, the transfection conditions were
down-scaled from immunoblot experiments to a smaller volume in 96-well plates. 5 or 0.5 pmol
RNA in this assay equal 250 or 25 nM transfected RNA during immunoblot experiments, respec-
tively.
At the time point when cells were harvested for immunoblot experiments (4 hours after trans-
fection), none of the aptamers or control RNAs showed any e↵ects on cell viability (Figure 5.37A).
24 hours after transfection, a clear relationship existed between cell survival and lipid-mediated
RNA delivery. Incubation with 5 pmol RNA led to a reduction of cell proliferation by 50%, regard-
less of the sequence (Figure 5.37B). This e↵ect was not observed for mock transfected cells and,
thus, seems to reflect RNA-mediated toxicity. This toxic phenotype seems to be concentration-
dependent because no toxicity was observed at lower RNA concentrations (0.5 pmol).
Incubation with 5 pmol C3, C5, and C3sc led to identical levels of cell death as were observed
after 24 hours (Figure 5.37C). Quite notably, cell proliferation was completely inhibited in C5sc
and TRA transfected samples. The transfection of 0.5 pmol RNA did not a↵ect cell proliferation
after 72 hours (Figure 5.37C). Hence, toxic secondary e↵ects can be abolished by using lower RNA
concentrations.
In summary, there has been a strong correlation between cell survival and lipid-mediated RNA
delivery under the assay conditions. These e↵ects are both concentration - and time - dependent.
Furthermore, it was shown that o↵-target e↵ects of this assay are capable of inducing strong, quan-
tifiable phenotypes that impact Erk1/2 substrate protein phosphorylation (Sections 5.3.3.3, 5.3.3.4).
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Figure 5.37: Transfection of in vitro transcribed RNAs impairs cell viability. The diagrams
show the relative cell viability after transfection and incubation with the indicated RNAs (0.5 or 5 pmol)
or transfection reagent (mock) at the indicated time-points. The relative cell viability was determined
by using a MTT assay. The data are normalized with the untreated control cells set as 100% (n=4,
mean ± SEM). mock: mock transfection.
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5.4 Aptamer-based control of neuronal Erk1/2 signaling
So far, none of the transfection experiments have revealed any inhibition of Erk1/2 signaling. In
contrast, only o↵-target e↵ects, which occurred in a time - and concentration dependent manner,
were monitored.
The lack of the inhibitory e↵ects of the aptamers could be due to distinct features. For exam-
ple, it might have been possible that the aptamers are located in a cellular compartment, which
could have prevented their direct access to Erk1/2. In addition, it could have been possible that
any putative e↵ects on Erk1/2 activation or activity are masked by cross-talk with other signal
transduction pathways.
Based on this hypothesis, I decided to use microinjection as a delivery method to introduce
the aptamers into the cell. This technique enables to directly inject the aptamers into the cytosol
and allows for direct access to Erk1/2. More importantly, the aptamers e↵ects on Erk1/2 signaling
can be monitored on single-cell level and in real-time within minutes after application. This could
minimize cross-talk with other signal transduction pathways.
Contrary to the previous transfection experiments, the microinjection experiments were not
performed with cultured cells. Our group is collaborating with Prof. Becks working group at the
University Hospital on another project. Since Prof. Beck´s lab is widely renowned for electro-
physiological recording techniques and has expertise in monitoring neuronal Erk1/2 activity [353],
we developed an assay in which we could both introduce the aptamers into cells and monitor the
aptamers e↵ects on cellular Erk1/2 signaling in real-time. To this end, we introduced the aptamers
into the soma of CA1 pyramidal neurons in murine brain slices and monitored their e↵ect on neu-
ronal Erk1/2 signaling with whole-cell patch clamp recordings (Figure 5.38). Erk2 is activated this
area of the hippocampus following high-frequency stimulation that induce a certain form of long
term potentiation [281].
Because this assay required expertise in electrophysiological recording and in-depth training in
neurobiology in order to optimize the assay conditions, the whole-cell recordings were performed
by Therese Alich (Beck lab) during her Master´s Thesis [354]. I performed all binding data.
CA1
CA3
Stim
Rec + Aptamer
Figure 5.38: Whole-cell recording setup. Schematic representation of a hippocampus slice showing
stimulating (Stim) and recording (Rec) sites. The aptamers were introduced into the soma of CA1
pyramidal neurons via the recording electrode.
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5.4.1 Truncation of C3, C5, and C5 B2.
The tip diameter of the patch pipette is in the low µM range [355]. In order to facilitate the
di↵usion of the aptamers through the tip, C5 and C5 B2 were truncated from 112 to 71 nucleotides
and C3 was truncated from 101 to 59 nucleotides by removing the primer-binding sites of the
original aptamers. The resulting aptamers C5.71 and C3.59 are shown in Figure 5.39. C3.59 and
C5.71 were tested for Erk2 binding with filter retention assays and revealed the same a nities as
the full-length aptamers C3 and C5, respectively (Figure 5.39, Table 5.14).
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Figure 5.39: Truncated variants of C3 and C5. Proposed secondary structure of the truncated
aptamers A) C5.71, and B) C3.59. C) Filter retention assay of full-length aptamers C3 and C5 and
their truncated variants binding to Erk2 in 1x PBS, 3 mM MgCl2. KD values are listed in table 5.14.
Table 5.14: KD values and Hill coe cients (h) according to Figure 5.39.
Aptamer KD [nM] h
C5 130 ± 6.3 2.2 ± 0.2
C5.71 170.7 ± 15.8 3.5 ± 0.8
C3 67.8 ± 6.5 2.2 ± 0.4
C3.59 167.9± 22 3.2 ± 1.0
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5.4.2 Distribution of aptamers within neurons
Next, the truncated aptamers were introduced into the soma of CA1 pyramidal neurons via the
recording electrode and their spatio-temporal distribution was monitored by two-photon microscopy.
Therefore, the aptamers the RNA sequences were 5´-labeled with fluorescein. In addition, cells were
co-labelled with Alexa594 for better visualization of the neurons morphology.
The observed fluorescence signal of aptamer C5.71 could be detected in the soma after 5 minutes
(Figure 5.40). Within the ensuing 15 minutes, the fluorescence signal of aptamer C5 increased in
the distal dendrite. Hence, this data implicates that the introduction of the aptamers into the soma
and dendrite with the whole-cell recording setup occurs rapidly.
20 µm 
Alexa 594     C5 - FITC (10µM) Merged 
3 µm 
5 min 
20 min 
20 µm 
Figure 5.40: C5.71 di↵uses into the distal dendrite. Images of a CA1 pyramidal neurons with
fluorescein - labeled aptamer C5.71 (C5-FITC, green) and Alexa595 (red). The upper left panel shows
the soma and apical dendrite of a CA1 pyramidal neuron and the recording pipette. The white box
shows the distal dendrite, which is magnified on the right side.
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5.4.3 U1026 inhibits neuronal Erk1/2 signaling
As mentioned in the introduction, Erk1/2 can be activated by certain electric stimulation patterns
in the hippocampus. Among other substrates, activated Erk1/2 catalyze the phosphorylation of
the KV 4.2 ion channel and thereby modulate the channels activity [281, 282]. Erk1/2 activity is
also linked to decrease the channels outward K+ current [283].
Kv4.2
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Figure 5.41: Model of neuronal Erk1/2 signaling. A) Dendritic excitability is modulated by
ion channels, especially by A-type K+ channels, such as the KV 4.2 potassium channel subunits [356].
B) Erk1/2 catalyze the phosphorylation of KV 4.2 [281]. In addition, phosphorylation by Erk1/2 was
described to inhibit the channels activity [282] and to decrease the outward K+ current [283].
First, it was tested if the inhibition of cellular Erk1/2 signaling in response to the Mek1/2
inhibitor could be monitored by e↵ects on the voltage potential after stimulation (Figure 5.41).
This has been previously been described in the literature [282, 357].
To monitor the e↵ects of Erk1/2 inhibition on neuronal functions, 40 µM U0126 was dissolved
in the recording solution and introduced into the soma. After a stable baseline was recorded for 10
minutes, Erk1/2 activity was induced [354].
A stable increase in voltage potential could be monitored within the first 15 minutes (Figure
5.42). Afterwards, the membrane potential reached a plateau. In turn, the Mek inhibitor U0126
blocked any alterations in membrane potential recordings. Hence, this readout is suitable to monitor
inhibition of Erk1/2 activity in neurons.
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Figure 5.42: E↵ect of the Mek inhibitor U0126 on Erk1/2 signaling. A) This diagram
shows membrane potential recordings during the experiments performed with 40 µM U0126 or solvent
(0.4% DMSO). Stimulation started at the timepoint 0. Y axes depict membrane potential amplitudes
normalized to the baseline amplitudes before stimulation. Experiments were performed at least eight
times (mean ± SEM). B) For comparison, the recordings between 20 - 30 minutes of each slice were
were averaged. Comparison were made with the Wilkinason rank-test. ** indicates significance between
DMSO and U0126 (p-value <0.01).
5.4.4 E↵ect of C3.59 and C5.71 on neuronal Erk1/2 signaling
To monitor now the aptamers impact on neuronal Erk1/2 signaling, 1 µM C3.59, C5.71, or the
control RNA C5 B2.71 were dissolved in the recording solution and introduced into CA1 pyramidal
neurons via the patch pipette. Again, a stable baseline was monitored for 10 minutes before Erk1/2
activity was induced by high frequency stimulation.
The experiments are summarized in Figure 5.43. Recordings taken with the control sequence
C5 B2.71 displayed an increase in membrane potential after 15 minutes (Figure 5.43A). In contrast,
no alterations in voltage potential were monitored when C5.71 was introduced into the neuron (p
= 0.026, Kruskall-Wallis test with non-parametric multi comparison post - test).
Importantly, these inhibitory e↵ects are in accordance with previous biochemical assays that
employed the Mek1/2 inhibitor U0126 [282, 357] and implicate that C5.71 modulates Erk1/2 ac-
tivity.
In contrast, experiments performed with C3.59 revealed a rapid rise of the membrane potential
directly after stimulation started (Figure 5.43B). However, at the concentration used in this assay,
C3.59 did not significantly interfere with potentiation during the measurements.
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Figure 5.43: E↵ect of C3.59 and C5.71 on neuronal Erk1/2 signaling. A) These diagrams show
membrane potential recordings during the experiments performed with 1 µM A) C5 B2.71, and C5.71,
or B) B2.71 and C3.59. Stimulation started at the timepoint 0. Y axes depict membrane potential
amplitudes normalized to the baseline amplitudes before stimulation. Experiments were performed at
least six times (mean ± SEM). C) For comparison, the recordings between 20 - 30 minutes of each slice
were were averaged. Comparison were made with the Kruskall-Wallis test with non-parametric multi -
comparison post - test. ** indicates significance between C5 B2.71 and C5.71 (p-value <0.01), n.s. not
significant.
5.4.5 C5.71 and C5 B2.71 do not a↵ect neuronal Erk1/2-independent
functions
In order to further validate that the e↵ect of C5.71 on voltage potential recordings after stimula-
tion was indeed dependent on the inhibition of Erk1/2 by C5.71, several control experiments were
performed.
The alteration in voltage-potential in response to the induced electric stimulation pattern com-
bines the activity and cross-talk of several kinases (PKA, PKC, CaM kinase II) and second messen-
ger cascades in addition to Erk1/2 [358]. Hence, it was verified that the change in voltage potential
observed after the addition of C5.71 is indeed dependent on Erk1/2. To achieve this, an Erk1/2-
independent increase in voltage potential was induced [357].
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Figure 5.44: E↵ect of C5.71 and C5 B2.71 on neuronal Erk1/2-independent signaling.
A) This diagram shows membrane potential recordings during the experiments performed with 1 µM
C5 B2.71 and C5.71. Stimulation started at the timepoint 0. Y axes depict membrane potential
amplitudes normalized to the baseline amplitudes before stimulation. Data are show mean ± SEM. B)
For comparison, the recordings between 20 - 30 minutes of each slice were were averaged.
Stimulation with the Erk1/2-independent protocol resulted in an instant increase in voltage
potential (Figure 5.44A). Thereby, no di↵erence between the control sequence C5 B2.71 and the
aptamer C5.71 was observed (Figure 5.44A, B), which further proves that the aptamer C5.71 indeed
inhibits neuronal Erk1/2 activity.
Moreover, it was investigated if the introduction of C5.71 or the C5 B2.71 control sequence
during recording had induced o↵-target e↵ects that could interfere with neuronal functions. Since
neither C5.71 and C5 B2.71 altered the passive or active properties of CA1 neurons [354], the e↵ects
observed by C5.71 also do not seem to be mediated by o↵-target e↵ects.
Taken together, it was shown in this chapter that aptamer C5 e↵ectively inhibits a neuronal
function that requires Erk1/2 activity. The introduction of the aptamer directly into the cytosol of
neurons during whole-cell patch-clamp recordings provided a novel and generally applicable strategy
which allowed both to modulate and to monitor kinase activity on single-cell level and in real-time.
These data implicate that RNA aptamers can provide a new class of potent tools to manipulate
intracellular kinase activity and to study signal transduction pathways in neurons.
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Protein kinase inhibitors represent valuable tools for therapeutic applications and chemical biology
research. In order to investigate if RNA aptamers might represent a promising class of molecular
tools that overcomes the limitations of other types of pharmacological inhibitors, distinct strategies
were followed in this study:
First, the co-crystal structure of aptamer C13 and its target GRK2 was determined to unravel
the molecular determinants which constitute to an ATP-competitive aptamers specificity (Section
5.1).
Furthermore, two novel Erk2-recognizing aptamers were throughly characterized (Section 5.2).
Remarkably, both aptamer C3 and C5 bound to their target with huge tolerance to ionic conditions
(Section 5.2.1.2). C3 and C5 also revealed high specificity (Section 5.2.3) and addressed distinct
sites on Erk2 (Sections 5.2.4.1, 5.2.4.3). Thus, C3 and C5 were able to inhibit distinct functions
of Erk2 (Sections 5.2.4.2, 5.2.4.4), highlighting the potential of RNA aptamers as domain specific
inhibitors.
Most importantly, this study revealed that aptamers can be applied as intracellular inhibitors
of kinase activity (Section 5.4). When introduced into neurons, aptamer C5 inhibited a neuronal-
function that is known to require Erk1/2 activity (Section 5.4.4).
6.1 The co-crystal structure of GRK2 and C13 variants
In order to be used as research tools, protein kinase inhibitors should exhibit high specificity. In
contrast to many small molecule protein kinase inhibitors, RNA aptamers have been shown to
inhibit the function of their respective kinases with high specificity [127, 209, 210]. However, the
precise aspects how ATP-competitive aptamers derive their specificity were yet unknown. For the
investigation of the molecular determinants of this interaction, the co-crystal structure of RNA
aptamer C13 with GRK2 was determined [209].
Figure 6.1 shows the co-crystal structure of GRK2 with the C13.28 aptamer variant in com-
parison to the ATP-competitive small molecule inhibitor Paroxetine [359]. ATP-competitive small
molecules form one to three hydrogen bonds with the amino acids located in the hinge region of
the kinase [33]. Thereby, they mimic the hydrogen bonds that are normally formed by the adenine
ring of [35, 360]. They usually do not exploit the ribose binding site or the triphosphate binding
site of ATP [33]. Due to the high conservation of the active site, ATP-competitive inhibitors often
lack specificity [87–91].
The co-crystal structure demonstrates that aptamer C13.18 targets about 1,100 A2 of accessi-
ble surface area, which is about the same surface area size involved in mediating protein-protein
interactions [115]. Additionally, the co-crystal structure also shows that C13.28 is sterically more
demanding than the small molecule inhibitor. Thus, the aptamer exhibit a higher likelihood of
blocking protein-protein interactions. In general, these attributes may contribute to the capability
of aptamers to be highly specific research tools.
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A" B"
Figure 6.1: Interactions between the kinase domain of GRK2, C13.28 and a small molecule
inhibitor. The interactions between C13.28 and the kinase domain of GRK2 (yellow, PDB entry 3UZS)
comprise a bigger surface on the protein than the small molecule inhibitor Paroxetine (red, PDB entry
3V5W).
The co-crystal structure reveals the existence of a previously unknown conformation of GRK2
in which the axis of the kinase domain were rotated by 8  as compared to other ATP-bound GRK-
complexes. Domain reorganization indicates that the aptamer not only binds to GRK2, but also
induces a conformational shift in the protein structure. The reorganization of the kinase domain
could prevent kinase activity and might be exploited by small molecule inhibitors that can be
identified in C13 displacement assays.
Domain reorganization is not a unique feature of C13 but has also been demonstrated for the
NF-KB- p50 aptamer complex [361]. A smaller degree of GRK2 kinase domain reorganization has
previously been observed in structures of GRK2 bound to small molecule inhibitors [237, 239].
In summary, it could be demonstrated that C13 stabilizes a unique inactive conformation of
GRK2 through multiple interactions, both within and outside of the kinase domain. It could be
observed that a small part of the aptamer (nucleotides A49-C52) forms extensive interaction within
the active site of GRK2 (Section 5.1.2). The most striking feature of the complex is the adenine
nucleotide at position 51. Adenine 51 mimics the AMP moiety of ATP and is the key element of the
aptamers interaction with GRK2. In this regard, C13 di↵ers to ATP-competitive small molecule
inhibitors, which usually do not exploit the ribose or the triphosphate binding sites [33]. Due to the
low resolution of the complex, it was not possible to determine precise interactions at the atomic
level. Nevertheless, it is very likely that A51 also forms a hydrogen bond to the hinge region of
GRK2.
Outside of the active site, basic residues of the ↵F-↵G-loop are also essential for aptamer binding
(Section 5.1.4), likely because they form electrostatic interaction with the RNA backbone. Since
all members of the GRK superfamily contain a basic ↵F-↵G-loop but adopt di↵erent inactive con-
formation [315], the shape and size of the kinase domain seems to be important for the aptamer´s
binding and specificity. In this regard, the aptamer di↵ers from previously described GRK2 in-
hibitors, such as the rather unspecific inhibitor Balanol [362] or the Takeda compounds [238]. They
achieve selectivity solely by conformational di↵erences within the active site of a kinase domain
[237, 239].
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6.2 Sequence homology between ATP-competitive aptamers
Elucidating the precise determinants which contribute to aptamer C13´s high specificity has not
only gained intriguing insights into the interaction of an ATP-competitive aptamers interaction
with its target. This information has also aided in the identification of a novel inhibitor sca↵old
that might be applied to other aptamers.
Various ATP-competitive small molecule receptor tyrosine kinase inhibitors employ quinazoline
moieties as sca↵olds within their structure (Figure 6.2) [363, 364]. These sca↵olds can serve as
building blocks for kinase inhibitors in medicinal chemistry [365, 366].
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Figure 6.2: Quinazoline sca↵olds in protein kinase inhibitors. The ATP-competitive small
molecule cancer drugs Gefitinib and Erlotinib contain quinazoline sca↵olds.
Nucleotides C47-C52 of the aptamer C13 have been shown to interact within the active site of
GRK2 and could represent a nucleotide sca↵old. A derivation of this motif was discovered in another
RNA aptamer, termed K16 (Figure 6.3) [367]. K16 was selected against cyclin G-associated kinase
(GAK) [367]. GAK belongs to the CMGC kinase family and not to the AGC family as GRK2.
Except for this motif, aptamer K16 shows no overall sequence identity with C13. It is not clear yet
if K16 also interacts with GRK2.
GGGAGAGGAGGGAAGUCUACAUCUUAUCAGAAAGCGCCCAACUGAGAGCGUUGUUGC
GGCUGAUGCCACACGGAUAGUUUCUGGAGUUGACGAAGCU
GGGAGAGGAGGGAGAUAGAUAUCAACUGCAGUUCGGGUAGCAC  AGA
           CCAUACGGGAGAGAAACUUGUGCAACCCGGGGCUACUUUCGUGGAUGCCACAGGAC
K16
C13
K16
C13
Figure 6.3: Sequence homology between C13 and K16. A variation of the ATP-mimicking motif
of C13 was also found in the ATP-competitive aptamer K16.
K16 competes with ATP for binding to GAK. Thus, it is extremely likely that the motif also
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mimics ATP-binding in the active site of cyclin G-associated kinase. The sequence of the motif in
aptamer K16 is CCACACGG. The substitution of uracil for cytosine is in accordance with data
from the co-crystal of C13 and GRK2, which revealed that the nucleotide at this position contributes
its phosphate backbone for binding to the active site and not the nucleotide base (Section 5.1.2).
The existence of the ATP-mimicking motif of C13 in another aptamer may pave the way towards
the development of other specific aptamers. For example, this motif might be included into a
constrained library for the selection of novel aptamers with inhibitory properties. The specificity of
these aptamers might be guided by unique epitopes outside of the active sites, or by shape, and/or
size control.
Interestingly, the ATP-mimicking motif of C13 and K16 is absent in C5, TRA [210], or the PKC
targeting aptamers [324]. Nevertheless, another putative ATP-mimicking motif can be found TRA
and C5 (Figure 6.4).
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Figure 6.4: The putative ATP-binding sca↵old of TRA and C5. Secondary structure prediction
of A) TRA and B) C5. The putative ATP-binding motifs are annotated.
Hence, aptamers that inhibit kinase activity might employ versatile motifs for kinase recognition
and specificity. Elucidating these motifs will not only clarify the aptamers mode of action, but may
also reveal new, unresolved inhibitory entities that may serve as sca↵olds for the identification of
novel kinase inhibitors.
6.2.1 Identification of kinase inhibitors by aptamer displacement
Specific kinase inhibitors represent valuable tools for chemical biology research and therapeutic
applications. Because of its excellent specificity, aptamer C13 represents a promising research tool to
study GRK2 function. However, the lack of suitable techniques for systemic in vivo administration
limits its potential as a drug in therapeutic settings [125]. For such purposes, small molecule
inhibitors would be preferable [206]. Thal and co-workers used the C13.28 variant of aptamer C13
in a displacement assays for the identification of small molecule GRK2 inhibitors and identified
Paroxetine as a direct inhibitor of GRK2 activity (Figure 6.5) [359].
Paroxetine also shares similar inhibitory properties as C13.28 and recognizes the ATP-binding
site of GRK2 [359]. Paroxetine inhibits GRK2 activity within cells and increases cardiac contrac-
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Figure 6.5: Chemical structure of Paroxetine. Chemical structure of Paroxetine. Paroxetine
is a FDA-approved psychotropic drug for the treatment of mental disorders, e.g. major depression
and anxiety disorders [368]. Paroxetine was also identified as a GRK2 inhibitor in a C13-28 aptamer
displacement assay [359].
tility in isolated cardiomyocytes and myocardial  -adrenergic receptors inotrophic reserve in living
mice. Strikingly, Paroxetine (DB00715) is actually a long known, FDA-approved psychotropic drug
for the treatment of mental disorders, such as major depression, and anxiety disorders [368]. As
such, Paroxetine is known to inhibit the human serotonin transporter (SERT) and to prevent the
neuronal re-uptake of serotonin [369]. Furthermore, Paroxetine is described to inhibit the activ-
ities of the norepinephrine transporter (NET), cytochromes CYP2D6 and P450, and nitric oxide
synthase [369, 370].
Not surprisingly, this lack of specificity limits the application of Paroxetine as a research tool.
Like two sites of a coin, lack of specificity does not hamper the application of Paroxetine for mental
disorders. However, at clinically relevant doses, Paroxetine has not been correlated with a large
cardiovascular e↵ect in adults [359], which limits its use for the treatment of heart failure. Subse-
quently, structure-activity relationship studies of Paroxetine were conducted to reduce the inhibitors
activity towards the serotonin transporter [371]. The Paroxetine analogue designed exhibited a 20-
fold decrease of activity towards serotonie uptake but also revealed an increase in the potency for
inhibition of other AGC kinases.
The study by Thal and co-workers has shown that aptamer displacement assays o↵er a promising
alternative to inhibitor identification with conventional strategies (Section 3.2.1.1). Many kinase
inhibitors are obtained by the high-throughput screening of large compound libraries against a
target kinase of interest [81, 82]. However, this approach is often based on in vitro kinase assays
to detect hit compounds [372]. In cases where active kinase conformations or interaction partners
are unknown, or when the identification of non ATP-competitive inhibitors is desired [373], it is
challenging to identify a putative inhibitor.
In theory, aptamers might facilitate the identification of drug candidates for the complete
disease-relevant kinome. They can be easily selected without any structural knowledge about the
target protein or interaction partner [133]. Moreover, automated platforms nowadays enable the
identification of highly a ne and specific aptamers against hundreds of disease relevant targets in
a short time [374, 375].
6.3 Characterization of the novel Erk2 aptamers C3 and C5
Aptamer C13 has proven that RNA aptamers can be powerful, selective protein kinase inhibitors
that can even serve in the identification of novel aptamer- or small molecule-based kinase inhibitors.
Next, the potential of aptamers as kinase inhibitors was investigated for the MAP kinases Erk1/2
(Section 5.2). Erk1/2 are particularly relevant targets because their pathway is deregulated in more
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than 30% of all human cancers [304].
6.3.1 Sensitivity to ionic strength
Aptamers can easily be obtained from an iterative in vitro selection process, termed SELEX [131,
132]. This technique allows to pre-select for molecules that are stable and can bind to their target
under desired conditions. TRA, the first Erk2-recognizing aptamer, was selected in the absence of
monovalent cations [210]. However, the aptamer lost its ability to interact with Erk2 in the presence
of monovalent cations. (Section 5.2.1.1).
Metal ions play a crucial role in determining the structure, stability, and biological properties of
RNA [376]. Cations can accumulate near the RNA backbone and shield electrostatic interactions
[377–379] or contact electronegative pockets within the RNA structure itself [376]. In addition
to RNA folding, metal ions can also be critical for structural and functional aspects of proteins
[380, 381]. The addition of monovalent cations could interfere with the recognition of Erk2 by
destabilizing structural elements within the structure of TRA. A study by Lambert and co-workers
has shown that some secondary and tertiary structures, such as a hairpin and a pseudoknot struc-
ture, were insensitive to ion identity, whereas other tertiary structures become more stable with
decreasing ion size [382]. Smaller ions seem to be able to approach the RNA surface more closely
and thereby a↵ect stacking or electrostatic interactions. This, in turn, might a↵ect the RNA fold.
Thus, new selections were performed to identify aptamers with the ability to bind to Erk2 in the
presence of monovalent cations. Aptamer C3 and C5 were selected in an isotonic high salt bu↵er and
revealed their remarkable ability to bind to Erk2 with high tolerance to distinct monovalent cations
and magnesium ion concentrations (Section 5.2.1.3). However, this was quiet surprising because C3
and C5 were selected without any selection pressure towards ionic strength. This selection scheme
could have also resulted in a loss of a nity for Erk2 in the absence of monovalent cations or presence
of cytosolic ion concentrations.
Although C3 and C5 was not selected for binding to Erk2 under cytosolic conditions, their
tolerance to ionic strength could have played an important role for the application of C5 as an
intramer. Therefore, for future aptamers with the final goal of intracellular application, the pres-
ence of monovalent cations, cytosolic bu↵er conditions or selection pressure towards insensitivity
to monovalent cations during the SELEX process, should be considered. Literature suggests that
many intramers have been selected in the presence of monovalent cations and magnesium, either in
PBS bu↵er [182, 183], or in Hepes but with MgCl2 and with additional NaCl [195] or KCl [186, 202].
One reason why C3 and C5 are not a↵ected by di↵erent monovalent cation concentration could
be presence of secondary and tertiary structures, which are independent of cation identity [382]. C5
could be less sensitive to monovalent cations than TRA due to twelve mutations, which are located
mainly in the central stem and upper bulged region (Figure 3.15). These mutations could lead to
a stabilization of the central stem and allows the building of additional base pairs at the upper
stem, rendering its overall fold less sensitive to cationic strength. Therefore, it should be investi-
gated which mutation and structural di↵erences between C5 and TRA a↵ect their (in)sensitivity
to monovalent cations.
As mentioned above, metal ions can also be critical for structural and function aspects of proteins
[380, 381]. ATP-competition and kinase activity assays strongly suggest that C5 and TRA target
the active site of Erk2. Most protein kinases, including Erk2, require Mg2+ ions within their active
site for coordinating ATP and catalytic reactions [383]. Hence, it is not unlikely that the interaction
of TRA or C5 within the active site is facilitated by a bridging magnesium ion, as was observed
for C13 and GRK2. A decrease in magnesium concentrations could lead either to a decrease of
bridging magnesium ions, rendering TRA and C5 unable to bind to Erk2.
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6.3.2 A nity and specificity
As was already shown for aptamer C13 (Section 5.1), this study confirms that a ne and specific
aptamers can be seleceted for by SELEX. A magnetic bead-based SELEX strategy (Section 3.4.2.5)
led to the identification of aptamers C3 and C5, which bound with high a nities in the low nM
range to Erk2 (Section 5.2.1.2). Their a nities are in the same range as the a nities of aptamers
for other kinase targets [209, 210, 324]. The Hill coe cients of the interactions lay between 1.1-2.2,
which argues that indeed only one aptamer binds to the target molecule.
A detailed comprehensive assessment of the specificity of C3 and C5 was performed across the
kinome families. It revealed that aptamers C3 and C5 bind to the MAP kinase Erk1 and Erk2,
which share sequence homology of 85%. The main di↵erence between Erk1 and Erk2 is the presence
of 19 additional amino acids in the N-terminus of Erk1. The N-terminus of Erk1 was shown to be
responsible for the slower nuclear shuttling rate of Erk1 in comparison to Erk2 [384].
Moreover, no binding of C3 or C5 to other JNK and p38 MAP kinases, which share >40% overall
homology within the kinase domain [385], could be detected. Additionally, C3 and C5 do not bind
to other tested kinases from di↵erent subfamilies.
High specificity is an important requirement for the application of protein kinase inhibitors as
research tools. There are on the order of 20,000 di↵erent types of proteins in the cell [323]. At high
inhibitor concentrations, it becomes increasingly likely that an inhibitor will bind to unintended
targets [386]. Even weak interactions with other kinases within cells, could bring out the so-called
”albumin problem”, which was described by Gold and co-workers for analyte detection [387]. For
example, an inhibitor could bind with an a nity of 1 nM to a kinase target and with an a nity of 1
µM to a second, unintended kinase. If the unintended kinase is present at 1 µM, the inhibitor would
bind to half to the intended and half to the unintended kinases, and thus, could induce secondary
e↵ects.
With an intracellular concentration of 1 µM [337], MAP kinases belong to the most abundantly
expressed kinases in mammalian cells [388–390]. A study in yeast cells has shown that 63 % of
the cellular protein kinases are expressed at a concentration between 1 and 50 nM, and only 11
kinases (13 %) are expressed at higher concentrations than 150 nM [391]. These values provide
an estimation that the protein concentration used in the specificity panel (Section 5.2.3) was far
higher than the intracellular concentration of most protein kinases. Hence, the lack of binding of
C3 and C5 to other kinases suggests a high degree of specificity against the remainder of the kinome.
6.4 Modes of action
This study has shown that aptamers do not only bind with high a nity and specificity to their
target. It could also been demonstrated that aptamers bind to distinct sites on one target and block
kinase functions in ATP-competitive or non-ATP competitive manner (Sections 5.2.4.2, 5.2.4.4).
6.4.1 Aptamer C5
Aptamer C5 was identified by performing a reselection against active Erk2 with a partially con-
strained library based on the sequence of TRA (Section 3.4.2.5). Aptamer C5 competes with ATP
for Erk2 binding and inhibits Erk2 activity (Section 5.2.4.2).
The potential of C5 to inhibit Erk2 activity was evaluated in two distinct kinase assays. In
the first assay reported here, active Erk2 was employed and its ability to phosphorylate target
proteins was measured (Section 5.2.4.2). The addition of C5 resulted in a marked reduction in
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phosphorylated MBP and Elk-1. In this assay, C5 demonstrates similar potency as the ATP-
competitive inhibitor FR180204 [310, 325].
The second assay utilized a kinase cascade in which inactive Erk2 becomes activated by a consti-
tutive active Mek1 kinase [332]. Erk2 activity was measured by substrate phosphorylation (Section
5.2.4.3). C5 also inhibited Erk2 activity in this assay. However, it was observed that higher con-
centrations of C5 were needed to inhibit Erk2 activity than in the Erk2 activity assay. It should be
kept in mind that the lowest IC50 value that can be measured equals half the kinase concentration
in the assay [323]. Since higher kinase concentrations were utilized in the second assay (Erk2 ac-
tivity assay: 60 nM Erk2, Erk2 activation assay: 1000 nM Erk2), higher concentrations of C5 were
needed to inhibit Erk2 activity.
The ability of C5 to compete with ATP strongly suggests that C5 acts via the ATP-binding site
of Erk2. In addition, the higher a nity of C5 to the active conformation of Erk2 also hints into the
direction that C5 targets a structural aspect which is more prominent in active Erk2 than inactive
Erk2. These structural features that discriminate active from inactive Erk2 include the activation
loop, the MAP kinase insert and the L16 segment from the N-terminal domain [392]. Since the
binding of C5 was not a↵ected by mutations within the MAP kinase insert or D-site recruitment
site (DRS) docking domain (Section 5.2.4.3), these domains likely do not contribute to the binding
region of C5.
The precise inhibition mechanism of C5 remains to be investigated. The interaction of C5 with
Erk2 could prevent ATP or substrates from binding to Erk2, and could induce conformational
changes in the kinase domain that lock Erk2 into an inactive state, as was shown for C13 and
GRK2 [315].
Given the high specificity of C5, the aptamer provides great advantages over other ATP-
competitive Erk1/2 inhibitors to study signal transduction pathways. For example, Ohori and
co-workers identified FR180204, an Erk2 inhibitor that recognizes the ATP-binding pocket of Erk2
[304, 389]. Its specificity was tested against only four kinases belonging to the MAP kinase family
[389]. Another ATP-dependent inhibitor of Erk1/2, called FR148083, was identified by screening
compounds generated from a fermentation culture broth [390]. This compound interacts with Mek1
and probably other kinases [390].
6.4.2 Aptamer C3
Aptamer C3 was selected against the inactive conformation of Erk2 (Section 3.4.2.5). C3 binds
with similar a nities to active or inactive Erk2 (Section 5.2.1.2). In contrast to C5 or TRA, it
does not compete with ATP for Erk2-binding and does not inhibit the catalytic activity of Erk2
(Sections 5.2.4.2, 5.2.4.4).
6.4.2.1 The putative binding site of C3 comprises the MAP kinase insert of Erk2
Binding studies with Erk2 docking domain mutant proteins were performed to investigate the
putative binding site of C3 (Section 5.2.4.3).
These studies revealed a complete loss of a nity of C3 for point mutations at tyrosine 261 to
asparagine (Y261N), and serine 264 to proline (S264P). A mutation of histidine 230 to arginine
(H230R), or aspartate 319 to asparagine (D319N) did not a↵ect the binding of C3 to Erk2. Tyrosine
261 and serine 264 are located in close proximity to the activation loop of Erk2 (Section 5.2.4.3).
As crystal structures of the Erk2-C3 complex are not available, it can only be estimated how the
mutations described here might impair C3-Erk2 complex formation. It is possible that C3 might
directly interact with both tyrosine 261 and serine 264 in Erk2-C3 complexes. This accentuates the
fact that mere changes of amino acids can have great impact on the binding of C3 to Erk2. The
substitution of tyrosine 261 to asparagine could prevent stacking interactions between the aromatic
side-chain of tyrosine with the ribonucleic acid bases. Furthermore, the asparagine side-chain could
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form hydrogen bond interactions with the aptamer that could a↵ect its fold or interaction with other
residues. The S264P mutation might impair hydrogen bond interactions that could be formed by
serine 264.
More likely, the mutations Y261N or S264P might a↵ect the binding of C3 indirectly, by altering
the conformations of other Erk2 residues critical for aptamer binding.
The Erk2 point mutants H230R, Y261N and YS264P have been identified in a yeast two hybrid
screen based on their inability to interact with Erk2 [295]. Some mutant proteins were described
to have an adverse e↵ect on protein kinase activity. The Y261N mutant protein showed a 3.5-fold
increase in the apparent KM for MBP (Erk2: 11 µM, Y261N: 38 µM) whereas the S264P and
N236K mutants retained similar kinetic behavior as Erk2 wild-type [295].
The reduced catalytic activity of the tyrosine mutant raises the possibility that the conformation
of the activation loop or other structural aspects of the C-terminus of Erk2 were a↵ected by the
point mutation Y261N [295, 393]. Tyrosine 261 is located in close proximity to other residues that
form direct contacts with the activation loop [295]. In turn, local conformational changes could
explain the more pronounced e↵ect of the Y261N mutation on C3 binding as compared to the S264P
mutation.
The mutation of tyrosine 261 to alanine has previously been reported to disrupt the interactions
between Erk2 and Elk-1 in a GST-pulldown assays [293]. The finding that C3 was not able to
inhibit Elk-1 phosphorylation (Section 5.2.4.2) supports the notion that the binding of C3 to Erk2
induces conformational changes in the Erk2 structure.
Serine 264 is not located in close proximity to amino acids that directly engage in interactions
with the activation loop [295]. The substitution of serine to proline might induce smaller alterations
within the local conformation of the MAP kinase insert which a↵ects the aptamers binding. Prolines
are known to disrupt protein secondary structures because they are unable to adopt a normal alpha-
helix or beta-sheet conformation [394, 395].
Although the binding data obtained in this study provide strong hints about the putative bind-
ing region of aptamer C3, high-resolution crystal structures of the Erk2-C3 complex should be
obtained in the future. Such structures will provide substantial insight into the recognition of Erk2
by C3 and will reveal how specific mutations disrupt this interaction.
The putative binding site of C3 on Erk2 was shown to be comprised of residues 261 and 264.
It is also likely that C3 recognizes a positively charged amino acid cluster (bold letters, Erk2
residues 257-275: KARNYLLSLPHKNKVPWNR) that surrounds tyrosine 261 and serine 264.
This cluster was described to mediate the DNA binding activity of Erk2 and thus, might engage in
the C3-Erk2 complex via electrostatic interactions [301].
Tyrosine 261 has been reported to belong to the F-site recruitment site (FRS) docking domain
of Erk2 which interacts with many targets, including Elk-1, c-fos, SAP1 and the kinase suppressor
of Ras (KSR) [57]. Tyrosine 261 and serine 264 are also located within the MAP kinase insert
domain of Erk2. The MAP kinase insert has been associated with diverse functions, including tran-
scriptional regulation or protein-protein interactions [329]. It is located at the C-terminus (Section
3.4.2.2 ), which would explain both the inability of C3 to compete with ATP-binding for Erk2
(Section 5.2.4.1), and to block kinase activity towards MBP (Section 5.2.4.2).
The MAP kinase insert domain is unique for MAP kinases, cyclin-dependent kinases and
glycogen-synthase kinase 3 (GSK3) [396–398]. Hence, the aptamers high specificity might be de-
rived from the inserts unique sequence composition. By targeting a unique region on Erk1/2, it is
very likely that increased selectivity of aptamer C3 will be achieved compared to ATP-competitive
Erk2 inhibitors.
89
6. DISCUSSION
6.4.2.2 C3 inhibits the activation of Erk2 by Mek1
Investigating the functions of individual protein domains is extremely challenging. A common
method to study the function of a domain is the overexpression of a mutated variant of the pro-
tein [399]. However, this approach can a↵ect protein folding, complex assembly and downstream
regulation, and thereby provide inaccurate results [400].
Employing specific inhibitors that target a specific domain without a↵ecting kinase activity,
would avoid the problems associated with protein over-expression. There are only few domain-
specific Erk2 inhibitors available for the D-site recruitment site (DRS), which include small molecule
inhibitors [401, 402], or peptides that were derived from Mek kinases [403]. In addition, Kummer
and colleagues described E40, a protein derived from ankyrin repeat proteins (DARPin), which
targets the Thr-Glu-Tyr phosphorylation motif and the MAP kinase insert of inactive Erk2 [404].
However, this inhibitor cannot be used to study MAPK domain specific functions without targeting
the activation loop at the same time.
At present, no small molecule inhibitor for the MAP kinase insert of Erk2 is available. In
this study, it was investigated if C3 could block a specific function which is associated with the
MAPK insert, namely the activation of Erk2 by its upstream kinase Mek1 [328]. In an in vitro
kinase activation cascade assay, aptamer C3 inhibited the activation of Erk2 by a constitutive Mek1
mutant [332] and prevented downstream phosphorylation (Section 5.2.4.4). This indicates that C3
is indeed a domain-specific inhibitor.
The inhibitory concentration of C3 of 1 µM is in accordance with data from the literature.
Similar kinase activation assays were used to monitor the potency of small molecule inhibitors that
target the MAP kinase inserts of either JNK or p38 MAP kinases by Comess and co-workers [405].
Their most potent candidate inhibited the activation of JNK by its respective MAPK kinase with an
IC50 value of 3.8 µM [405]. Additionally, C3 blocks Erk2 activation as potent as the Mek1-derived
peptide inhibitors (2.5 µM, [403]).
DARPin E40 was also shown to inhibit the activation of Erk2 inside cells [404]. However, it was
not investigated if this inhibition resulted from blockage of the Thr-Glu-Tyr phosphorylation motif
alone or required the combination with the MAP kinase insert. The distinct a nities of C3 and E40
do not imply that C3 and DARPin E40 share the same molecular mechanism for the inhibition of
Erk2 activation. DARPin E40 targets only the inactive Erk2 conformation and likely prevents the
activation of Erk2 by Mek1 by shielding the Thr-Glu-Tyr phosphorylation motif [404]. In contrast,
C3 binds with similar a nities to the active and inactive conformation of Erk2. Therefore, it is
unlikely that C3 and DARPin E40 share the same modes of action.
More likely, however, would be an unique allosteric mode of action of C3, which was also
postulated for the MAP kinase insert -specific inhibitors of JNK or p38 MAP kinases [405]. For
example, C3 could impair Mek1-Erk2 complex formation by binding to tyrosine 261, serine 264, and
other Erk2 residues. Another possibility would be that C3 induces a conformational change that
does not necessarily prevent Mek1 from binding but inhibits the conformational rearrangement
required for Erk2 activation. For example, binding of C3 might alter the conformation of the
activation loop or enforce the conformation of the activation loop to a catalyticaly inactive state.
It has been described that Mek1 phosphorylates Erk2 on Tyr185 prior to phosphorylating Thr183
[406, 407]. Tyr185 is buried in unphosphorylated Erk2 and requires a conformational rearrangement
in the activation loop for the hydroxyl of Tyr185 to enter the active site of Mek1 [408]. Hence,
binding of C3 might block this conformational change. This notion is supported by the fact that
the putative binding side residues of C3, serine 264 and tyrosine 261, are located in close proximity
to the activation loop [295].
It could also be observed that C5 inhibits the activation of Erk2 by Mek1, albeit more than
10 times higher concentrations of C5 were needed than C3 to yield an inhibitory e↵ect (Section
5.2.4.4). One reason for this could be that the aptamer interferes with Mek1 binding or blocks
conformational changes.
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In summary, this study implicates that C3 blocks Erk2 activity with a novel mode of action.
The MAP kinase insert was described to contribute to diverse kinase-dependent and -independent
functions of Erk2 [324]. C3 could provide a valuable tool to study them.
6.5 Investigation of aptamers as intracellular kinase inhibitors
Given their high specificity and ability to disrupt distinct kinase functions, aptamers may provide
a novel class of molecular tools to dissect the function of particular protein kinases within complex
signal transduction cascade. To estimate the capability of aptamers as protein kinase inhibitors
within cells, several methods for their delivery into cells, cellular assays, and possible o↵-target
e↵ects, are discussed here. Taken together, these findings enabled the discovery that aptamers
can be applied in neurons to elucidate the involvement of individual protein kinases in neuronal
function.
6.5.1 Aptamer expression vector
In order to investigate if aptamers can be employed as intracellular kinase inhibitors, it was ana-
lyzed if expression of RNA aptamers within cells allows for targeting of intracellular protein kinase
activity. In an initial approach, the aptamers or control sequences C5sc, C3sc, and C5 B2, were
cloned into a Polymerase III-based expression vector, which is usually employed to facilitate the
expression of high levels of shRNA via a U6 promoter [338]. An aptamer against the transcription
factor NF-kappaB has been successfully transcribed and used with a similar expression system [181].
In the luciferase reporter gene assay, which was conducted in HEK 293 cells, no influence of the
aptamers C3 or C5 was observed under the tested conditions (Section 5.3.2.3). Curiously, only the
control sequence C5sc and small molecule inhibitors blocked luciferase activity after 24 hours.
The activity of C5sc in the luciferase assay argues to the fact that the RNAs were indeed
transcribed inside the cell. Strikingly, C5sc does not bind to Erk2 or any other tested kinases
in vitro (Section 5.2.3). Therefore, its e↵ect on Erk1/2 MAP kinase signaling in the luciferase
assay might result from interaction with one or more unintended proteins. This interaction might,
in turn, induce o↵-target e↵ects. The Erk1/2 signal pathway is frequently controlled by cross-
talk with other signal transduction pathways [409–411]. Interference of C5sc with another signal
transduction pathway, such as the stress-activated JNK MAPK pathway [412], can promote an
decrease in Erk1/2 activity, which could be measured by a drop in luciferase activity.
Despite the biological activity of C5sc, it is not clear if su ciently high concentrations of C3 and
C5 RNAs were transcribed to block Erk1/2 activity. A study has shown that expression of anti-Rev
aptamers via U6 constructs in cell culture yields 103 to 104 molecules per cell [170]. If similar RNA
concentrations would be obtained by the expression system in this study, the intracellular RNA
concentration may be too low to block Erk1/2 signaling.
Another plausible way to describe the discrepancy between the NF-kappa B aptamer and the
Erk2 recognizing aptamers might be their a nities. The NF-kappa B aptamer was described to bind
with a KD value of 1 nM to its target in vitro [195]. In contrast, the Erk2 recognizing aptamers were
more than 15-times less a ne (Section 5.2.1.2), which might result in a lack of biological activity.
For intracellular expression, aptamer sequences are often expressed between flanking regions or
as multivalent constructs [185]. To achieve this, the aptamers are fused to tRNAs, self-cleaving
ribozymes, aberrantly spliced mRNAs, or embedded into U6 small nucleolar RNA [175, 184, 185].
For some aptamers, the addition of sequences from small RNA molecules, such as U6 snRNA, may
lead to 10-fold higher expression levels and sometimes also to increased stability [170]. In turn, the
design of expression constructs of C3 and C5 without any flanking sequences could have impaired
their stability.
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The expression constructs of C3 and C5 contain of about 110 nucleotides, which is four times
the length of the NF-kappaB aptamer [181]. Speculations can be made if the longer constructs of
C3 and C5 were more prone to misfolding or instability. The termination of transcription of the
RNA constructs should stop at a defined stretch of 6 thymidines, which is located directly at the
3´-end of the coding DNA sequence [413]. It is supposed that the aptamers or control sequences
contain 3 uridine residues, which have been shown not to a↵ect their interaction with Erk2 in vitro
(Section 10.5). Of course, it is possible that incorrect transcription occurs.
Additionally, the intracellular stability of C3 and C5 could be influenced by the endogenous
ncRNA processing machinery. Cellular RNAs often undergo post-transcriptional modification dur-
ing their maturation [414]. For example, mature U6 RNA, which is involved in splicing [415],
undergoes site-specific pseudouridylation, 2´-O-methylation and acquires a gamma-monomethyl-
phosphate cap structure [416]. It could be possible that modifications are introduced into C3 or
C5. These modifications might a↵ect their interaction with Erk1/2.
In turn, a lack of modifications could also target C3 and C5 as aberrant RNAs for degradation
by RNA surveillance system. For polymerase III transcripts, this can occur via poly(A) addition
by the TRAMP complex and 3´ degradation by the exosome [417]. Evidence for this mechanism
was reported for 5S rRNA, U6 snRNA, the RNA component of signal recognition particle, and
pre-tRNAs [418, 419].
Another regard has to be made about the intracellular localization of of C3 and C5. shRNAs are
expressed in the nucleus and are recognized by the endogenous RNAi machinery, which facilitates
further processing and export from the nucleus [420]. In contrast, U6 RNA is retained in the cytosol
[421]. Due to a lack of obvious nuclear export or retention sequences, it is not clear if the aptamers
are retained in the cytoplasm or nucleus. However, Erk1/2 is active in both cellular compartments
[245]. Therefore, the aptamers should block Erk1/2 activity independently of its localization.
Aptamers have been transcribed through RNA polymerase II or III promoters in the expression
cassette (Section 3.3.3). In turn, modulation of target protein function was achieved for distinct
classes of proteins, such as transcription factors, or viral proteins [167, 168]. However, neither C3
nor C5 blocked Erk1/2 activity under the tested conditions. The intracellular RNA concentration,
stability, and localization should be investigated in future studies in order to answer the ques-
tion which expression system does allow to monitor aptamer-based control of intracellular Erk1/2
activity.
6.5.2 E↵ect of C3 and C5 on Erk1/2 signaling after transfection
Subsequently, it was tested if transfection of in vitro transcribed aptamers represents a suitable
strategy to study the aptamers e↵ect on Erk1/2 MAP kinase signaling. Exogenously synthesized
aptamers do not rely on the host cells transcription machinery and can be tested for binding and
functionality before their application inside cells. Moreover, in vitro transcribed RNAs can easily
be modified to improve stability, and to introduce chemical functionalities (Section 3.3.2).
Several preliminarily experiments have validated the suitability of this experimental set-up. As
can be seen in Section 5.3.1, both aptamers recognized not only recombinant Erk2, but also the
endogenous protein. In addition, it was observed that fluorescein-labeled RNA aptamers can easily
be transfected in a concentration-dependent manner (Section 5.3.3.1). In theory, intracellular RNA
concentrations up to 6 µM could have been achieved. This concentration was high enough to block
Erk2 activity and activation in vitro.
In comparison to the aptamers, the application of small molecule inhibitors induced a reduction
of Erk1/2 signaling (Section 5.3.3.2), which is in line with previous observations [310, 422]. Thereby,
the Mek1/2 inhibitor U0126 revealed higher potency than the Erk1/2 inhibitor FR180204 (Section
5.3.3.2). The lower potency of the ATP-competitive inhibitor FR18204 can be explained by the
fact that the inhibitor must compete with high intracellular ATP levels [423].
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The discrepancies between the Mek1/2 and Erk1/2 inhibitors might also result from lower cell-
permeability of FR180204 or o↵-target e↵ects which are mediated by U0126 [88, 89]. For example,
U0126, which was identified as a Mek1/2 specific inhibitor, is known to inhibit the activation of
Erk5 by Mek5 as potently as the activation of Erk1/2 [424, 425]. This, for example, could explain
the stronger e↵ects on p90-RSK1 phosphorylation, which is also mediated by Erk5 [426].
However, when C3 and C5 were transfected into H460 or A431 cells, no inhibitory e↵ect on
Erk1/2 activation or target protein phosphorylation was observed (Sections 5.3.3.3, 5.3.3.4). Strik-
ingly, C5sc, which inhibited Erk1/2 signaling in the luciferase assay (Section 5.3.2.3), induced an
increase in p90-RSK1 phosphorylation in distinct cells lines. Moreover, transfection of RNA into
H460 impaired cell viability in a time- and concentration-dependent manner (Section 5.3.3.5).
Although nuclease-mediated degradation is a major concern when working with RNA aptamers,
it is unlikely that the RNAs were completely degraded inside the cytoplasm because of the observed
secondary e↵ects. Theis et al. have also shown that a RNA aptamer and a random library were
stable for 18 hours after transfection [188]. However, studies with siRNA showed that 4 hours after
transfection, the majority of transfected siRNA remained in lipid vessels [427]. It might be possible
that the aptamers were stuck in the endosomal/lysosomal compartment and the concentration of
C3 and C5 might have been too low to block Erk1/2 signaling in the cytoplasm or nucleus.
Since the intracellular RNA localization and stability are unknown, it cannot be completely
excluded that transfection of RNA aptamers represents a suitable method to study signal trans-
duction pathways. Therefore, future studies should investigate the aptamers endosomal escape,
cellular localization, and stability after transfection.
However, at one point, the cytosolic concentration was high enough to induce secondary e↵ects.
Only a few studies described the use of unmodified RNA aptamers to block intracellular signal
transduction cascades but did not mention if o↵-target e↵ects occurred [188, 189]. Studies with
siRNA have shown that RNAs can elicit a variety of unintended responses in the cells [76, 77].
The cytotoxic e↵ects of siRNAs or shRNAs can be associated with activation of RNA receptors
[428], oversaturation of the endogenous microRNA processing machinery [429, 430], or sequence
complementarity to other RNAs [431]. These e↵ects can induce a reduction of cell viability similar
to the e↵ects observed in this study.
RNA receptors serve as an integral component of the human innate immune response to an
invasion of RNA viruses [432]. Ultimately, RNA receptors can initiate pro-apoptotoc signaling
cascades and up-regulate the expression of cytokine and chemokines, including type I interferons
[433–435]. In non-immune cells, RNA receptors include double-stranded (ds)RNA-activated protein
kinase (PKR) [436] and the retinoid acid-inducible gene (RIG)-I-like helicase (RLH) family members
RIG-I and melanoma di↵erentiation - associated protein 5 (MDA-5) [437–440].
The RNA aptamers contain several elements which makes them suitable targets for recognition
by RNA receptors: Both RIG-1 and PKR are known to recognize in vitro transcribed RNA with
5´-triphosphate moieties as ligands [432, 441]. The 5´-triphosphate serves a hallmark to identify
RNA as non-self and potentially pathogenic because cellular RNAs are typically capped by 7-
methylguanosine at its 5´-end [432].
In addition to the presence of the 5´-triphosphate, structural aspects also play a role in RNA
recognition by RIG-1 and PKR. RIG-1 requires the minimal combination of a double stranded
stretch of 5-10 bases of RNA, together with a 5´-triphosphate end, to induce a response [442].
PKR can be activated by highly structured single-stranded RNAs with imperfect loops, bulges and
single-strand tails [443–447] or unstructured ssRNA transcripts if a 5´-triphosphate is present [448].
Of course, it might be possible that the aptamers bind unspecifically to endogenous RNAs or
are subjected to processing, as discussed before (Section 6.5.2).
In addition, this study shows that control sequences must be chosen with great care because
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some RNA sequences elicit stronger secondary e↵ects. Transfection of C5sc resulted in hyperphos-
phorylation of p90-RSK1 in C5sc transfected H460 cells (Section 5.3.3.3). A likely candidate that
could mediate this phosphorylation might be Erk5, as it is known to phosphorylate p90-RSK on
the same sites as Erk1/2 [426]. Erk5 activity has been found to increase in response to growth
factors, serum, oxidative stress, and hyperosmolarity [449], and might also be activated due to the
cytotoxic e↵ects of C5sc.
The di↵erent e↵ects of TRA on p90-RSK1 phosphorylation in H460 and A431 cells might be
explained by di↵erences in the genetic backgrounds of the cell lines. For example, both cell lines
have di↵erent status of the tumor suppressor protein p53. A431 cells express mutated p53 whereas
H460 cells contain wild-type p53 [450–452]. The p53 gene status, e.g. has been reported to mod-
ulate the chemosensitivity of non-small cell lung cancer cells by Lai and co-workers [452]. Their
study suggests that an increase in chemosensitivity was attributable to wild-type p53 mediation of
apoptosis. Hence, p53 gene status might also mediate distinct responses to cytotoxic RNA e↵ects
that could lead to variable side-e↵ects.
Because of the secondary e↵ects that were observed, assay conditions should be optimized to
reduce these e↵ects. Studies with siRNA and shRNA have shown that secondary e↵ects can be
prevented if lower concentrations of RNAs or chemical modified RNAs are used [453–456]. Thus,
the selection for modified aptamers with higher a nity should be considered. By employing modi-
fied nucleotides [387], capillary electrophoresis (CE), or high-throughput sequencing–RNA a nity
profiling [457] to SELEX, a vast improvement of selection e ciency and aptamer a nity for protein
targets could be achieved [458].
6.5.3 Investigation of the aptamers e↵ect on the Erk1/2 signal transduc-
tion pathway in neurons
In order to circumvent any problems which could be associated with cellular RNA localization
and endosomal escape, the RNAs were directly injected into CA1 pyramidal neurons. By using
fluorescent dyes, it was implicated that the aptamers di↵use within 20 minutes from the recording
electrode into the distal dendrite (Sections 5.4.2).
Furthermore, this study has shown that C5 inhibits a rise in voltage potential, which is known
to be dependent on Erk1/2 activity, and does not a↵ect any of the tested neuronal Erk1/2 inde-
pendent functions. These data are in accordance with previous studies, which utilized the Mek1/2
inhibitor U0126 [282, 357], and indicate that C5 inhibits a neuronal Erk1/2 function (Section 5.4.4).
In summary, the application of aptamers during whole-cell patch clamp-recordings has emerged
as a unique and generally applicable strategy to monitor spatio-temporal e↵ects on protein kinase
inhibition during neuronal functions (Section 5.4). One main advantage of the microinjection mea-
surements is that fact that the RNAs were injected directly into the cytosol and allowed to bypassed
the endosomal/lysosomal compartment. The aptamers e↵ects on kinase function could be moni-
tored relatively rapidly, so that indirect or prolonged secondary e↵ects on Erk1/2 signaling, such
as decrease in cell viability or cross-talk with other signal transduction pathways, might have been
minimized.
Since the cellular RNA concentration and stability after RNA transfection and expression are
unknown, future studies should validate the aptamers ability or inability to block growth factor
induced signaling on single-cell level after microinjection.
Another reason that could explain the aptamers e↵ect on neuronal Erk1/2 signaling might re-
sult from high local Erk1/2 concentrations in the soma as opposed to putatively low local Ek1/2
concentrations within the dendrites. In cultured cells, Erk1/2 are known to translocated within 5
minutes into the nucleus after growth factor stimulation which leads to a decline in cytoplasmic
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Erk1/2 [245]. The increase in nuclear Erk2 upon stimulation of dendritic spines takes at least 10
minutes [459]. However, it is yet unclear if the dendritic Erk1/2 pool depletes after stimulation and
migrates from the dendrites into the nucleus [460] or if the pool of dendritic Erk1/2 is even lower
than the pool of somatic Erk1/2.
The inability of C3 to inhibit neuronal Erk2 function might be considered as a further indication
that intracellular activity of aptamers underlies functionality. C3 was neither capable of blocking a
MAP kinase-independent function in vitro (Sections 5.2) nor in neurons (assuming that C5 a↵ects
KV 4.2 activity, Section 5.4.4).
The putative binding site of KV 4.2 for Erk2 contains a cluster of positively charged residues on
the channels C-terminus channel [461]. This cluster argues for D-site mediated Erk1/2 - KV 4.2 -
interaction [50]. Nevertheless, C3 revealed the ability to block both Erk2 activation and downstream
signaling in vitro (Section 5.2.4.4). Hence, by blocking the activation of Erk1/2, it would have been
likely that C3 is capable of altering the increase in voltage potential associated with Erk1/2 activity.
Notably, the e↵ect of C3 on Erk2 activation was tested with both artificial activators and
substrates under conditions that di↵er from the cytoplasm. Inside the cytoplasm, inactive Erk1/2
are either tethered to Mek1/2 or other anchor proteins [462] or exist with Mek1/2 and other
upstream components in macrocomplexes with sca↵old proteins [262]. Hence, the binding site of
C3 would already be occupied within the cytoplasm. Since the interaction of the MAPKK-MAPK
complex has been reported to be in the low nM range, e.g. 65 nM for Erk5 and Mek5 [463], it
is very likely that higher concentrations of aptamer C3 will be needed to disrupt this interaction,
block Erk1/2 activation, and neuronal functions.
In light of the observation that MAP kinase insert inhibitors of JNK were reported to be active
at higher concentrations (10 µM) than a respective ATP-competitive inhibitor (1 µM) [405], C3s
e↵ect on neuronal MAP functions will be investigated at higher concentrations (10 µM).
6.6 Aptamers represent promising tools for chemical biology
research
Protein kinases are key regulators of signal transduction pathways and control virtually all aspects
of cellular life [66]. Protein kinases are so important for maintaining cellular homeostasis that
deregulated kinase activity can cause or contribute to the progression of severe human diseases.
For example, kinases have been identified to be the most frequently mutated proteins in cancer
and are linked to cancer cell proliferation and survival [464, 465]. Over the last decades, a strong
desire has emerged to unravel the precise biological role of the more than 500 human kinases during
cellular homeostasis and disease biology [7, 24]. This knowledge can aid in the development of novel
therapies [62].
Unfortunately, the comprehensive functional analysis of individual protein kinases within com-
plex signal transduction cascades has remained one of the greatest challenges in molecular biology.
Research into the biological role of single kinases has been hampered by a lack of specific tools
[64, 65]. A key reason for the continued failure to produce specific inhibitors arises from the fact
that the vast majority of kinase inhibitors are small molecules that target the ATP-binding site,
which is highly conserved among the kinome [94]. ATP-competitive small molecule inhibitors are
often found to exhibit undesirable o↵-target e↵ects on multiple kinases or non-kinases, including
ion channels [321, 466]. In fact, the side-e↵ects have precluded these inhibitors from being useful
research tools [467].
Aptamers are an emerging class of molecules that could represent a promising alternative to
other types of pharmacological agents. Aptamers can be selected rapidly without the need for
high-throughput screening facilities or even any structural information about the target protein or
its interaction partners [468]. Like small molecules, aptamers can easily be synthesized, modified
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in large scale, and can be administered in a dose-dependent manner [130, 167].
Importantly, the application of aptamers o↵ers promising advantages over small organic molecules
for diverse applications: aptamers can be linked with other RNA aptamers or functional entities
to form multifunctional complexes, such as fluorescent biosensors for live-cell imaging. This has
been demonstrated by using genetically encoded aptamer sensors for cellular metabolites [199, 200],
proteins [201] or RNA [202–205]. Aptamers with one or more photolabile groups (so-called ”caged
aptamers”) [469], whose activity can be turned on or o↵ by light irradiation, can be utilized to
study spatio-temporal e↵ects on protein function.
This study has established the potential of aptamers as selective kinase inhibitors for chemical
biology research. As was shown herein, aptamers can bind with high a nity and specificity in an
ATP-competitive or non-ATP dependent manner to their target kinase (Sections 5.1, 5.2). The
aptamers high specificity to even closely related protein kinases can be attributed to several ele-
ments, including the recognition of epitopes both within and outside of the kinase domain as well
as the adaption to specific kinase conformations (Section 5.1) or the recognition of unique epitopes
(Section 5.2.4.3).
It was also demonstrated that aptamers exhibit tremendous potential in inhibiting protein kinase
functions (Sections 5.2.4.2, 5.2.4.4). This is mainly related to the ability of aptamers to address
a functional surface epitope or domain, which enables them to competitively interfere with the
binding of natural interaction partner, such as ATP (Section 5.2.4.1). The ability of aptamers
to disrupt kinase activity or domain-specific functions makes them an attractive tool for research
applications. Protein kinases are frequently controlled by protein interactions, which are mediated
by docking domains [52, 53]. Since docking domain interactions are a key feature in mediating
specificity during signal transduction, aptamers can become a valuable tools for extremely precise
disruption of domain-specific functions.
So far, only a small fraction of the human kinome has been annotated with ”specific” kinase
inhibitors [64, 65]. Aptamers combine many features of chemical or biological kinase inhibitors and
exhibit an intriguing potential for the interference with kinase activity inside cells. For example,
the application of aptamer C5 in neurons could unravel further roles the Erk1/2 signal transduction
pathway during di↵erent forms of long term potentiation and assist in the identification of direct
targets during synaptic plasticity.
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The work described in this thesis contributes significantly to the development of aptamers as a
novel molecular class of tools for chemical biology research. The high a nity, impressive speci-
ficity, ability to inhibit domain-specific functions or kinase activity by C3, C5, and C13 and, most
importantly, the potential of C5 to block kinase-dependent neuronal functions opens the avenue
towards the application of aptamers as tools to dissect intraneuronal signal transduction cascades.
According to the findings of this study, several exiting questions have emerged.
7.1 Intracellular application of C13
Aptamer C13 and its target GRK2 have been used to identify the molecular determinants which
contribute to an ATP-competitive aptamers high specificity for its target. However, reliable func-
tional data about its cellular application and ability to block GRK2 signaling have not been obtained
during this thesis. Since throughly characterized small molecule inhibitors of GRK2 are still rare,
the application of C13 as an intramer could aid in the identification of disease-dependent and in-
dependent functions of GRK2.
The availability of appropriate delivery strategies and cellular assays o↵ers exciting opportunities
to elucidate the intracelular performance of C13.
GRK2 regulates many targets in the cytoplasm, including G protein-coupled receptors, receptor
tyrosine kinases and cytoskeletal proteins [211]. In order for C13 to target GRK2 activity within
the cytoplasm, a suitable delivery strategy should be chosen.
For instance, GRK2 can be transfected into the cytoplasm. Since this method can induce secondary
e↵ects (Section 5.3.3.5), any functional data should be verified by using the available non-binding
point mutants of C13 as control sequences.
Additionally, C13 could be expressed in a construct that allows for delivery into the cytoplasm.
To this end, a chimeric aptamer and ribozyme construct could be utilized, as was shown for the
hepatitis delta virus (HDV) ribozyme and an aptamer against the NS3 protease domain of the
hepatitis C virus [173]. The ribozyme processed the aptamer, which was then able to inhibit target
function in the cytosol of mammalian cells. In this case, intracellular localization was mediated by
employing a polymerase II promotor and cytoplasmic transport signal sequences.
Of course, it would also be possible to inject C13 into cells and monitor its e↵ects on GRK2
activity on single-cell level.
A detailed investigation of the aptamers intracellular e↵ect can be obtained by diverse cellular
assays. GRK2 is known to phosphorylate many receptor and non-receptor substrates [211]. How-
ever, analysis of target protein phosphorylation is limited as specific antibodies for most targets, in
particular GPCRs, are not available [470–472].
Another approach would be to study the interaction of GPCRs and arrestin which requires
GRK2 activity. This interactions could be analyzed by FRET [473, 474] or fluorescence microscopy
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[475]. Should C5 inhibit GRK2 activity, a decrease in FRET signal or reduced receptor internal-
ization would be observed.
Single cell and microinjection experiments can be performed by monitoring the aptamers e↵ect
on  2-AR-mediated cardiomyocyte contractility ex vivo [476]. Contraction tracings of single ven-
tricular cardiomyocytes should reveal an increase in cardiomyocyte contractility if GRK2 activity
is inhibited. The blockage of GRK2 activity and its role on cardiomyocyte contractility has previ-
ously been validated by utilizing Paroxetine-treated mice [359] and a inhibitory peptide-expressing
animal model of heart failure [477].
Future studies should also throughly investigate if C13 binds to GRK2 in a bu↵er that mimics
cytosolic conditions as was shown for Erk2 and C3 or C5. Although bu↵er conditions represent an
estimation and not a final proof of intracellular applicability, they could provide valuable informa-
tion about the aptamers performance in cellular studies. As preliminary experiments have hinted
into the direction that the interaction of C13 with GRK2 depends on the concentration of K+ and
Na+ ions [209], the application of C13 in cellular studies might be hampered. Hence, it might be
contrivable to perform a re-selection with a partially constrained library based on the sequence of
C13 in a bu↵er that resembles intracellular conditions.
7.2 Sensitivity to ionic strength and secondary structure
prediction
The Erk1/2-recognizing aptamers TRA, C3, and C5 were throughly characterized for cation de-
pendency. This characterization revealed that the binding of TRA is a↵ected by the presence of
monovalent cations. In contrast, the binding of C5 (and C3) showed only little dependency for
monovalent cations.
Since aptamer C5 and its progenitor TRA di↵er in only 12 nucleotides (Section 3.4.2.5), future
studies should try to elucidate the reason for these di↵erences. One explanation could be given
when looking at the predicted secondary structures. The mutations could lead to a stabilization
of both the central stem and the upper stem of C5 when compared to TRA. Hence, it is plausible
that di↵erences in sensitivity to cations might come from these secondary structural motifs. Point
mutants of TRA and C5 should be designed to investigate this. For example, mutations that
originate from the sequence of C5 can be introduced into TRA and its binding under di↵erent
bu↵er conditions can be analyzed. Perhaps, this could allow for the identification of individual
nucleotides that influence cation sensitivity by promoting conformational changes.
These point mutants could be employed for secondary structure prediction, such as chemical
or enzymatic probing studies [478] or SHAPE (Selective 2’-hydroxyl acylation analyzed by primer
extension) analysis [479], to define important secondary structural motifs that mediate or influence
RNA fold in the presence of cations.
More importantly, secondary structure prediction of C3 and C5 should also be performed to
investigate which nucleotides might directly engage in the interaction with Erk2. In turn, this can
aid in the identification of novel point mutants or truncated variants of the aptamers.
7.3 Detailed investigation of the binding sites and modes of
action of C3 and C5
Aptamer C5 was shown to recognize Erk2 in an ATP-competitive manner and to inhibit kinase
activity whereas C3 was able to block the activation of Erk2 by Mek1 (Section 5.2). Of course,
although in vitro data suggests that C5 targets the kinase domain and C3 the MAP kinase insert
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of Erk2, this has yet to be proven. In order to achieve this, the crystal structure of the C5-Erk2 or
C3-Erk2 complexes should be obtained.
Since C5 does not share the same sequence motif as the other ATP-competitive aptamers C13
and K16, it would be particularly interesting to observe if the aptamer positions an adenine residue
to mimic ATP binding into the active site and derives specificity by charge and size complementarity
as C13, or if C5 derives specificity by recognizing unique epitopes both within and outside of the
active site.
By targeting a unique domain on Erk2, C3 could represent a valuable tool for chemical biology
research. Hence, it will also be of utmost interest to define the complete binding surface of C3
on Erk2. Additionally, this information could provide valuable assets for studying the Mek-Erk
interaction because no crystal structures of the Mek1-Erk2 complex are available yet. For instance,
amino acid residues of Erk2 that comprise the binding site of C3 could also engage in direct inter-
action with Mek1 and could provide a novel druggable target. This could be extremely relevant
because Mek1/2 are validated targets for cancer therapy [480, 481].
A putative epitope that could engage in the interaction of C3 and Erk2 is a cluster of positively
charged amino acids that surrounds tyrosine 261 and serine 264 (Section 6.4.2.1). The interaction
between this cluster and C3 could be investigated, e.g. by mutagenesis strategies or by using an
assignment-free NMR approach that has recently been published for p38 MAP kinase [482].
In order to further elucidate the putative mode of action of C3, several strategies should be
followed: First, it should be investigated if binding of C3 excludes the binding of Mek1. To achieve
this, competition assays could be performed in which Mek1 would be titrated to a radioactively
labeled C3 and Erk2. If binding of C3 blocks the binding of Mek1 either sterically or allosterically, a
decrease in binding of C3 should be observed. Putative conformational changes could be monitored
by obtaining the co-crystal complex of Erk2 and C3.
7.4 Specificity
Although the high specificity of C3 and C5 within the same kinase family and among distinct groups
(Section 5.2.3) implicates high overall selectivity among the kinome, further examination is needed
to evaluate the aptamers interaction with other kinases and non-kinases. The aptamers e↵ects on
other kinases could, in theory, be examined with large activity panels that include several hundred
kinases. This service is commercially available and allows for e cient specificity profiling. However,
as RNAse-free assay conditions can not be guaranteed, these specificity tests were not performed
during this work
Nevertheless, it would also be possible to investigate the binding to endogenous proteins, in-
cluding non-kinases, by conjugating the aptamer to a matrix and subsequently incubated with cell
lysate [483–485]. After elution, the captured proteins can be subjected to mass spectrometry anal-
ysis [483]. Thereby, a biotinylated variant of C3 or C5 can be coupled to a Streptavidin-matrix, as
was shown in the pulldown assays (Section 5.3.1).
Since C3, C5, or other aptamers could be useful as new tools to elucidate signal transduction
pathways, adverse e↵ects on other signal transduction pathways or interference with cell viability
should be assessed early. If a decrease in cell viability or impact on other signal transduction
pathway is observed, the readout or delivery method should be changed.
Aptamer C5 demonstrated the ability to inhibit a certain form of long term potentiation, which
is known to require Erk1/2 activity (Section 5.4.4). In contrast to C5, the application of aptamer
C3 did not block the increase in voltage potential but exhibited a shift of the action potential
threshold to more depolarizated states [354]. Therefore, it should be examined if C3 targets the
activity of voltage-gated potassium or sodium channels, which could be involved in regulating the
action potential threshold. This can be achieved, for example, by examining the rise and decay
time of the action potentials more closely. Furthermore, it would be exciting to investigate if any
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changes in potassium or sodium channel activity by C3 could be mediated by blocking a hitherto
unknown function of the MAP kinase insert of Erk1/2.
7.5 Cellular studies
Transfection of in vitro transcribed RNA and intracellular expression have been utilized to study the
e↵ect of C3 and C5 on growth factor - induced Erk1/2 signaling (Sections 5.3.3.3, 5.3.3.4, 5.3.2.3).
It is yet unclear why the aptamers did not reveal inhibitory e↵ects under the tested conditions.
Although the FACS experiments (Section 5.3.3.1) indicated that the aptamers had entered the
cytoplasm, the intracellular stability, localization, and RNA concentrations should be examined. In
order to determine the intracellular RNA concentration and stability, the total RNA of cells will
have to be isolated after transfected with RNA or expression plasmids. The total RNA can then
be reverse transcribed into cDNA and amplified by quantitative real-time PCR. The quantification
of the absolute amount of RNA present in the cell will allow to assess if the intracellular aptamer
concentration has been below the KD value of C3 and C5. Subcellular fractionation by di↵erential
centrifugation will make it possible to examine the concentration and localization of the RNA
aptamers in distinct cellular fractions, such as the nucleus [486].
In situ hybridization techniques based on antisense probes or fluorescently labeled aptamers
could be used to explore the aptamer localization within the cells. These techniques could be coupled
with super-resolution microscopy methods, such as STED, to further understand the aptamers
distribution [487]. By staining for specific endosomal markers, such as distinct Rab proteins, the
dynamics and complexity of endosomal escape could be investigated [488].
To this end, microinjection has emerged as a suitable strategy to monitor the aptamers e↵ect
on kinase function on single-cell level. Thus, it should be investigated if the aptamers would be
able to block Erk1/2 signaling after growth factor stimulation by employing this delivery method.
Perhaps the most promising strategy for monitoring changes in single-cell Erk1/2 activity after
growth factor stimulation would be the use of a live-cell imaging FRET approach. By employing
cells that co-express a FRET-based Erk1/2 kinase activity reporter construct and a mCherry-Erk2
fusion protein [489], changes in Erk1/2 activity could be monitored after or during injection of C3
and C5.
7.6 Identification and characterization of a putative novel
Erk1/2 inhibitors
Aptamers that target unique epitopes and block domain-specific functions could provide an at-
tractive starting point for the identification of non ATP-competitive kinase inhibitors by aptamer
displacement screenings (Section 3.3.4).
Small molecule inhibitors that block kinase-domain independent functions may exhibit the same
high specificity as their parental aptamers. Importantly, non ATP-competitive small molecule
inhibitors may possess the key advantage of cell-permeability, which makes them attractive tools
for elucidating signal transduction pathways. Displacement screening assays based on non ATP-
competitive aptamers have the advantage that neither structural knowledge of a druggable spot
nor the development of cumbersome target-independent assays for high-throughput screenings are
required.
Aptamer C3, which targets the MAP kinase insert of Erk1/2, should be used in an aptamer
displacement assay. These assays can be performed, for example, by using RiboGreen. a specific
nucleic acid-binding dye, for the detection of C3 bound to immobilized Erk2. The putative small
molecule inhibitor´s a nity for Erk2 can then be measured by microscale thermophoresis. This
technique allows the determination of dissociation constants based on the movement of molecules
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along a temperature gradient [490]). For this, one of the reaction partners has to be fluorescently
labeled. This can be achieved, for example, by labeling the cysteine side chains of Erk2 with
sulfhydryl-specific reagents.
Afterwards, the specificity of the compound should be assessed. Importantly, it should be
evaluated if the compound can be utilized as a domain specific inhibitor. These experiments should
be underlined by monitoring the compounds e↵ects on Erk1/2 activation or other MAP kinase-
specific functions within cells.
7.7 Identification of novel intramer candidates
So far, specific inhibitors for many kinases are still elusive and more than half of the human kinome
is largely uncharacterized [64, 65]. Specific aptamers have only been identified against very few
kinases, including PKC [324], GRK2 [209] and Erk2 [210]. Hence, many intriguing kinase targets
are left to be explored.
7.7.1 Reduction of o↵-target e↵ects
The greatest challenge of employing aptamers as protein kinase inhibitors inside cells is the avoid-
ance of o↵-target e↵ects (Section 5.3.3.5). Therefore, the use of lower RNA concentrations should
be considered. For some siRNAs, this has been reported to reduce o↵-target e↵ects [453–456].
To achieve this, aptamers with high a nities should be applied. Instead of bead-based selection
strategies, aptamers should be selected with CE- [431] or high-throughput sequencing–RNA a n-
ity profiling [457] - based selection strategies, which have previously given rise to aptamers with
a nities in the picomolar range.
Being that they are ribonucleic acids with 5´-triphosphate moieties, RNA aptamers employ
the intrinsic ability to activate RNA receptors that can distinguish non-self from self-RNA. Future
aptamers might show improved cellular performance when side-e↵ects are limited. In order to
achieve this, several modifications should warrant consideration.
First, the removal of the 5´- triphosphate moiety of ssRNA may prevent 5´- triphosphate de-
pendent activation of intracellular RNA receptors. The removal of the 5´- triphosphate has been
reported to abrogate PKR activation in a study by Nallagatla and co-workers [448]. The role of the
5´- triphosphate has remained controversial for RIG-1 and seems to be dependent on the structural
context. Many studies claimed the 5´- triphosphate to be essential for RIG-1 activation, whereas
recent studies have demonstrated a 5´- triphosphate independent activation of RIG-1 by ssRNA
aptamers [190].
In addition, nucleotide modifications might be introduced into RNA aptamers during or after
the SELEX process [129]. Cellular RNAs often undergo post-transcriptional modification which
might contribute to distinguishing cellular RNA from non-self RNA [491]. To date, more than 50
unique naturally occurring modified nucleosides have been identified in eukaryotes [492, 493]. It
has recently been shown that nucleoside modifications can modulate RIG-1 [441, 494] or PKR ac-
tivity [491, 495] in a RNA structure-specific manner. For example, in 5´- triphosphate-containing
ssRNA, many base and sugar modifications, e.g. pseudouridine, 2´-thio-uridine (base) or 2´-O-
methyl-uridine (backbone), abrogate PKR activation, although 2´-fluoro-modified ssRNA does not
[190, 491, 495]. Chemical nucleotide modifications can also increase the thermodynamic stability
of aptamers and prevent enzymatic degradation [496].
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7.7.2 Identification of domain-specific inhibitors
The ability of aptamers to recognize kinases in an ATP-competitive or non ATP-competitive manner
can easily be transferred onto other kinases. The identification of domain-specific aptamers can be
achieved, e.g. by utilizing active or inactive kinase conformations that display the particular epitope
[210], or by using individual sub-domains [133] during the SELEX process. Thereby, it is important
that the epitope is surface exposed and highly conserved [114]. Additionally, the ATP-recognizing
consensus motif that was found in aptamer C13 and K16 can be utilized in a doped library for the
identification of a novel ATP-competitive aptamers.
7.7.3 Insensitivity to ionic strength
The lack of sensitivity to ionic strength of any aptamer could play an important role for the suc-
cessful intracellular application of aptamers. In this regard, it could be possible that the presence
of intracellular cationic strength, especially that of monovalent cations, during the SELEX process,
will lead to successful performance of the aptamer within cells. However, although the ionic com-
position of the selection bu↵er is certainly important, there is no guideline which ionic strength
during the SELEX process will give raise to functional intramers.
Literature suggests that functional intramers have been selected under many di↵erent conditions:
Some intramers were selected in PBS bu↵er, which resembles extracellular ionic strength [182, 183].
The NF-kappaB aptamer was selected in a bu↵er consisting of Hepes and 0.1 mM NaCl [195] which
also does not resemble intracellular monovalent cation concentrations, whereas other aptamers, e.g.
the Spinach aptamer [202] or the E2F aptamer [186] were selected in Hepes bu↵er with cytosolic
potassium concentrations.
Nevertheless, for aptamers with the final goal of intracellular application, the presence of mono-
valent cations, cytosolic bu↵er conditions or selection pressure towards insensitivity to monovalent
cations during the SELEX process, will be beneficial.
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8.1 Working with nucleic acids
8.1.1 Agarose gel electrophoresis
Usually, 2.5% agarose gels were used to monitor PCR products or in vitro transcribed RNAs. For
a 2.5 % agarose gel, 2.5 g agarose was dissolved in 100 ml 1x TBE bu↵er and boiled for several
minutes. After cooling down, 40 ml gels were purred and Ethidium bromide solution was added
at a 1:10000 dilution. Samples were diluted with 2x DNA or 2x RNA loading bu↵er to a final
concentration of 1x. For electrophoresis, gels were run in 1x TBE bu↵er at 150V for 15 minutes.
Due to the intercalating Ethidium bromide, bands were visualized in a UV transilluminator (VWR)
and compared to standard DNA ladders (Fermentas).
Table 8.1: Bu↵er for agarose gel electrophoresis
1x TBE 1x DNA loading dye 1x RNA loading dye
90 mM Tris, pH 8.0 25 mM Tris pH 8.0 50% Formamide
90 mM Borat 25% Glycerol (v/v) 0.013% SDS
2 mM EDTA 25 mM EDTA 0.25 mM EDTA
Bromophenol Blue Bromophenol Blue
Xylenecyanol Xylenecyanol
8.1.2 Polymerase chain reaction (PCR)
For the amplification of dsDNA that was later used as template for in vitro transcription, the
following cycles were usually performed ten times.
Table 8.2: PCR programme
Step Temperature [ C] Time [min]
Denaturation 95 0.5
Annealing 55 0.5
Elongation 72 0.5
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Table 8.3: Pipetting scheme for 1 PCR reaction
Reagent Volume [µl] Stock concentration Final concentration
Pfu reaction bu↵er 10 10x 1x
MgCl2 8 25 mM 2 mM
dNTPs 1 25 mM 0,25 mM
5´-primer 1 100 µM 1 µM
3´-primer 1 100 µM 1 µM
dsDNA template 1 1-20 nM
Pfu polymerase 1 2.5 U/µl 0.0225 U/µl
MilliQ water ad 100µl
8.1.3 PCR product purification
PCR products were purified with the commercially available “PCR and gel purification Kit” from
Machery and Nagel according to the manufactorers protocol: Briefly, 2.5 PCRs were pooled for 1
column and eluted with 50 µl MilliQ water.
8.1.4 In vitro transcription (TK)
In vitro transcription of dsDNA containing a T7-RNA polymerase promotor sequence was per-
formed as described in table 8.4. dsDNA resulting from approximately one purified PCR reaction
was used as template per 100 µl transcription reaction. After over night incubation at 37 C, 0.5U
DNAseI (Fermentas) was added per 1x TK. Afterwards incubation at 37 C for 30 minutes, RNA
was precipitated as described in Section 8.1.9by polyacrylamide gel electrophoresis (Section 8.1.10)
and subsequent RNA workup protocol (Section 8.1.11).
Table 8.4: Pipetting scheme for in vitro transcription reactions
Reagent Volume [µl] Stock Final concentration
Hepes, pH 7.9 20 200 mM 40 mM
MgCl2 1.6 1.5 M 25 mM
NTPs 10 25 mM 2.5 mM
DTT 5 100 mM 25 mM
Inorganic Pyrophosphatase 0.2 2 U/µl 0.02 U/µl
RNAsin 1.24 40 U/µl 0.5 U/µl
dsDNA template 10 150-300 pmol
T7 RNA polymerase 10 30 U/µl 1 U/µl
MilliQ water ad 100 µl
8.1.5 Radioactive transcription
For radioactive transcriptions using 32P -GTP, 2 µl ↵-32P -GTP was added to the reaction (Table
8.4). After incubation at 37 C for 2 hours, tin vitro transcribed RNA was purified using the “PCR
and gel purification Kit” from Machery and Nagel according to the manufacturers instructions.
Briefly, 200 µl bu↵er NTC was added to a 100 µl in vitro transcription reaction. Elution was
performed with 50 µl MilliQ water.
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8.1.6 GMPS transcription
For the generation of 5´-labeled RNA, in vitro transcription reactions were supplemented with 10
mM Guanosine-5´-Thiophosphate (GMPS, Genaxxon Biosciences). The GMPS moiety can later
react with the Iodoacteyl-moiety via nucleophilic substitution.
Table 8.5: Pipetting scheme for GMPS transcription reactions
Reagent Volume [µl] Stock Final
Hepes, pH 7.9 20 200 mM 40 mM
MgCl 1.6 1.5 M 25 mM
NTPs 10 25 mM 2.5 mM
DTT 5 100 mM 25 mM
Inorganic Pyrophosphatase 0.2 2 U/µl 0.02 U/µl
GMPS 6.7 150 mM 10 mM
RNAsin 1.24 40 U/µl 0.5 U/µl
dsDNA template 10 150-300 pmol
T7 RNA polymerase 10 30 U/µl 1 U/µl
MilliQ water ad 100 µl
After incubation for 6 hours at 37 C, the reaction mixture was Phenol-Chloroform extracted
(Section 8.1.8) and precipitated (Section 8.1.9). The pellet was suspended in 10 µl MilliQ water/100µl
TK and subsequently passed through G-25 Microspin columns (GE Healthcare) twice.
8.1.7 Generation of 5´- biotinylated or 5´-fluorescein-labeled RNA
A crump of 5-(Iodoacetamido)fluorescein (Sigma Aldrich) or EZ-link Iodoacetyl-PEG2-Biotin (Pierce)
was dissolved in DMF. In the meantime, RNA was suspended in labeling bu↵er (1xTE pH 8.0, 2.3 M
Urea, RNAsin 0.4 U/µl) and heated for 1 minute at 80 C. Afterwards, the mixture was cooled down
on ice for 5 minutes. 40 µl Iodoacteyl- Biotin or –Fluorescein were added to 360 µl labeling mix.
The reaction was allowed to proceed for 2 hours at 37 C. Afterwards, the RNA was precipitated
(Section 8.1.9) and purified as described below.
Table 8.6: Pipetting scheme for labeling reactions
Reagent Volume [µl] Stock Final
TE, pH 8.0 40 800 mM Tris, 500 mM EDTA 80 mM Tris, 50 mM EDTA
Urea 100 8.3 M 2.3 M
RNAsin 4 40 U/µl 0.4 U/µl
GMPS transcription 100
MilliQ water ad 360
8.1.8 Phenol-Chloroform extraction and precipitation
One volume of Phenol (SIgma Aldrich) was added to one volume of nucleic acids solution. Samples
were vortexed and centrifuged at 14000 rpm for 5 minutes. The upper, aqueous phase was then
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transferred into a new 1.5 ml tube. Two volumes of Chloroform (AppliChem) were then added
to the aqueous phase. Samples were mixed and centrifuged at 14000 rpm for 5 minutes. Again,
the upper phase was transferred into a new 1.5 ml tubei. 1/10 volume 3M NaOAc, pH 5.4, and
3 volumes 100% Ethanol were added. The tube was inverted and centrifuged at 20000g for 30
minutes (4 C). The supernatant was discarded and the pellet was washed with 70% Ethanol and
centrifuged for 5 minutes at 20000g (4 C). The pellets were air-dried and suspended in 10µl MilliQ
water/100 µl transcription.
8.1.9 Ethanol precipitation
Ethanol precipitation is a common used technique for the de-salting and concentration of nucleic
acids. Nucleic acids are polar and easily dissolve in water. The addition of monovalent cations
(e.g. Na+) neutralizes the negative charge of the phosphodiester backbone, making nucleic acids
less soluble in water. Ethanol has a lower dielectric constant than water, making it easier for
monovalent cations to interact with the negatively charged phosphodiester backbone, and causes
the precipitation of nucleic acids.
Samples were split into 100 µl/1.5 ml tube. 1/10 Volume DNAseI 10x Bu↵er (Roche) and 0.5 U/µl
DNAseI (Roche) were added to the mixture and incubated for 30 minutes at 37 C. Afterwards,
50 µl MilliQ water, 50 µl 0.5 M EDTA, pH 8.0, 100 µl 6 M NH40Ac and 1 ml ice-cold 1000%
Ethanol were added. The tube was inverted and centrifuged at 20000g for 60 minutes (4 C). The
supernatant was discarded and the pellet was washed with 700% Ethanol and centrifuged for 10
minutes at 20000g (4 C). The supernatant was discarded again. The pellets were air-dried and
pooled in 140 µl PAA loading bu↵er.
Table 8.7: PAA loading bu↵er
PAA loading bu↵er
60% Formamide
5% SDS
0.25 mM EDTA
Bromophenol Blue
Xylenecyanol
8.1.10 Polyacrylamide gel electrophoresis (PAGE)
Polyacrylamide gel electrophoresis was employed to separate RNA molecules for analytical or
preparative purposes.
The mixture for a 10% gel was prepared as described in (table 8.9) and poured between two glass
plates. The gel was allowed to polymerize for at least 1 hour. The gel was placed into a running
chamber and bu↵er reservoirs were filled with 1x TBE bu↵er. The gel was pre-run for 15 minutes
at 350V. Before loading samples, the pockets were rinsed twice with 1x TBE. Samples were boiled
for 3 minutes at 95 C and 70 % were loaded per lane. The gel was run for approximately 1.5-2
hours at 350 V.
106
8.1. Working with nucleic acids
Table 8.8: Pipetting scheme for one PA gel (10 %)
Solution Volume [ml]
C (Rothiphorese sequencing gel concentrate) 28
D (8.3 M Urea) 35
B (8.3 M Urea in 10X TE) 7
APS (10%) 0.56
TEMED 0.028
8.1.11 RNA work-up
Once the Xylenxyanole band of the PAA loading bu↵er had reached the lower third of the PA gel,
the gel was stopped. The glass plates were removed and the gel was wrapped in plastic foil. RNA
bands could be detected by UV-shadowing at 254 nm. The right sized bands were then cut out
with a sterile razor blade and transferred into a 1.5 ml tube. The gel slice was then crushed with
a 1 ml pipette tip and suspended in 500 µl 0.3 M NaOAc, pH 5.4. The gel suspension was then
frozen at -80 C for 30 minutes and incubated at 65 C for 1.5 hours under vigorous shaking (1300
rpm). Afterwards, gel suspension was filtered through a 5 ml syringe packed with silanized glass
wool. The syringe was washed for three more times with 100 µl 0.3 M NaOAc, pH 5.4. The RNA
was precipitated by the addition of 3 volumes 100% Ethanol and centrifugation at 20000g for 60
minutes (4 C). The supernatant was discarded and the pellet was washed with 70% Ethanol and
centrifuged for 10 minutes at 20000g (4 C). The supernatant was discarded again. The pellets were
air-dried and suspended in MilliQ water (10 µl water/100 µl TK).
8.1.12 Concentration measurements
The concentration of nucleic acids solutions was determined by employing a UV-spectrophotometer.
A UV-spectrophotometer measures the absorption at a wavelength of 260 nm (A260) in a quartz
cuvette. The concentration was calculated by using the following equitation:
c =

mmol
l
 
=
OD260 · k · d
⌃nt ·Mw
d=dilution factor, k=absorption coe cient (ssRNA: 40 µg/ml), Mw=molecular weight (g/mol),
nt=number of nucleotides
8.1.13 Determination of the labeling e ciency (5´-Biotin or 5´-FITC
labeled RNA)
The yield and quality of biotinylated RNA was analyzed by gel shift assays. In this assay, equimolar
concentrations of biotinylated RNA and Streptavidin were incubated in MilliQ water at 30 C for 30
minutes. Afterwards, the samples were suspended in RNA loading bu↵er and immediately loaded
on a 2.5 % agarose gel. Control samples without Streptavidin or with non-biotinylated RNAs were
run for validation. Biotinylation e ciency was determined by band quantification using GelDoc
software (Biorad). Fluorescein-labeled RNA was run on a 2.5% agarose gel and detected using
fluorescence reading option of the Phosphoimager (Fuji).
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8.1.14 Coupling of biotinylated RNA to Streptavidin-coated Dynabeads
Usually 200 pmol biotinylated RNA was used to detect the interaction of aptamers or control RNA
with endogenous proteins in pull-down experiments. The RNA was suspended in 200 µl 1x Binding
and Wash (BW) bu↵er.
200 µl Streptavidin-coated Dynabeads (Invitrogen) were employed for the reaction. The super-
natant of the beads was discarded. The beads were suspended in 200 µl 1x BuW bu↵er. Beads
were separated from the mixture with a magnet and the supernatant was discarded again. Beads
were washed 4 more times with 1200 µl 1x BW bu↵er. For labeling reactions, 200 µl RNA solution
was added to the Dynabeads. The mixture was incubated at room-temperature on a over-head-
tumbler for 45 minutes. Afterwards, beads were washed 4 times with 200 µl 1x PBS. Beads were
suspended in 200 µl 1x PBS and kept on ice.
Table 8.9: Bu↵er recipe for the coupling of biotinylated RNA to Streptavidin-coated Dynabeads
1x BW bu↵er 1x PBS
5 mM Tris/HCl, pH 7.5 137 mM NaCl
0.5 mM EDTA 2.7 mM KCl
1 M NaCl 6.5 mM Na2HPO4
1.47 mM NaH2PO4
8.2 Working with bacteria and bacterial plasmids
8.2.1 LB Medium and agar plates
For 10 10cm2 dishes, 3.8 g agarose and 5 g LB broth (Sigma) were mixed in 250 ml MilliQ water
and autoclaved for 15 minutes at 121 C. After cooling down, Ampicillin (AppliChem) was added
to yield a final concentration of 100 µg/ml. Plates were kept at 4 C. LB medium was obtained by
mixing 10 g LB broth with 500 ml water. LB medium was autoclaved for 15 minutes at 121 C and
stored at room temperature.
8.2.2 Transformation of E.coli XLI blue or DE3
Chemically competent cells (Invitrogen) were thawed on ice for 3-5 minutes. 100 ng plasmid DNA
or 5µl ligation mixture were added to 100µl competent cells. The cells were kept on ice for 30 min-
utes. Afterwards, bacteria were heat-shocked at 42 C for 45 seconds and immediately put back on
ice. After 2 more minutes, 500µl pre-warmed SOC medium (Invitrogen) was added and cells were
incubated at 37 C , 300 rpm. After 30 minutes, cells were centrifuged at 1000 rpm for 2 minutes.
500 µl medium was discarded and the pellet was suspended in the remaining 100µl medium. The
bacteria were then plated on LB-Ampicillin plates and incubated over night at 37 C. Plated were
stored for 1 month at 4 C.
8.2.3 Cultivation of E.coli XLI blue or DE3
The bacteria were cultivated in LB medium with the appropriated antibiotic (usually 100 µg/ml
Ampicillin) at 37 C under vigorous shaking (150 rpm).
108
8.3. Working with proteins
8.2.4 Preparation of Glycerol stocks
To store bacteria for a longer period at -80 C, 250 µl Bacteria were incubated with 500µl glycerin
(AppliChem) for 30 minutes at room temperature. Afterwards, bacteria were transferred to the
-80 C freezer.
8.2.5 Plasmid preparation from E.coli
For plasmid preparation in a small scale, 10 ml E.coli cultures were grown over night at 37 C,
150 rpm. Plasmids were extracted with the ”NucleoSpin Plasmid” Kit from Machery and Nagel
according to the manufacturers recommendation.
For plasmid preparation in a small scale, 200 ml E.coli cultures were grown over night at 37 C, 150
rpm. Plasmids were extracted with the ”NucleoBond Midi” Kit from Machery and Nagel according
to the manufacturers recommendation.
8.2.6 Plasmid preparation for sequencing
For sequencing reactions, DNA was quantified (Section 8.1.12) and diluted to a concentration of 30-
100 ng/ml. Sequencing reactions were performed with the appropriative primer at GATC Biotech,
Germany.
8.3 Working with proteins
8.3.1 Induction of protein expression
200 ml pre-cultures were inoculated with glycerol stocks and incubated with 100 µg/ml Ampi-
cillin over night under vigorous shaking. 800 ml fresh LB-Amp medium was then poured to the
pre-culture. Bacteria were grown until an OD600= 0.6-0.7 was reached. Protein expression was
induced with 1 mM Isopropyl-D-1-thiogalactopyranoside (IPTG, AppliChem) for 6 hours at 37 C.
8.3.2 Protein purification
Cells were harvested by centrifugation at 5000g for 20 minutes. The supernatant was discarded and
pellets were stored at -80 C. The cell pellet was resuspended in 20 ml lysis bu↵er. The cells were
disrupted with a French Press. For this, the bacterial suspension was sucked into the French Press
and released with a definite pressure (1200 psi). The lysate was then cleared by centrifugation at
20000g at 4 C.
The Erk2 proteins are expressed as a His6-tag fusion protein, which allows for the a nity pu-
rification with Ni-NTA-beads (Qiagen).The protein supernatant was then incubated with 2 ml
Ni-NTA-beads in a head-top-tumbler for 30 minutes at 4 C. The beads were the transferred onto
disposable columns (BioRad) and flow through (containing unbound proteins) was removed with a
peristaltic pump. To elute the proteins bound to the Ni-NTA-matrix, 2 ml elution bu↵er was added
and the flow through was collected. This step was repeated two more times. To purify recombinant
proteins from Imidazole or protein aggregates, proteins were purified by size-exclusion or desalting
columns using the Akta FPLC system. For size-exclusion, a Superdex200 column (GE healthcare)
was equilibrated with 2 volumes of storage bu↵er . For desalting, a HiTrap5 columns (GE health-
care) was equilibrated with 2 volumes of storage bu↵er. Samples were injected and collected in 1
ml scale. Distinct protein fractions were pooled and stored at -80 C
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Table 8.10: Bu↵ers used for Erk2 purification
lysis bu↵er/wash bu↵er elution bu↵er storage bu↵er
Tris/HCL 50 mM, pH 7.8 50 mM, pH 7.8 50 mM, pH 7.8
NaCl 300 mM 300 mM 300 mM
Imidazole 20 mM 500 mM
Glycerin 5% 5% 5%
8.3.3 Determination of protein concentration: Bradford Assay
For quantification, the concentration of the protein samples is compared to a BSA standard curve
(-3 mg/ml). The Coomassie Brilliant Blue G250 dye (Biorad) was diluted 1:10 and 150 µl were
added to 2 µl protein sample. Absorbance was measured at 595 nm with the Varioscan platereader.
8.3.4 SDS-PAGE
For SDS-PAGE, protein samples were boiled for 3 minutes at 95 C in 1x SDS sample bu↵er (La¨mmli
bu↵er).
Seperating and stacking gel mixtures were cast between two thin glass slides. Either 5 µl recombi-
nant protein, 40 µg cell lysate or 10µl precipitate from pulldown assays were loaded per lane. Page
Ruler Pre-Stained Ladder (Fermentas, 5 µl /lane) served as size standard. Gels were run at 160 V
for 60 minutes.
Table 8.11: Pipetting scheme for SDS-PAGE gels
10% seperating gel 4% seperating gel
Acrylamide mix (30% 1667 µl l 213 µl l
water 2045 µl l 975 µl l
4x seperating bu↵er 1250 µl
4x stacking bu↵er 400 µl
TEMED 30 µl 10.4 µl
APS (10% w/v) 8 µl 2 µl
8.3.5 Coomassie Staining
The recombinant proteins were subjected to SDS-PAGE gel analysis (Section 8.3.4) and Coomassie-
Staining in order to analyze their purity. SDS-PAGE gels were incubated for 30 minutes in
Coomassie Staining solution. Afterwards, the gel was destained until the protein bands became
visible.
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Table 8.12: Coomassie staining bu↵er
Coomassie staining (1l) 300 ml Methanol
100 mll acetic acid
600 ml water
700 mg/ml Coomassie Brilliant Blue G250
Destaining solution (1l) 300 ml Methanol
100 mll acetic acid
600 ml water
8.4 In vitro RNA-protein interaction and kinase assays
8.4.1 Filter binding assay
The interaction of RNA with proteins was monitored by filter retention assays. In order to detect
the a nity of the RNA-protein complex, 32P -labeled RNA was incubated with increasing concen-
trations of proteins in 25 µl binding bu↵er (for Erk2, binding bu↵er usually contained PBS, 3 mM
MgCl2, for GRK2, binding bu↵er usually contained PBS, 3 mM MgCl2, 1mg/ml Heparin) and
incubated at 37 C for 30 minutes. In the meantime, the nitrocellulose membrane (0.45 µM, Schle-
icher and Schuell) was incubated in cathode bu↵er. After 25 minutes, the membrane was rinsed
with MilliQ water and vacuum manifold was assembled. The membrane was equilibrated with 200
µl washing bu↵er (PBS, 3mM MgCl2). 20 µl sample was loaded. Afterwards, the membrane was
washed two more times with 200 µl washing bu↵er (PBS, 3 mM MgCl2). 0.8 µl of 32
P -labeled RNA
was spotted on the membrane to allow for the quantification of the percentage of RNA bound to
the proteins. The amount of radioactively labeled RNA bound to proteins was then detected with
a Fujifilm FLA-3000 (Fujifilm) and quantified using AIDA image software. Dissociation constant
values (KD) were determined by fitting data from at least two independent measurements to a
one-site specific binding curve with a 4 parameter hill slope using GraphPad Prism 5.0.
Table 8.13: Bu↵ers for filter retention assay
Cathode bu↵er Binding bu↵er
25 mM Tris-HCl, pH 9.4 137 mM NaCl
40 mM Glycin 2.7 mM KCl
6.5 mM Na2HPO4
1.47 mM NaH2PO4
2 mM MgCl2
8.4.2 Competitive binding assays with ATP
In competition experiments employing inactive Erk2, 300 nM Erk (2x KD for C5) or 200 nM Erk
(2x KD for C3) were incubated in binding bu↵er (PBS, 3 mM MgCl22) with radioactively labeled
RNA and increasing concentrations of ATP or UTP (0-20000 µM, Larova). Erk2 was added last to
the mixture. After incubation at 37 C for 30 minutes, samples were passed through a nitrocellulose
membrane and quantified as described above.
In competition experiments employing active Erk2, 100 nM active Erk2 was incubated in binding
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bu↵er (PBS, 3 mM MgCl2) with radioactively labeled RNA and increasing concentrations of ATP
or UTP (0-20000 µM). Erk2 was added last to the mixture. After incubation at 37 C for 30 minutes,
samples were passed through a nitrocellulose membrane and quantified as above (Section 8.4.1).
IC50 values were calculated from a dose-response curve and fitted using a three-parameter slope.
8.4.3 Competitive binding assays with aptamers in the recording solu-
tion
For experiments validating the functionality of C3, C5 or C5 B2 in recording solution, 300 nM Erk2
was incubated in 20 µl binding bu↵er (PBS, 3 mM MgCl2). Indicated RNA concentrations were
frozen in PBS or recording solution, thawed and 5 µl were used as competitors for radioactively
labeled C3 or C5. The amount of radioactively labeled RNA bound to proteins was quantified as
described as above.
8.4.4 Erk2 activity assays
Erk2 activity assays were performed in kinase assay bu↵er (20 mM Hepes, pH 7.4, 10 mM MgCl2,
100 µM ATP and 0.1 µCi-P 32-ATP). 60 nM active Erk2 was incubated with indicated RNA con-
centrations and 10 µM MBP (Sigma Aldrich) or 1 µM GST-Elk1 (Cell Signaling Technology). The
reaction was started with the addition of active Erk2 and was allowed to proceed for 15 minutes at
30 C. Afterwards, samples were passed through a nitrocellulose membrane and quantified as above
(Section 8.4.1).
Table 8.14: Kinase assay bu↵er
Kinase assay bu↵er
20 mM Hepes, pH 7.4
10 mM MgCl2
100 µM ATP
60 nM active Erk2
0.1 µCi-P 32-ATP
10 µM MBP or 1 µM GST-Elk1
8.4.5 Mek1-Erk2-activation assay
Erk2 activity assays were performed in kinase assay bu↵er. 1 µ Mek1 G7B, 1 µM Erk2 and
10 µM MBP were incubated with indicated RNA concentrations. Erk2 was added last. The
reaction proceeded for 15 minutes at 30 C and was terminated by boiling the samples in La¨mmli
bu↵er (3 minutes, 95 C). Afterwards, samples were dissolved on a 10% SDS-PAGE gel (8.3.4) and
phosphorylation of Erk2 and MBP was detected with a Fujifilm FLA-3000 (Fujifilm) and quantified
using AIDA image software.
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Table 8.15: Kinase activation assay bu↵er
Kinase activation assay bu↵er
20 mM Hepes, pH 7.4
10 mM MgCl2
100 µM ATP
0.1 µCi-P 32-ATP
1 µM Erk2
1 µ Mek1 G7B 10 µM MBP
8.5 Working with eukaryotic cells
8.5.1 Cultivation
Cell lines were cultivated in the indicated media (PAA) supplemented with 10% FBS (Signa) at
37 C, 5% C02. Cells were cultivated until they reached a confluence of 80% and subsequently were
splitted every 2-3 days.
Table 8.16: Cell lines and standard media
Cell line medium species origin
H460 RPMI human NSCLC
Hek293 DMEM high glucose human Embryonic kidney
A431 RPMI human Epidermoid cancer
8.5.2 Freezing and thawing
Approx. 5x106 cells were collected per cryotube. The supernatant was discarded and cells were
resuspended in 500 µl Medium (10% FCS) and 500 µl cryoprotective medium (Lonza). Cells were
immediately transferred into the -80 C freezer and placed into the liquid nitrogen tank 24 hours
later.
For thawing, one cryovial was placed into the waterbath (37 C) until the cell suspension was com-
pletely thawed. Cells were then transferred into a new 75-cm2-flask. Medium was changed after 12
hours.
8.5.3 Mycoplams test
Mycoplasm tests were routinely performed according to the manufacturers protocol (Minerva Bio-
sciences).
8.5.4 Transfection with RNA for Immunoblot analysis and Flow Cytom-
etry
For RNA transfection by lipofection, indicated cell numbers were seeded 48 hours before transfec-
tion. Cells were cultivated for 24-30 hours in standard medium with FCS. On the second day, the
standard medium was replaced with serum-free medium and cells were cultivated for further 16
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hours. Before transfection, cells were washed with PBS once and fresh medium without FCS was
added.
Table 8.17: Number of cells seeded for RNA transfection
Well format Total volume Cell line no of cells RNA [pmol/µl]
6-cm 3 ml H460 600,000 750
6-cm 3 ml A431 600,000 750
24 well 0.2 ml H460 30,000 ¡20
96-well 0.1 ml H460 2000 ¡2
96-well 0.1 ml diverse 1000-3000 ¡2
RNA was transfected at indicated concentrations of aptamer or control RNA. For this, the com-
mercially available transfection reagent Lipofectamine LTX (Invitrogen) was mixed at a ration of
4:1 with Lipofectamine Plus and incubated with RNA in serum-freemedium for 30 minutes at room
temperature. Afterwards, the mixture was added drop wise to the cells. After 5-6 hours, cells were
stimulated with 50ng/ml EGF (AF-100-15, Peprotech) for 10 minutes.
Table 8.18: Pipetting scheme for RNA transfection
Well format RNA [pmol/µl] LTX [µl] Plus [µl] volume [µl]
6-cm 750 10 2.5 200
6-cm 750 10 2.5 200
24 well ¡20 2 0.5 50
96-well ¡2 0.1 0.025 100
96-well ¡2 0.1 0.025 100
8.5.5 Transfection with DNA plasmids
For plasmid transfection by lipofection, 20000-3000 cells were seeded in 24 well plates 18 hours
prior to transfection in standard medium with FCS. On the second day, the standard medium was
changed with 300 µl fresh medium and cells were transfected as described below.
The transfection mix was incubated for 30 minutes at room-temperature and added drop-wise to
the cells. It was removed 12-24 hours after transfections and cells. Cells were incubated for 24-72
hours after transfection started.
Table 8.19: Pipetting scheme for RNA transfection
Transfection mix
300 ng Luciferase vector
700 ng expression vector
2 µl Lipofectamine LTX
0.7 µl Lipofectamine Plus
ad 50 µl OptiMEM
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8.5.6 Inhibitor treatment
For treatment with inhibitors, cells were seeded as described above and allowed to grow for 24-30
hours in standard medium with FCS. Cells were then serum-starved and treated with inhibitors or
DMSO over-night. Cells were stimulated with 50 ng/ml EGF for 5 minutes.
8.5.7 Cell lysis for SDS-PAGE and Immunoblot analysis
Before cell lysis, medium was discarded and cells were washed once with ice-cold PBS. Cells were
harvested in cold PBS bu↵er on ice using a cell scraper. Subsequently, cells were centrifuged at 1000
rpm, 5 minutes, 4 C. Pellets were suspended in 25 µl 1x lysis bu↵er supplemented with protease-
inhibitor mix. After incubation on ice for 20 minutes, cell debris was separated by centrifugation
(20000g, 20 minutes, 4 C).
Protein concentration was determined by Bradford assay (Section 8.3.3). For SDS-PAGE and im-
munoblot analysis, 40 µg protein lysate was boiled in 1x La¨mmli bu↵er (Section 8.3.4).
Table 8.20: Lysis Bu↵er
1x Lysis Bu↵er
20 mM Tris-HCl, pH 7.5
150 mM NaCl
1 mM EDTA
1 mM EGTA
2.5 mM sodium pyrophosphate
1 mM glycerophosphate
1 mM sodium vanadate
1% (v/v) Triton X-100
8.5.8 Pull-down of endogenous MAP kinases from cell lysate
Approximately 6x 106 H460 cells were washed three times with ice-cold PBS. Cells were detached
on ice by using a cell scraper and collected by centrifugation (1000 g, 5 min, 4 C). The cell pellet
was suspended in 1 ml 1x PBS (supplemented with 1% proteinase inhibitor mix, Serva) and homog-
enized (Polytron, Kinematica) at 4 C. Afterwards, the cell suspension was centrifuged at 20.000 g
for 60 minutes. The supernatant was then supplemented wit MgCl2 and Heparin (Sigma Aldrich)
to final concentrations of 3 mM and 0.8 µg/µl, respectively.
RNA was biotinylated and coupled to magnetic beads as described previously (Section 8.1.14).
After incubation, the cell lysate was added to the beads and incubated for 30 min at 37 C. Subse-
quently, the lysate was removed and the beads were washed 4x with 200 µl 1x PBS supplemented
with 3 mM MgCl2. Finally, the beads were suspended in 10 µl MilliQ water and 4x La¨mmli bu↵er,
boiled for 5 min at 95 C and subjected to SDS-Page gel analysis (Section 8.3.4).
8.5.9 Semi-dry blotting
Semi-dry blotting and Immunoblots were performed to detect proteins or phosphorylated proteins in
cell lysates. Proteins were run on a SDS-PAGE gel and transferred onto a nitrocellulose membrane
(0.45 µm, Schleicher and Schuell). The gel was stacked between di↵erent layers of paper that were
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equilibrated in the annotated bu↵ers. Transfer took place by applying 2 mA/cm2 gel (here: 9x6cm,
108 mA) for 90 minutes.
Table 8.21: Schematic representation
Anode
2 filter paper in Anode bu↵er I
1 filter paper in Anode bu↵er II
nitrocellulose membrane in Anode bu↵er II
gel in cathode bu↵er
3 filterpaper in cathode bu↵er
Cathode
Table 8.22: Bu↵ers used for semi-dry blotting
Anode bu↵er I 300 mM Tris-HCl, pH 10.5
Anode bu↵er II 25 mM Tris-HCl, pH 10.4
Cathode bu↵er 25 mM Tris-HCl, pH 9.4
40 mM Glycin
8.5.10 Immunoblot analysis
After transfer, membranes blocked under agitation with 5% BSA/1xTBS-T for 45 minutes at room-
temperature. Afterwards, membranes were rinsed 3 times for 5 minutes with 1x TBS-T. Primary
antibodies were diluted 1:500-1:10000 in 5 % BSA/1x TBS-T and incubated over-night at 4 C under
agitation. Primary antibodies were used up to 4 times. Antibodies were removed and membranes
were washed 3 times for 5 minutes with 1x TBS-T. Secondary antibodies coupled to Horseradish-
Peroxidase (HRP) or IRDyes were diluted 1:10000 in 5% BSA/1x TBS-T and incubated for 45-60
minutes at room-temperature in the dark. Afterwards, membranes were washed 3 times for 5 min-
utes with 1x TBS-T. For HRP antibodies, visualization of the corresponding bands was achieved
by enhanced Chemiluminescence and a VersaDoc Camera (Biorad). IRDye-labeled antibodies were
detected by a Odyssey scanner (LiCor). Bands were quantified using the QuantityOne software
from Biorad.
Table 8.23: Bu↵ers for semi-dry blotting
10x TBS 1x TBS-T
200 mM Tris, pH 7.6 20 mM Tris, pH 7.6
1.36 M NaCl 136 mM NaCl
0.1 % (v/v) Tween-20
8.5.11 Proliferation assay
1500-6000 cells were seeded into a 96-well plate (PAA). Cells were cultivated in standard medium
with 10 % FCS for 24 hours. On the second day, medium was discarded and cells were cultivated in
116
8.5. Working with eukaryotic cells
standard medium without FCS over night. For RNA transfection, cells were incubated for 6 hours
with the reaction mixture. For inhibitor treatment, cells were incubated over night with inhibitors
or solvent.
Afterwards, medium was discarded and cells were cultivated in standard medium with 1 % FCS.
After 24-72 hours, 15 µl MTT dye solution was added to the cells. The cells were then incubated
for 4 more hours at 37 C. Then, 100 µl MTT lysis bu↵er was added to the cells. After 1-2 hour
incubation at 37 C, absorbance was measured at 570 nm in the Varioscan platereader.
Table 8.24: Bu↵ers for MTT assays
MTT dye solution MTT lysis bu↵er
5 mg/ml MTT dye in 1x PBS 250 ml DMF
250 ml water
100 g SDS
10 ml acetic acid
8.5.12 Luciferase Assay
SRE-Luciferase assays were performed according to the Luciferae Glo assay protocol by Promega.
Briefly, cells were stimulated with 50 ng/ml EGF for 6 hours prior to cell lysis. Afterwards, cells
were washed twice with PBS and 400 µl 1x Reporter Lysis Bu↵er (Promega) was added to each
well. The mixture was incubated for 30 minutes at 37 C.
In order to normalize the Luciferase signal onto the intrinsic GFP expression level, 100 µl cell lysate
was transferred into black half-area plates (Firma) and fluorescence was detected at 488 nm using
the ENspire platereade. 100 µl Luciferase assay substrate (Promega) was transferred into a half-
area 96 well plate (Firma) and 15 µl l cell lysate (previously used to the detect GFP expression)
was added. After incubation for 5 minutes in the dark, Luciferase signal was detected with the
ENspire platereader. The luciferase signal was normalized onto the GFP signal for quantification.
GFP and Luciferase measurements were performed in duplicates.
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9.1 Oligos
Table 9.1: C13 aptamer and point mutants
Name Type Sequence
5´-Primer (C-47) DNA AATTCTAATACGACTCACTATAGGGAGAGGAGGGAGATA
GATATCAA
3´-Primer (P20) DNA GTCCTGTGGCATCCACGAAA
C13 RNA GGGAGAGGAGGGAGAUAGAUAUCAACUGCAGUUCGGGU
AGCACAGACCAUACGGGAGAGAAACUUGUGCAACCCGGGG
CUACUUUCGUGGAUGCCACAGGAC
C13 A49C RNA GGGAGAGGAGGGAGAUAGAUAUCAACUGCAGUUCGGGU
AGCACAGACCCUACGGGAGAGAAACUUGUGCAACCCGGGG
CUACUUUCGUGGAUGCCACAGGAC
C13 U50G RNA GGGAGAGGAGGGAGAUAGAUAUCAACUGCAGUUCGGGU
AGCACAGACCAGACGGGAGAGAAACUUGUGCAACCCGGGG
CUACUUUCGUGGAUGCCACAGGAC
C13 A51C RNA GGGAGAGGAGGGAGAUAGAUAUCAACUGCAGUUCGGGU
AGCACAGACCAUCCGGGAGAGAAACUUGUGCAACCCGGGG
CUACUUUCGUGGAUGCCACAGGAC
C13 C52A RNA GGGAGAGGAGGGAGAUAGAUAUCAACUGCAGUUCGGGU
AGCACAGACCAUAAGGGAGAGAAACUUGUGCAACCCGGGG
CUACUUUCGUGGAUGCCACAGGAC
C13 G53U RNA GGGAGAGGAGGGAGAUAGAUAUCAACUGCAGUUCGGGU
AGCACAGACCAUACUGGAGAGAAACUUGUGCAACCCGGGG
CUACUUUCGUGGAUGCCACAGGAC
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Table 9.2: Erk2 aptamers and control sequences
Name Type Sequence
C3 5´-Primer (5´-C-47) AATTCTAATACGACTCACTATAGGGAGAGGAGGGAGATAGA
TATCAAGATATCAA
C3 3´-Primer (3´-C-20) GTCCTGTGGCATCCACGAAA
C3 RNA GGGAGAGGAGGGAGAUAGAUAUCAACUGCAGUUCGGGUA
GCACACGAAGGGCACCGUAGCAAUACGGUUGUUCUGGUU
AACUUUCGUGGAUGCCACAGGAC
C3sc 5´-Primer (5´-C-47) AATTCTAATACGACTCACTATAGGGAGAGGAGGGAGATAGA
TATCAAGATATCAA
C3sc 3´-Primer (3´-C-20) GTCCTGTGGCATCCACGAAA
C3sc RNA GGGAGAGGAGGGAGAUAGAUAUCAAAGGAUCUAGGUCCG
CGCUCUUGUUAAGCUACGUACGGAGGCCACACGAUUAGAU
GGUUUCGUGGAUGCCACAGGAC
C5 5´-Primer (5´-P2-45) AATTCTAATACGACTCACTATAGGGAGAGAGCGAGAGGTA
ACTAA
C5 3´-Primer (3´-C-20) GTCCTGTGGCATCCACGAAA
C5 RNA GGGAGAGAGCGAGAGGUAACUAAGAGGAAAGGCGCUAGG
CAAGUGGCUCCUCGAAAGGGCAUGCGCCAUUAAGAAACCA
GUAUUUCCUCGAGUUUCGUGGAUGCCACAGGAC
C5sc 5´-Primer (5´-P2-45) AATTCTAATACGACTCACTATAGGGAGAGAGCGAGAGGTA
ACTAA
C5sc 3´-Primer (3´-C-20) GTCCTGTGGCATCCACGAAA
C5sc RNA GGGAGAGAGCGAGAGGUAACUAAGACCGAGGACGGAUCGC
AGAUGUCCGAGCUACACCAUACACAGGCGAAGGAGUGAUU
AAUAGGUCUUGCUUUCGUGGAUGCCACAGGAC
C5 A1 5´-Primer (5´-P2-45) AATTCTAATACGACTCACTATAGGGAGAGAGCGAGAGGTA
ACTAA
C5 A1 3´-Primer (3´-C-20) GTCCTGTGGCATCCACGAAA
C5 A1 RNA GGGAGAGAGCGAGAGGUAACUAAGAGGAAAGGGCCUAGGC
AAGUGGCUCCUCGAAAGGGCAUGCGCCAUUAAGAAACCAG
UAUUUCCUCGAGUUUCGUGGAUGCCACAGGAC
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Table 9.3: Erk2 aptamers and control sequences continued
Name Type Sequence
C5 B2 5´-Primer (5´-P2-45) AATTCTAATACGACTCACTATAGGGAGAGAGCGAGAGGT
AACTAA
C5 B2 3´-Primer (3´-C-20) GTCCTGTGGCATCCACGAAA
C5 B2 RNA GGGAGAGAGCGAGAGGUAACUAAGAGGAAAGGCGCUAG
GCAAGUGGCUCCUCGAAAGGGCAUGCGCCAUUAAGAAA
GGAGUAUUUCCUCGAGUUUCGUGGAUGCCACAGGAC
TRA 5´-Primer (5´-Tra4f) AATTCTAATACGACTCACTATAGGGAGAGCCATACCTGGG
AAAG
TRA 3´-Primer (3´-Tra4rev) GGGATGCGTAACCTGGGA
TRA RNA GGGAGAGCCAUACCUGGGAAAGACGCUAGCGAAUUGG
UUCCUCGAAAGGGGAAAGCGUUAUUAAGAAACCAAAA
UUUCCCAGGUUACGCAUCCC
Table 9.4: Truncated Erk2 aptamers and control sequence used for whole-cell recordings
Name Type Sequence
C3.59 5´-Primer (5´-C3.59f) AATTCTAATACGACTCACTATAGGTAGCACACGAAGGG
CACCGTA
C3.59 3´-Primer (3´-C3.59r) GGCATCCACGAAAGTTAACCA
C3.59 RNA GGUAGCACACGAAGGGCACCGUAGCAAUACGGUUGUU
CUGGUUAACUUUCGUGGAUGCC
C5.71 5´-Primer (5´-C5.71f) AATTCTAATACGACTCACTATAGGAGGAAAGGCGCTAG
GCAAGT
C5.71 3´-Primer (3´-C5.71r) CGTCGAGGAAATACTGGTTTCTTAATGG
C5.71 RNA GGAGGAAAGGCGCUAGGCAAGUGGCUCCUCGAAAGG
GCAUGCGCCAUUAAGAAACCAGUAUUUCCUCGACG
C5.B2.71 5´-Primer (5´-C5.71f) AATTCTAATACGACTCACTATAGGAGGAAAGGCGCTAG
GCAAGT
C5.B2.71 3´-Primer (3´-B2.71r) CGTCGAGGAAATACTCCTTTCTTAATGG
C5.B2.71 RNA GGAGGAAAGGCGCUAGGCAAGUGGCUCCUCGAAAGG
GCAUGCGCCAUUAAGAAAGGAGUAUUUCCUCGACG
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9.2 Expression constructs
Figure 9.1: pRNAT U6.neo RNA expression vector. Full-length aptamers or control sequences
were cloned with BamHI or HindIII into this vector.
9.2.1 Oligos
Table 9.5: Erk2 aptamers and control sequences used for intracellular expresion
Name Sequence
C3 GGGAGAGGAGGGAGAUAGAUAUCAACUGCAGUUCGGGUAGCACACGAAGGGC
ACCGUAGCAAUACGGUUGUUCUGGUUAACUUUCGUGGAUGCCACAGGACUUU
C3sc GGGAGAGGAGGGAGAUAGAUAUCAAAGGAUCUAGGUCCGCGCUCUUGUUAAG
CUACGUACGGAGGCCACACGAUUAGAUGGUUUCGUGGAUGCCACAGGACUUU
C5 GGGAGAGAGCGAGAGGUAACUAAGAGGAAAGGCGCUAGGCAAGUGGCUCCUC
GAAAGGGCAUGCGCCAUUAAGAAACCAGUAUUUCCUCGAGUUUCGUGGAUGCC
ACAGGACUUU
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Table 9.6: Erk2 aptamers and control sequences used for intracellular expresion continued
Name Sequence
C5sc GGGAGAGAGCGAGAGGUAACUAAGACCGAGGACGGAUCGCAGAUGUCCG
AGCUACACCAUACACAGGCGAAGGAGUGAUUAAUAGGUCUUGCUUUCGU
GGAUGCCACAGGACUUU
C5 B2 GGGAGAGAGCGAGAGGUAACUAAGAGGAAAGGCGCUAGGCAAGUGGCUC
CUCG AAAGGGCAUGCGCCAUUAAGAAAGGAGUAUUUCCUCGAGUUUCGU
GGAUGCCACAGGACUUU
9.3 Proteins
Protein expressed during this thesis:
Erk2 wild-type
MAHHHHHHAMAAAAAGPEMVRGQVFDVGPRYTNLSYIGEGAYGMVCSAYDNLN
KVRVAIKKISPFEHQTYCQRTLREIKILLRFRHENIIGINDIIRAPTIEQMKDVYIVQDLM
ETDLYKLLKTQHLSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLLNTTCDLKIC
DFGLARVADPDHDHTGFLTEYVATRWYRAPEIMLNSKGYTKSIDIWSVGCILAEMLS
NRPIFPGKHYLDQLNHILGILGSPSQEDLNCIINLKARNYLLSLPHKNKVPWNRLFPN
ADSKALDLLDKMLTFNPHKRIEVEQALAHPYLEQYYDPSDEPIAEAPFKFDMELDDL
PKEKLKELIFEETARFQPGYRS
Erk2 N236K
MAHHHHHHAMAAAAAGPEMVRGQVFDVGPRYTNLSYIGEGAYGMVCSAYDNLN
KVRVAIK KISPFEHQTYCQRTLREIKILLRFRHENIIGINDIIRAPTIEQMKDVYIVQDLM
ETDLYK LLKTQHLSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLLNTTCDLKIC
DFGLARVADPDHDHTGFLTEYVATRWYRAPEIMLNSKGYTKSIDIWSVGCILAEMLS
NRPIFPGKHYLDQLKHILGILGSPSQEDLNCIINLKARNYLLSLPHKNKVPWNRLFPNA
DSKALDLLDKMLTFNPHKRIEVEQALAHPYLEQYYDPSDEPIAEAPFKFDMELDDLPK
EKLKELIFEETARFQPGYRS
Erk2 Y261N
MAHHHHHHAMAAAAAGPEMVRGQVFDVGPRYTNLSYIGEGAYGMVCSAYDNLN
KVRVAIKKISPFEHQTYCQRTLREIKILLRFRHENIIGINDIIRAPTIEQMKDVYIVQDLM
ETDLYKLLKTQHLSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLLNTTCDLKIC
DFGLARVA DPDHDHTGFLTEYVATRWYRAPEIMLNSKGYTKSIDIWSVGCILAEML
SNRPIFPGKHYLDQLNHILGILGSPSQEDLNCIINLKARNNLLSLPHKNKVPWNRLF
PNADSKALDLLDKMLTFNPHKRIEVEQALAHPYLEQYYDPSDEPIAEAPFKFDME
LDDLPKEKLKELIFEETARFQPGYRS
Erk2 S264P
MAHHHHHHAMAAAAAGPEMVRGQVFDVGPRYTNLSYIGEGAYGMVCSAYDNLN
KVRVAIKKISPFEHQTYCQRTLREIKILLRFRHENIIGINDIIRAPTIEQMKDVYIVQDLM
ETDLYKLLKTQHLSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLLNTTCDLKIC
DFGLARVADPDHDHTGFLTEYVATRWYRAPEIMLNSKGYTKSIDIWSVGCILAEMLS
NRPIFPGKHYLDQLNHILGILGSPSQEDLNCIINLKARNYLLPLPHKNKVPWNRLFPN
ADSKALDLLDKMLTFNPHKRIEVEQALAHPYLEQYYDPSDEPIAEAPFKFDMELDDL
PKEKLKELIFEETARFQPGYRS
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Mek1 wild-type
HHHHHHGMASMTGGQQMGRDLYDDDDKDRWGSGGVGSALPGSKMPKKKPTPIQLN
PAPDGSAVNGTSSAETNLEALQKKLEELELDEQQRKRLEAFLTQKQKVGELKDDDFEKI
SELGAGNGGVVFKVSHKPSGLVMARKLIHLEIKPAIRNQIIRELQVLHECNSPYIVGFYGA
FYSDGEISICMEHMDGGSLDQVLKKAGRIPEQILGKVSIAVIKGLTYLREKHKIMHRDVKPS
NILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMSPERLQGTHYSVQSDIWSMGLSLV
EMAVGRYPIPPPDAKELELMFGCQVEGDAAETPPRPRTPGRPLSSYGMDSRPPMAIFELL
DYIVNEPPPKLPSGVFSLEFQDFVNKCLIKNPAERADLKQLMVHAFIKRSDAEEVDFAGW
LCSTIGLNQPSTPTHAAGV
Mek G7B
HHHHHHGMASMTGGQQMGRDLYDDDDKDRWGSGGVGSALPGSKMPKKKPTPIQLNPA
PDGSAVNGTSSAETNLEALQKKLEELELDAFLTQKQKVGELKDDDFEKISELGAGNGGVV
FK VSHKPSGLVMARKLIHLEIKPAIRNQIIRELQVLHECNSPYIVGFYGAFYSDGEISICMEH
MDGG SLDQVLKKAGRIPEQILGKVSIAVIKGLTYLREKHKIMHRDVKPSNILVNSRGEIKLC
DFGVSGQ LIDDD ADDFVGTRSYMSPERLQGTHYSVQSDIWSMGLSLVEMAVGRYPI PPPD
AKELELMFG CQVEGDAAETPPRPRTPGRPLSSY GMDSRPPMAIFELLDYIVNEPPPKLPSG
VFSLEFQDFVN KCLIKNPAERADLKQLMVHAFIKRSDAEEVDFAGWLCSTIGLNQ PST
PTHAAGV
Proteins from other sources:
Table 9.7: Proteins and suppliers
Name Supplier
human Erk2, active Proqinase, Germany
JNK2alpha2/SAPK1a, inactive Merck Millipore, Germany
p38alpha MAPK, inactive Marie-Sophie Raddatz, University of Bonn
GRK2 Prof. Dr. J. Tesmer, University of Michigan
RSK4 Prof. Dr. S. Knapp, University of Oxford
PKB? Prof. Dr. S. Knapp, University of Oxford
VRK1 Prof. Dr. S. Knapp, University of Oxford
CK Prof. Dr. S. Knapp, University of Oxford
DRAK1 Prof. Dr. S. Knapp, University of Oxford
AAK Prof. Dr. S. Knapp, University of Oxford
NEK1 Prof. Dr. S. Knapp, University of Oxford
TOPK Prof. Dr. S. Knapp, University of Oxford
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9.4 Antibodies
Table 9.8: Antibodies
Antigen Epitope Company Clone
Elk1 p-Ser383 Santa Cruz B-4
p90-RSK1 p-T359/363 Epitomics/Biomol E238
Erk1/2 p-T202/Y204 Cell Signalling 197G2
Erk1/2 subdomain XI Santa Cruz K-23
p38a n.d. Cell Signalling 9212
JNK1 amino acids 1-384 Santa Cruz F-3
Actin C-terminus Santa Cruz C-11
Hsc70 n.d Stressgen/Biomol N27F34
DyLight 700 Conjugated Rabbit IgG (H+L) Thermo Scientific
DyLight 800 Conjugated Mouse IgG (H+L) Thermo Scientific
9.5 Commercially available kits
Table 9.9: Commercially available kits
Application Kit Supplier
Luciferase Luciferase Assay System E1501 Promega
Mycoplama tests VenorGeM Classic Mycoplasma
PCR Detection Kit Minerva Biolabs
PCR purification NucleoSpin Extract II Gel and PCR Clean-up Macherey-Nagel
Plasmid purification (small scale) NucleoSpin Plasmid Macherey-Nagel
Plasmid purification (midi) NucleoBond Xtra Midi Macherey-Nagel
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9.6 Reagents and chemicals
Table 9.10: Reagents
Reagent Supplier
Agar Sigma
Agarose Invitrogen
Ampicillin sodium salt AppliChem
Ammoniumacetate Gruessing
Ammomiumperoxodisulfate (APS) Roth
Bis-Acrylamid, Rotiphorese Roth
Biotin Sigma-Aldrich
Bovine Serum Albumin (BSA, nuclease and protease free) Calbiochem
Bradford-reagent BioRad
Bromphenol blue Merck
Calf intestine alkaline phosphatase (CIAP) Promega
Cell culture media PAA
Chloroform AppliChem
Coomassie Brilliant Blue G250 BioRad
Dimethylformamide (DMF) Fischer Scientific
1,4-Dithiothreitol (DTT) Roth
DPBS (1x), pH 7.4 PAA
di-Sodiumhydrogenphosphate-dihydrate Merck
DNase Roche
dNTPs Larova
Dynabeads M-280 Streptavidin Invitrogen
EGF; AF-100-15 Peprotech
Ethanol abs. Sigma
Ethidium bromide Roth
Ethylendiamintetraacetic acid (EDTA) p.A. AppliChem
EZ-link PEO-iodoacetyl biotin Genaxxon Biosciences
Fetal Bovine Serum (FBS), DE14-870F1 Lonza
FBS (Instant), F0685-3G, Lot 119K33962 Sigma
Formaldehyde (36) Fluka
GeneRuler 100 bp DNA Ladder Thermoa
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Table 9.11: Reagents
Reagent Supplier
Glycine Roth
Guanosine-5’-thiophosphate disodium salt Emp Biotec
Hepes Roth
HiTrap5 columns GE healthcare
Hydrochloric acid (HCl) Roth
Imidazole AppliChem
Iodacetamido-fluorescein Sigma
Iodacetamido-biotin (EZ-link PEG2) Thermo Scientific
Isopropanol Merck
Lennox Broth (LB) Sigma
Lipofectamin LTX + Plus reagent Invitrogen
Magnesiumchloride-hexahydrate AppliChem
Methanol VWR
MTT dye solution AppliChem
Ni-NTA-beads Qiagen
NTPs Larova
Page Ruler Prestained Protein Ladder Fermentas
Pfu polymerase In house production
Potassium chloride (KCl) Gruessing
RNasin Promega
Rotiphorese Sequenziergel Konzentrat Roth
Salt optimized carbon medium (SOC) Sigma
Sodium Acetate Gruessing
Sodium chloride p. A. AppliChem
Sodium dodecylsulfate (SDS) Roth
Sodium hydrogenphosphate Sigma Aldrich
Sodium hydroxide Gruessing
Sodium orthovanadate AppliChem
Sodium pyrophosphate AppliChem
Streptavidin Sigma
Superdex200 column GE Healthcare
T7 polymerase In house production
N,N,N’,N’ -Tetramethylethylendiamide (TEMED) Roth
Tris Roth
Triton X-100 Merck
Trypsin/EDTA (10x) PAA
Tween-20 Calbiochem
Urea AppliChem
XL10 Gold Ultracompetent Cells Invitrogen
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9.7 Equipment
Table 9.12: Equipment
Equipment Supplier
Agarose gel and equipment in house construction
Analytical balance Sartorius
Autoclave Systec
Beaker Schott
BioMate 3 Photometer Thermo Spectronic
Cell culture media PAA
Cell scraper TPP
Centrifuges Eppendorf
Culture dishes TPP
Culture flask TPP
Culture plates TPP
Counter for radioactivity Berthold
Cryo tubes Roth
Disposable cuvettes Roth
DPBS (1x), pH 7.4 PAA
Electrophoresis chambers BioRad
Eppi vials Sarstedt
Erlenmeyer flask Schott
Fluorescence spectrometer Enspire
G25 columns GE Healthcare
Glass plates for PAGE Baack
Glass bottles Schott
Glasswool silanized Serva
Gloves Peske
Head-top-tumbler Heidolph
Heating blocks Bachofer
Hood (bacteria) Antares
Hood (eukaryotic cell lines) Hera
Incubator shaker Innova
Incubator (37  C-90  C) VWR
Incubator (cell culture) Hera
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Table 9.13: Equipment
Equipment Supplier
Magnetic stirrer IKA
Microwave Bosch
Multichannel pipette Eppendorf
Multipette Eppendorf
NanoQuant infinite 200 Tecan
Nitrocellulose membrane (Protran 0.45 µM) Schleicher and Schuell
Parafilm Faust
PCR Thermocycler Biometra
pH Paper Macherey-Nagel
Phosphorimager screens and cassettes Fuji
Phosphorimager FLA-3000 Fujifilm
Pipets Eppendorf
Pipet tips Sarstedt
Pipetboy Accu-Jet pro Brand
Power supply for PAGE Consort
Radioactivity protection gear (goggles, shields etc.) Sigma
Reaction tubes (2 ml, 1.5 ml, 0.5 ml) Sarstedt
Scalpel blades Labomedic
Sterile filters (syringe filter) Merck Millipore
Sunrise plate reader Tecan
Tips for multipettes Eppendorf
Thermomixer Eppendorf
UV Transilluminator VWR
VarioSkan Thermo
Vortex mixer Neolab
Vaccum manifold (filter binding assays) Schleicher and Schuell
Water bath GFL
Water purification system Werner
96 well plates, half area, flat, black Greiner Bio One
96 well plates, U-shape Roth
Tecan Ultra reader Tecan
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10.1 Negative control sequences
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Figure 10.1: Binding assays with all negative control sequences. The amount of radioactively
labeled RNA is plotted against the Erk2 concentration. Experiments were performed twice (mean ±
SEM). None of the utilized negative control sequences for C3 or C5 revealed any a nity for Erk2.
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10.2 Aptamer competition assays
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Figure 10.2: Aptamer competition assays. Binding of C3 to Erk2 in the presence of B50 library
RNA or C3 in PBS bu↵er. The amount of radioactively lebeled C3 RNA without additional RNA was
set to 1 (n=4, mean ± SEM). Data were obtained during my diploma thesis [497].
10.3 Kinase assays
10.3.1 Binding tests
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Figure 10.3: Binding assays. Binding assays with proteins utilized for kinase assays in Hepes bu↵er
with 10 mM MgCl2. The amount of radioactively labeled RNA bound to Erk2 is plotted against the
protein concentration (n=2, mean ± SEM).
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10.4. Recombinant Erk2 proteins
10.3.2 Activity towards Mek1 G7B
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Figure 10.4: E↵ects on Mek1 catalytic activity. The aptamers e↵ect on Mek1 activity was
analyzed at a concentration of 12.5µM. As a readout, Mek1 autophosphorylation was measured. Data
were normalized with the C5 B2 treated samples set as 100 %. Neither C3 nor C5 show any inhibitory
activity towards Mek1 (n=3, mean ± SEM).
10.4 Recombinant Erk2 proteins
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Figure 10.5: Recombinant Erk2 proteins. 5 ul recombinant proteins were utilized per lane of a 10
% SDS-PAGE gel. The molecular weight of Erk2 is approx. 42 kDa. Coomassie staining revealed high
purity of the recombinant proteins utilized for point mutant studies. The mutant 230 was omitted from
experiments.
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10.5 Expression Vector
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Figure 10.6: Binding assay of the aptamers with additional uracil residues. The amount or
radioactively labeled A) C3 or B) C5 or its respective expression constructs bound to Erk2 is plotted
against the Erk2 concentration (n=2, mean±SEM).
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Figure 10.7: Transfection e ciency in distinct cell lines. Transfection e ciency was monitored
24 hours after transfection of the empty RNA expression vector at distinct plasmid concentrations. GFP
expression was quantified by flow cytometry (n=2, mean±SEM).
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10.6. Expression Vector 2
10.6 Expression Vector 2
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Figure 10.8: Representative luciferase assay. These diagrams show absolute A) GFP intesity and
B) absolute luciferase units after transfection with the indicated vectors and stimulation with EGF. C)
Luciferase data were normalized for GFP intensity with the unstimulated, empty vector control cells set
as 1. This experiment was performed in duplicates.
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10.7 Whole-cell recordings
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Figure 10.9: C5.71 is functional in recording solution. A) In order to validate the function-
ality of C5.71 for the assay conditions utilized during the electrophysiological measurement, indicated
concentration of unlabeled or 5’-fluorescein-labeled C5.71 or C5 B2.71 control RNA were frozen in PBS
or recording bu↵er (ICS), thawed and used to compete the binding of radioactively labeled C5 from
Erk2. The amount of radioactively labeled C5.71 bound to Erk2 was normalized onto control samples
without additional RNA added. Unlabeled RNAs were tested twice, fluorescein-labeled RNA was tested
once (mean±SEM)). B) C5.71 RNA is not degraded during electrophysiological measurements. 25 pmol
C5.71 RNA was incubated without (w/o, lane 2) or with spit as degradation control (+RNAse digest,
lane 3). To validate the integrity of C5.71 for the assay conditions utilized during the electrophysiolog-
ical measurement, C5.71 RNA was directly taken from the microinjection needle (sample, lane 4). No
degradation could be observed after measurements.
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